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I.SUMMARY 
Neonatal sepsis contributes substantially to neonatal morbidity and mortality, and 
is a major global public health challenge worldwide. According to the age of onset, 
neonatal sepsis is divided into early-onset sepsis (EOS) and late-onset sepsis (LOS). 
EOS has been variably defined based on the age at onset, with bacteremia or bacterial 
meningitis occurring at ≤72 h in infants hospitalized in the neonatal intensive care unit 
versus <7 days in term infants. EOS reflects transplacental or ascending infections from 
the maternal genitourinary tract, whereas LOS is associated with the postnatal 
nosocomial or community environments, with a peak incidence reported to be between 
days 10 and 22 after birth. 
 Streptococcus agalactiae (Group B Streptococci, GBS) is one of the 
microorganisms most frequently involved in severe neonatal EOS cases. Women, men 
and children of all ages can be asymptomatically colonized with GBS, acting the 
gastrointestinal tract, vagina and urethra as reservoirs. The maternal colonization rate 
usually ranges from 12 to 28%. Recto-vaginal GBS screening at week 35-38 of 
pregnancy, and subsequent intrapartum antibiotic prophylaxis (IAP) to positive mothers, 
is the most common strategy used to prevent neonatal GBS neonatal infections.  
However, such strategy does not prevent GBS-related abortions, stillbirths and preterm 
births, may lead to increasing rates of antibiotic resistance among clinically relevant 
microorganisms, and has a very negative impact on the acquisition, composition and 
development of the infant microbiota. GBS vaccines are not available at present and, 
therefore, there is a need for alternative strategies to avoid GBS colonization during 
pregnancy. In this context, the general objective of this PhD Thesis was the selection of 
a safe probiotic strain with the ability to eradicate GBS from the intestinal and 
genitourinary tracts of pregnant women. 
 For this purpose, the first partial objective of the Thesis was the study of the 
vaginal microbiota of non-pregnant and pregnant women, including the assessment of 
the GBS colonization rates and the preliminary selection of lactobacilli strains from 
GBS-negative women. A total of 54 fertile healthy women (30 non-pregnant women and 
24 pregnant ones) participated in this study. Non-pregnant women provided 4 vaginal 
exudate samples (days 0, 7, 14 and 21 of their menstrual cycles) while pregnant women 
provided a single sample collected at week 35-37 of pregnancy. Samples were cultured 
on a wide variety of broth media and the identification of the isolates was performed by 
PCR sequencing of the 16S rDNA gene or MALDI-TOF. The percentage of GBS 
positive women was 19% and 25% among pregnant and non-pregnant women, 
respectively.  
 A total of 89 Lactobacillus isolates were obtained from the vaginal swabs and, 
subsequently, submitted to RAPD genotyping to avoid duplication of isolates. Among 
them, 10 Lactobacillus salivarius strains were selected for further characterization on 
I.Summary/Resumen 
4 
 
the basis of the following criteria: (1) absence of S. agalactiae, Gardnella vaginalis, 
Candida spp., Ureaplasma spp. and Mycoplasma spp in the vaginal samples from which 
the lactobacilli were originally isolated; (2) Qualified Presumption of Safety (QPS) 
status conceded by EFSA; and (3) ability of the strain to grew rapidly in MRS broth 
under aerobic conditions (1 ×106 cfu/mL after 16 h at 37ºC).  
 Initially, an overlay method was used to determine the ability of the lactobacilli 
strains to inhibit the growth of 12 different S. agalactiae strains, 6 isolated from blood 
or cerebrospinal  fluid  in clinical cases of neonatal sepsis and the remaining 6 from 
vaginal samples of pregnant women. Clear inhibition zones (ranging from 2 to 20 mm) 
were observed around the lactobacilli streaks. In relation to the antimicrobials 
compounds that may be responsible for such activity, the concentration of L-lactic acid 
in the supernatants obtained from MRS cultures was similar (~10 mg/mL) for all the 
lactobacilli. In contrast, D-lactic acid was not detected in the supernatants of the tested 
strains. All the strains acidified the MRS-broth medium to a final pH of ~4 after 16 h of 
incubation. No bacteriocin-like activity could be detected against the tested S. agalactiae 
strains and two strains (L. salivarius V4II-90 and V7IV-1) were able to produce 
hydrogen peroxide (~7.4 μg/mL). The capacity of the lactobacilli strains to form large, 
well defined co-aggregates with S. agalactiae was strain-dependent.  
 Co-cultures with S. agalactiae seemed not to affect the growth of any of the L. 
salivarius strains. In contrast, most of the L. salivarius strains were able to interfere at a 
higher or lower degree with the growth of the different S. agalactiae strains included in 
this assay. Among them, L. salivarius V4II-90 showed the highest ability to inhibit the 
growth of S. agalactiae since the presence of two of the four S. agalactiae strains was 
not detectable in the co-cultures and the concentration of the other two showed a ~2.5 
log10 decrease after an incubation period of only 6 h at 37ºC. No viable streptococci 
could be detected when the co-cultures were incubated for 24 h. 
 The lactobacilli strains tested were strongly adhesive to both Caco-2 and HT-29 
cells and, in addition, all of them showed adhesion to vaginal epithelial cells. L. 
salivarius V4II-90 globally displayed the highest ability to adhere to both intestinal and 
vaginal epithelial cells.The lactobacilli strains tested showed a variable ability to adhere 
to porcine mucin. L. salivarius V4II-90 was the strain that showed the highest adherence 
ability followed by L. salivarius V7IV-1. None of the strains were able to degrade gastric 
mucin in vitro.  
 The viability of the strains after exposition to conditions simulating those found 
in the gastrointestinal tract varied from ~64% (L. salivarius V4II-90) to 30% (L. 
salivarius V3III-1). All the lactobacilli strains were sensitive to most of the antibiotics 
tested, including those with a special clinical relevance such as, gentamycin, 
tetracycline, clindamycin, chloramphenicol, and ampicillin, showing MICs equal to, or 
lower than, the breakpoints defined by EFSA (European Food Safety Authority). All the 
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strains were resistant to vancomycin and kanamycin, which are intrinsic properties of 
the L. salivarius species. None of the supernatants obtained from the L. salivarius strains 
generated phage-related inhibition halos or plaques of lysis on lawns of any of indicator 
strains tested in this Thesis. The L. salivarius strains neither produced biogenic amines 
nor harboured the genes required for the biosynthesis of this type of compounds. 
 Globally, L. salivarius V4II-90 was the strain that showed the best results as a 
candidate for future clinical trials. Subsequently, its potential acute and repeated dose (4 
weeks) oral toxicity was evaluated in a rat model; in addition, the potential translocation 
of this strain to blood and some organs was also investigated in the same animal model. 
 In the acute (limit test) study, 24 rats (12 males, 12 females) were distributed into 
two groups of 6 males and 6 females each. Each rat received skim milk (500 μl) orally 
(control group or Group 1), or a single oral dose of 1  1010 colony-forming units (cfu) 
of L salivarius V4II-90 dissolved in 500 μl of skim milk (treated group or Group 2). 
Animals were checked for clinical signs and mortality twice a day. At the end of a 14 
days observation period, the rats were weighed, euthanized and necropsied. No 
abnormal clinical signs, behavioural changes, body weight changes, macroscopic 
findings, or organ weight changes were observed. All animals survived the 2-week 
observation period. There were no statistical differences in body weights among groups. 
Similarly, no statistically significant differences in body weight gain, food and water 
consumption were noted. The hematological and clinical chemistry parameters assessed 
2 weeks after administration of the strain were not significantly different compared with 
those of controls. There were no statistical differences in organ weight or tissue: body 
weight ratios related to the test strain. L. salivarius V4II-90 was not associated with any 
incidence of macroscopic and microscopic changes. Therefore, L. salivarius V4II-90 has 
a low order of acute toxicity and the oral lethal dose (LD50) for male and female rats is 
higher than 1  1010 cfu. 
 The repeated dose (4 weeks) (limit test) study was conducted in 48 rats (24 males, 
24 females) divided in four groups of 6 males and 6 females each (control group or group 
3; treated group or group 4; satellite control group or group 5; and satellite treated group 
or group 6). Rats received a daily dose of either skim milk (groups 3 and 5) or 1  109 
cfu of L. salivarius V4II-90 dissolved in 500 μl of skim milk (groups 4 and 6) orally 
once a day over 4 weeks. Animals were checked for clinical signs and mortality twice a 
day. All rats of the groups 3 and 4 were euthanized and necropsied on day 29. All animals 
of the satellite groups (groups 5 and 6) were kept a further 14 days without treatment to 
detect delayed occurrence of toxic effects. All rats of the groups 5 and 6 were euthanized 
and necropsied on day 42. No mortality was observed. No treatment-related changes in 
the general condition and external appearance were observed in the treated rats. The 
development of the animals during the experimental period corresponded to their species 
and age. There was no significant difference in body weight, body weight gain water 
and food consumption among groups treated with L. salivarius V4II-90 in comparison 
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to the control groups at any time point of the experimental period. All hematology data 
were within normal limits and differences between groups were no observed. Clinical 
chemistry data showed no treatment-related alterations at the end of 4-weeks treatment 
period. Individual values and group mean values were within the physiologic ranges. 
Necropsies did not reveal any gross pathological changes or any differences in organ 
weights in comparison to the corresponding control groups. The no-observed-adverse-
effect level in this repeated dose oral toxicity study was the dose tested, i.e. 1  109 cfu 
of L. salivarius V4II-90. 
 In order to determine changes in the antioxidant defense because of the probiotic 
treatment, liver GSH concentration was determined. No significant differences in liver 
GSH concentration were observed between control and treated groups. This indicates 
that treatment with L. salivarius V4II-90 did not cause oxidative stress to rats and is 
consistent with the absence of bacteremia since no lactobacilli could be isolated from 
blood, liver or spleen of the rats. L. salivarius V4II-90 could be isolated from colonic 
material and vaginal swabs samples of all the treated animals (probiotic groups) at the 
end of the treatment while it could not be detected in any sample from the placebo 
groups. 
 Finally, the efficacy of L. salivarius V4II-90 to eradicate GBS from the intestinal 
and vaginal tracts of pregnant women was evaluated in a human clinical trial. A total of 
57 healthy pregnant women (39 rectal and/or vaginal GBS-positive women; 18 rectal 
and vaginal GBS-negative women at the start of the intervention) participated in this 
study. Volunteers were distributed into 3 groups. All the volunteers in the probiotic 
group (n = 25) were GBS-positive and consumed a daily sachet with ~50 mg of freeze-
dried probiotic (~9 log10 cfu of L. salivarius V4II-90) from week 26 to week 38 of 
pregnancy. Recto-vaginal GBS screening was performed at 28, 32 and 36-38 weeks. 
Placebo subgroup 1 (n=14) included GBS-positive women that were going to receive 
IAP because they had a previous baby that suffered a GBS sepsis. Placebo subgroup 2 
(n=18) included GBS-negative women.  
 All the women of the placebo subgroup 1 remained positive while all the women 
of the placebo subgroup 2 remained negative at the different sampling points. Women 
of the probiotic group also tested positive for GBS at 28 weeks, but an increasing number 
of GBS-negative results appeared in the successive swabs collected until delivery. At 30 
weeks, culture of rectal swabs taken from four women of this group rendered a negative 
result and the number of these samples increased to 18 (72% of the participants) at 38 
weeks. Similar results were obtained culturing vaginal swabs obtained from this group, 
although the proportion of women testing negative for GBS were always slightly higher 
when analyzing the rectal swabs than in the vaginal ones. In this group, the mean value 
for S. agalactiae counts decreased significantly with the administration time of L. 
salivarius V4II-90, from a mean value of 5.14 cfu/mL at 26 weeks (n=25) to 3.80 cfu/mL 
at 38 weeks (n=9). No adverse effects arising from the intake of L. salivarius V4II-90 
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were reported by any of the women that participated in this study. Therefore, the clinical 
trial indicates that L. salivarius V4II-90 is a safe and efficient method to reduce the 
number of GBS-positive women during pregnancy and, therefore, to significantly 
decrease the number of pregnant women receiving IAP during delivery. 
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I. RESUMEN 
 La sepsis neonatal contribuye sustancialmente a la morbilidad y la mortalidad 
neonatal, y constituye un problema de salud pública muy relevante en todo el mundo. 
De acuerdo con la edad en la que se inician los síntomas, la sepsis neonatal se divide en 
sepsis de inicio temprano (EOS) y sepsis de inicio tardío (LOS). Tradicionalmente se ha 
considerado que las EOS refleja infecciones transplacentarias o ascendentes del tracto 
genitourinario materno mientras que las LOS se asocian con infecciones nosocomiales 
o adquiridas en la comunidad, con una incidencia máxima entre los días 10 y 22 después 
del nacimiento. 
 Streptococcus agalactiae (Streptococcus del grupo B, GBS, EGB) es uno de los 
microorganismos más frecuentemente implicados en casos graves de EOS. Mujeres, 
hombres y niños de todas las edades pueden estar colonizados de manera asintomática 
por este microorganismo, que utiliza el tracto gastrointestinal, la vagina y la uretra como 
principales reservorios. La tasa de colonización materna generalmente oscila entre el 12 
y el 28%. El escrutinio recto-vaginal en la semana 35-38 de embarazo, y la subsiguiente 
aplicación de la profilaxis antibiótica intraparto (IAP) en aquellas madres positivas, es 
la estrategia más común para prevenir las infecciones neonatales por GBS. Sin embargo, 
dicha estrategia no previene los abortos y nacimientos prematuros relacionados con el 
GBS puede conducir a tasas crecientes de resistencia a antibióticos entre 
microorganismos clínicamente relevantes, y tiene un impacto muy negativo en la 
adquisición, composición y desarrollo de la microbiota infantil. Las vacunas frente al 
GBS no están disponibles en la actualidad y, por lo tanto, existe la necesidad de 
estrategias alternativas para evitar la colonización por GBS durante el embarazo. En este 
contexto, el objetivo general de esta Tesis Doctoral fue la selección de una cepa 
probiótica segura con la capacidad para erradicar el GBS de los tractos intestinal y 
genitourinario de las mujeres embarazadas. 
 Para ello, el primer objetivo parcial de la Tesis fue el estudio de la microbiota 
vaginal de mujeres embarazadas y no embarazadas, incluyendo la evaluación de las tasas 
de colonización por GBS y la selección preliminar de cepas de lactobacilos a partir de 
las muestras de aquellas mujeres GBS-negativas. Un total de 54 mujeres fértiles sanas 
(30 mujeres no embarazadas y 24 embarazadas) participaron en este estudio. Las 
mujeres no embarazadas proporcionaron 4 muestras de exudado vaginal (días 0, 7, 14 y 
21 de sus ciclos menstruales) mientras que las mujeres embarazadas proporcionaron una 
sola muestra recogida entre las semanas 35-37 de embarazo. Las muestras se cultivaron 
en una amplia variedad de medios de cultivo y la identificación de los aislados se realizó 
por secuenciación mediante PCR del gen 16S rDNA o por MALDI-TOF. El porcentaje 
de mujeres GBS-positivas fue del 19 y del 25% de las mujeres embarazadas y no 
embarazadas, respectivamente. 
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 Un total de 89 aislados pertenecientes al género Lactobacillus fueron aislaron a 
partir de las muestras vaginales y, posteriormente, se sometieron a un genotipado 
mediante RAPD para evitar la duplicación de aislados. Entre ellos, se seleccionaron 10 
cepas de Lactobacillus salivarius para su posterior caracterización sobre la base de los 
siguientes criterios: (1) ausencia de S. agalactiae, Gardnella vaginalis, Candida spp., 
Ureaplasma spp. y Mycoplasma spp en las muestras vaginales a partir de las cuales se 
habían aislado los lactobacilos; (2) presunción cualificada de seguridad (QPS; EFSA); 
y (3) la capacidad de la cepa para crecer rápidamente en caldo MRS bajo condiciones 
aeróbicas (~1 × 106 ufc/ml después de 16 h a 37ºC). 
 Seguidamente, se determinó la capacidad de los lactobacilos seleccionados para 
inhibir el crecimiento de 12 cepas de S. agalactiae, 6 aisladas de sangre o fluido 
cerebroespinal en casos clínicos de sepsis neonatal y las 6 restantes de muestras 
vaginales de mujeres embarazadas. Todas los lactobacilos mostraron capacidad para 
inhibir el crecimiento de las cepas de S. agalactiae. En relación con los compuestos 
antimicrobianos que pudieran ser responsables de dicha actividad, la concentración de 
ácido L-láctico en los sobrenadantes obtenidos a partir de los cultivos en MRS fue 
similar (~10 mg/ml) para todos los lactobacilos. Por el contrario, no se detectó ácido D-
Láctico en los sobrenadantes de las cepas probadas. Todas las cepas acidificaron el 
medio MRS hasta un pH final de ~4 tras 16 h de incubación. Ninguna cepa mostró 
actividad bacteriocinogénica frente a las cepas de S. agalactiae mientras que dos de ellas 
(L. salivarius V4II-90 y V7IV-1) produjeron peróxido de hidrógeno (~7,4 μg/ml). La 
capacidad de las cepas de lactobacilos para formar coagregados grandes y bien definidos 
con cepas de S. agalactiae fue variable dependiendo de cada cepa. 
 Los co-cultivos con S. agalactiae no afectaron al crecimiento de ninguna de las 
cepas de L. salivarius. Por el contrario, la mayoría de las cepas de L. salivarius 
interfirieron, en mayor o menor grado, el crecimiento de las diferentes cepas de S. 
agalactiae incluidas en este ensayo. Entre ellos, L. salivarius V4II-90 mostró la mayor 
capacidad para inhibir el crecimiento de S. agalactiae ya que la presencia de dos de las 
cuatro cepas de S. agalactiae no fue detectable en los co-cultivos tras 6 h de incubación 
a 37ºC mientras que la concentración de las otras dos mostró una disminución notable 
(~2.5 log10) en el mismo periodo. En ningún caso se pudieron detectar estreptococos 
viables cuando los co-cultivos se incubaron durante 24 h. 
 Las cepas de lactobacilos fueron fuertemente adhesivas a células Caco-2 y HT-
29 y, además, todas mostraron adhesión a células epiteliales vaginales. L. salivarius 
V4II-90 fue la cepa que mostró mayor capacidad para adherirse a las células epiteliales, 
tanto intestinales como vaginales. Las cepas de lactobacilos mostraron una capacidad 
variable para adherirse a la mucina porcina siendo nuevamente L. salivarius V4II-90 la 
cepa que mostró la mayor capacidad de adherencia. Ninguna de las cepas fue capaz de 
degradar mucina gástrica in vitro. 
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 La viabilidad de las cepas después de la exposición a condiciones que simulan 
las del tracto gastrointestinal osciló entre un 64 (L. salivarius V4II-90) y un 30% (L. 
salivarius V3III-1). Todas las cepas fueron sensibles a la mayoría de los antibióticos 
evaluados, incluidos aquellos clínicamente relevantes como gentamicina, tetraciclina, 
clindamicina, cloranfenicol y ampicilina, y mostraron CMIs iguales o inferiores a los 
puntos de corte definidos por la EFSA. Todas las cepas fueron resistentes a vancomicina 
y kanamicina, propiedades intrínsecas de la especie L. salivarius. Ninguna de las cepas 
parecía poseer fagos líticos y ninguna de ellas produjo aminas biogénicas ni albergaba 
los genes requeridos para la biosíntesis de este tipo de compuestos. 
 Globalmente, L. salivarius V4II-90 fue la cepa que mostró los mejores resultados 
como candidata para futuros ensayos clínicos. Posteriormente, se evaluó su posible 
toxicidad oral aguda y crónica (4 semanas) en un modelo de rata; además, también se 
investigó la posible translocación de esta en ese mismo modelo. 
 En el estudio de toxicidad aguda, se distribuyeron 24 ratas (12 machos, 12 
hembras) en dos grupos de 6 machos y 6 hembras cada uno. Cada rata recibió leche 
desnatada (500 μl) por vía oral (grupo control o Grupo 1), o una dosis oral única de 1 × 
1010 ufc de L salivarius V4II-90 disuelto en 500 μl de leche desnatada (grupo tratado o 
grupo 2). La posible presencia de signos clínicos y mortalidad se evaluó dos veces al 
día. Al final de un período de observación de 14 días, las ratas fueron pesadas, 
sacrificadas mediante eutanasia y sometidas a necropsia. No se observaron signos 
clínicos anormales, cambios en el comportamiento, cambios en el peso corporal, 
hallazgos macroscópicos anómalos o cambios en el peso de los órganos. Todos los 
animales sobrevivieron el período de observación de 2 semanas. No hubo diferencias en 
el peso corporal entre los dos grupos. Del mismo modo, no se observaron diferencias 
estadísticamente significativas en el consumo de alimentos y de agua. Los parámetros 
hematológicos y bioquímicos evaluados 2 semanas después de la administración de la 
cepa no fueron significativamente diferentes en comparación con los de los controles. 
La administración de L. salivarius V4II-90 no se asoció con cambios macroscópicos o 
microscópicos en los órganos de los animales. Por lo tanto, L. salivarius V4II-90 tiene 
una toxicidad aguda muy baja y la dosis letal oral (DL50) para ratas es superior a 1 × 10
10 
cfu. 
 El estudio de toxicidad a dosis repetidas (4 semanas) se realizó con 48 ratas (24 
machos, 24 hembras) divididas en cuatro grupos de 6 machos y 6 hembras cada uno 
(grupo control o grupo 3; grupo tratado o grupo 4; grupo control satélites o grupo 5, y 
grupo tratado satélite o grupo 6). Las ratas recibieron una dosis diaria de leche desnatada 
(grupos 3 y 5) o 1 × 109 ufc de L. salivarius V4II-90 disueltos en 500 μl de leche 
desnatada (grupos 4 y 6) por vía oral una vez al día durante 4 semanas. Todas las ratas 
de los grupos 3 y 4 fueron sacrificadas y necropsiadas el día 29. Todos los animales de 
los grupos satélites (grupos 5 y 6) se mantuvieron otros 14 días sin tratamiento para 
detectar la aparición tardía de posibles efectos tóxicos. No se observaron cambios 
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relacionados con el tratamiento en el estado general o la apariencia externa en las ratas 
tratadas. El desarrollo de los animales durante el período experimental correspondió a 
su especie y edad. No hubo diferencias significativas en el peso corporal, el aumento de 
peso corporal, el consumo de agua y el consumo de alimentos entre los grupos tratados 
con L. salivarius V4II-90 en comparación con los grupos control. Todos los datos 
hematológicos y de bioquímica clínica se encontraron dentro de los límites normales al 
final del período de tratamiento de 4 semanas. Las necropsias no revelaron ningún 
cambio patológico ni ninguna diferencia en el peso de los órganos en comparación con 
los grupos control correspondientes. El nivel de efecto adverso no observado en este 
estudio de toxicidad oral a dosis repetidas fue a la dosis probada, es decir, 1 × 109 cfu 
de L. salivarius V4II-90. 
 Tampoco se observaron diferencias significativas en la concentración de GSH 
hepático entre los grupos control y los tratados. Esto indica que el tratamiento con L. 
salivarius V4II-90 no causó estrés oxidativo a las ratas y es consistente con la ausencia 
de bacteriemia ya que no se pudieron aislar lactobacilos de la sangre, hígado o bazo de 
las ratas tratadas. L. salivarius V4II-90 se pudo aislar de muestras vaginales y rectales 
de todos los animales tratados al final del tratamiento, mientras que no se pudo detectar 
en ninguna muestra de los grupos control. 
 Finalmente, se evaluó la eficacia de L. salivarius V4II-90 para erradicar GBS del 
tracto intestinal y vaginal de mujeres embarazadas sanas. Un total de 57 mujeres 
embarazadas sanas (39 GBS-positivas y 18 GBS-negativas al inicio de la intervención) 
participaron en el estudio. Las voluntarias fueron distribuidas en 3 grupos. Todas las 
voluntarias del grupo probiótico (n = 25) eran GBS-positivas y consumieron un sobre 
diario con ~50 mg de probiótico liofilizado (~9 log10 cfu de L. salivarius V4II-90) desde 
la semana 26 hasta la semana 38 de embarazo. El cribado de GBS recto-vaginal se 
realizó a las 28, 32 y 36-38 semanas. El subgrupo placebo 1 (n = 14) incluyó mujeres 
con GBS-positivas que iban a recibir IAP durante el parto debido a que tuvieron un niño 
anterior que sufrió una sepsis neonatal por GBS. El subgrupo placebo 2 (n = 18) incluyó 
a las mujeres GBS-negativas. 
 Todas las mujeres del subgrupo placebo 1 siguieron siendo GBS-positivas y 
todas las mujeres del subgrupo placebo 2 GBS-negativas en todos los puntos de 
muestreo. Las mujeres del grupo probiótico también seguían siendo GBS-positivas a las 
28 semanas pero, a partir de ese momento, el número de GBS-negativas fue creciendo 
hasta la semana 38, en la que so tomó la última muestra. Así, cuatro mujeres de este 
grupo fueron negativas en las muestras rectales a las 30 semanas y su número aumentó 
hasta 18 (72% de las participantes) a las 38 semanas. Resultados similares se observaron 
con las muestras vaginales. En el grupo probiótico, los recuentos de S. agalactiae 
también disminuyeron significativamente durante el periodo de administración de L. 
salivarius V4II-90, desde un valor medio de 5,14 ufc/ml a las 26 semanas (n=25) hasta 
3,80 ufc/ml a las 38 semanas (n=9) Ninguna mujer sufrió efectos adversos derivados de 
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la ingesta de L. salivarius V4II-90. En conclusión, el ensayo clínico indicó que la 
administración de dicha cepa es un método seguro y eficaz para reducir el número de 
mujeres GBS-positivas durante el embarazo y, por lo tanto, para disminuir 
significativamente el número de mujeres embarazadas expuestas a la IAP durante el 
parto. 
 
 
  
 
 
 
 
 
 
 
 
                            II. INTRODUCTION  
  
 
           II. Introduction 
15 
 
II.1. NEONATAL SEPSIS 
Neonatal sepsis is a systemic infection occurring in infants at ≤28 days of life. The 
World Health Organization estimates that 1 million deaths per year (10% of all under-
five mortality) are due to neonatal sepsis and that 42% of these deaths occur in the first 
week of life (Lawn et al., 2005). There are wide disparities in neonatal care between 
high- and low-income countries. In high-income countries the major concerns are the 
high nosocomial infection rates associated to the increasing numbers of extremely 
preterm infants and the potential long term sequela while, in low-income ones, the more 
pressing issues are the high proportion of deliveries in unclean environments and the 
lack of suitable medical support, two facts predisposing to high rates of sepsis and death. 
Other risk factors for neonatal sepsis include prolonged rupture of membranes, preterm 
labor, low birth weight, underlying diseases, failure of early feeding with human 
colostrum and milk, and genetic factors, such as the polymorphism in immunity-
associated genes (Schuchat et al., 2000). 
Neonatal sepsis contributes substantially to neonatal morbidity and mortality, and 
is a major global public health challenge worldwide (Qazi and Stoll, 2009). According 
to the age of onset, neonatal sepsis is divided into early-onset sepsis (EOS) and late-
onset sepsis (LOS). EOS has been variably defined based on the age at onset, with 
bacteremia or bacterial meningitis occurring at ≤72 h in infants hospitalized in neonatal 
intensive care unit (NICU) versus <7 days in term infants (Vergnano et al., 2011). 
Traditionally, EOS has been considered to reflect transplacental or ascending infections 
from the maternal genitourinary tract, whereas LOS has been generally associated with 
the postnatal nosocomial or community environment, with a peak incidence between 
days 10 and 22 after birth (van den Hoogen et al., 2010). 
Since the early 1980s, epidemiological studies have observed a general reduction 
in EOS, probably due to advances in obstetric and neonatal care. In contrast, the 
incidence of LOS has increased in parallel with the higher survival rates of premature 
infants, especially of those with short gestational ages and/or extremely low or very low 
birth weights in developed countries, indicating the role of hospitalization and life-
sustaining medical devices in the pathogenesis of neonatal LOS. The characteristics of 
the microorganisms causing neonatal sepsis are of primary importance in guiding 
clinical practice, and strategies to prevent and treat them may, in turn, influence the 
pattern of pathogens involved in such infections. In fact, the etiology of neonatal sepsis 
varies with geographical location and changes over time (Ohlsson et al., 1986). 
The microorganisms most frequently involved in EOS, taking in account both term 
and preterm infants together, are Streptococcus agalactiae (group B streptococci, GBS) 
and Escherichia coli, which account for approximately 70% of infections (Simonsen et 
al., 2014). Additional pathogens to consider, which account for the remaining minority 
of cases, are other streptococci (most commonly viridans group streptococci but also 
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Streptococcus pneumoniae), Staphylococcus aureus, Enterococcus spp., other Gram-
negative enteric bacilli (such as Enterobacter spp.), Haemophilus spp., and Listeria 
monocytogenes (Simonsen et al., 2014). However, when only preterm infants are 
considered, the burden of disease attributable to E. coli and other Gram-negative rods 
increases, making Gram-negative sepsis the most common etiology of EOS in this 
population (Hornik et al., 2012). 
In relation to LOS, coagulase-negative staphylococci (CNS) have emerged as the 
predominant etiological agents, accounting for 53–78% of LOS in industrialized 
countries and 35–47% in some developing regions (Hammoud et al., 2012; Tsai et al., 
2014). Globally, CNS are not so virulent as Gram-negative bacteria and fungi, which 
partly explains the lower rates of short-term infectious complications and mortality 
associated with CNS sepsis (Tsai et al., 2014). However, the risk of neurodevelopment 
sequelae, such as cognitive and psychomotor impairment, cerebral palsy, and vision 
impairment was independent of the type of pathogen, indicating that CNS are capable 
to exert a long-term detrimental effect on the host, particularly on the most immature 
infants with a birth weight <1,000 g (Stoll et al., 2004). Recent data shows that CNS, 
predominantly Staphylococcus epidermidis, is highly variable in genetic background 
and can acquire pathogenic determinants, such as the ability to form biofilms and 
antimicrobial resistance in order to adapt to the nosocomial environment (Lepainteur et 
al., 2013; Dong and Speer, 2014). Gram-negative bacilli responsible for neonatal LOS 
are mainly E. coli, Klebsiella spp., Serratia spp., Enterobacter spp. and Pseudomonas 
spp. (Dong and Speer, 2014). In addition, fungi (especially Candida spp.) are reported 
to be major LOS pathogens in some regions, particularly in extremely low weight 
preterm neonates (Leal et al., 2012). 
The distribution pattern of causative pathogens varies across regions and may 
change over time within the same hospital due to demographic characteristics of 
patients, host and environmental microbiota and the policy of feeding and antibiotic use. 
It should be noted that the wide (and often empirical) use of broad-spectrum antibiotics 
in the past decades has contributed to an increasing incidence of multidrug (MDR)-
resistant Gram-negative bacilli, which account for approximately 20% of bacteremia 
cases, and are associated with a 2.8-fold increase in neonatal mortality rate when 
compared to cases of sepsis caused by non-MDR strains (Tsai et al., 2014). 
Globally, preterm birth is a significant contributor to neonatal death. Every year, 
approximately 6 000 000 births are preterm, and more than 500 000 neonates die due to 
prematurity, accounting for 44% of all deaths under the age of 5 years (Liu et al., 2015; 
Mokdad et al., 2016). The majority of early preterm births are due to microbial infection 
(Romero et al., 2014), and approximately 10% are attributable to GBS (Hitti et al., 2001; 
DiGiulio et al., 2008; Han et al., 2009). 
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II.2. Streptococcus agalactiae 
II.2.1. Historical perspective and general characteristics 
Streptococcus agalactiae (also known as group B streptococcus or GBS) is 
a Gram-positive coccus with a tendency to form chains. It is a beta-hemolytic, catalase-
negative, and facultative anaerobe bacteria. In general, GBS is a harmless commensal 
bacterium being part of the human microbiota colonizing the gastrointestinal and 
genitourinary tract of up to 30% of healthy human adults (asymptomatic carriers). 
Nevertheless, under certain circumstances, GBS can cause severe invasive infections.  
S. agalactiae is the species designation for streptococci belonging to group B of 
the Lancefield classification. GBS is surrounded by a capsule composed of 
exopolysaccharides. The species is subclassified into ten serotypes (Ia, Ib, II–IX) 
depending on the immunologic reactivity of their polysaccharide capsule. This is why 
the plural term group B streptococci (referring to the serotypes) and the singular term 
group B streptococcus (referring to the single species) are both commonly encountered. 
GBS grows readily on blood agar plates as colonies surrounded by a narrow zone 
of β-hemolysis although there are non-hemolytic strains. GBS is characterized by the 
presence in the cell wall of the antigen group B of Lancefield classification that can be 
detected directly in intact bacteria using latex agglutination tests. Before the availability 
of PCR and MALDI-TOF as the main techniques for bacterial identification, the CAMP 
test was also another important test for identification of GBS. The CAMP factor 
produced by GBS acts synergistically with the staphylococcal β-hemolysin inducing 
enhanced hemolysis of sheep or bovine erythrocytes. GBS is also able to hydrolyze 
Hippurate and this test was also used to identify presumptively GBS. Hemolytic GBS 
strains produce an orange-brick-red non-isoprenoid polyene pigment (granadaene) when 
cultivated on Granada medium that allows its straightforward identification.  The GBS 
properties that are relevant for laboratory identification of GBS have been reviewed 
recently (Rosa-Fraile and Spellerberg, 2017). 
GBS was first identified in 1887 as a cause of bovine mastitis (Nocard and 
Mollereau, 1887). Later it was isolated from the human vagina of asymptomatic carriers 
(Lancefield and Hare, 1935) and associated with cases of human disease (Fry, 1938). 
The first report of GBS sepsis in a neonate did not appear until 1964 (Eickhoff et al., 
1964). Since the 1970s, GBS is considered one of the main risk factors for preterm birth 
(Allen et al., 1999; Lawn et al., 2010) and one of the most common causes of neonatal 
infectious morbidity and mortality in Europe, North America and Australia (McCracken, 
1973; Bergqvist, 1974; Lloyd and Reid, 1976; Schröder and Paust, 1979; Allardice et 
al., 1982; Vesikari et al., 1989; Fliegner and Garland, 1990; Stoll et al., 2011; Le Doare 
and Heath, 2013). 
II. Introduction 
18 
 
GBS serotypes Ia, II, III and V are responsible for early onset episodes caused by 
this species (Harrison et al., 1998; Zaleznik et al., 2000; Weisner et al., 2004); In 
contrast, late onset disease is caused predominantly by serotype III (Le Doare and Heath, 
2013)]. Cases occurring later in infancy than 90 days are also described, but rare, and 
generally associated with extreme prematurity. In 1973, Baker and Barrett demonstrated 
that whilst all GBS serotypes were capable of causing neonatal infection, type III isolates 
were significantly increased amongst infants with GBS meningitis. GBS multilocus 
sequence typing (MLST) using a global collection of isolates demonstrated that capsular 
serotype does not strictly follow sequence type (ST) and that a single, bovine-derived 
ST (ST-17), appears to be overrepresented in neonatal disease (Bisharat et al. 2004). 
Further work from the USA and the UK determined that ST-17 in types II and III GBS 
are closely related to ancestral bovine isolates (Jones et al., 2006; Bohnsack et al., 2008). 
This sequence type appears to be associated with neonatal disease, irrespective of the 
capsular serotype, but not with adult disease (Jones et al., 2006).  
In the USA and Europe, invasive GBS-serotypes are predominantly Ia, Ib, II, III 
and V (Baker and Kasper, 1976; Baker et al., 1978; Lin et al., 2001; Lin et al., 2004) 
whilst a Gambian study reported serotype-V predominance (Suara et al., 1998). The 
recent global review of invasive isolates showed that serotype III was the most 
frequently identified serotype in all regions with available data (48.9%), followed by 
serotypes Ia (22.9%), V (9.1%), Ib (7.0%) and II (6.2%). There was little change in ST 
distribution over the last 30 years (Edmon et al., 2012). There was however, little data 
from low/middle income countries. 
II.2.2. GBS colonization and mother-to-infant transmission 
Women, men and children of all ages in both developed and developing countries 
can be colonized with GBS without having any symptoms. The gastrointestinal tract, 
vagina and urethra serve as reservoirs for GBS. In other words, S. agalactiae is a 
pathobiont that is often part of the normal microbiota found in the gastrointestinal and 
genitourinary tracts of healthy women (Katz et al., 1993; Blumberg et al., 1996; Wessels 
et al., 1997; Verani et al., 2010; Edwards et al., 2011).   
Pioneer studies showed that the maternal colonization rate was, approximately, 
18% (ranging from 12 to 28%), independently of the countries or socio-economical 
status of the screened women (Ohlsson, 1992; Stoll and Schuchat, 1998). A systematic 
review on the prevalence of maternal GBS colonization in European countries between 
1996 and 2006 revealed GBS vaginal colonization rates ranging from 6.5% to 36%, with 
one-third of the studies reporting rates of 20% or greater. The carriage rates in Southern 
Europe oscillated from 6.5 to 32% (Barcaite et al., 2008) while they have been reported 
to oscillate from 12 to 20% in Spain (Alos et al., 2012). 
A recent systematic review and meta-analyses found that adjusted estimate for 
maternal GBS colonization worldwide was 18% (95% confidence interval [CI], 17%–
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19%), with regional variation (11%–35%), and lower prevalence in Southern Asia 
(12.5% [95% CI, 10%–15%]) and Eastern Asia (11% [95% CI, 10%–12%]) (Russell et 
al., 2017). Bacterial serotypes I–V account for 98% of identified colonizing GBS isolates 
worldwide. Serotype III, associated with invasive disease, accounts for 25% (95% CI, 
23%–28%), but is less frequent in some South American and Asian countries (Russell 
et al., 2017). Serotypes VI–IX are more common in Asia GBS colonizes pregnant 
women worldwide, but prevalence and serotype distribution vary, even after adjusting 
for laboratory methods. Lower GBS maternal colonization prevalence, with less 
serotype III, may help to explain lower GBS disease incidence in regions such as Asia 
(Russell et al., 2017). 
The transmission rate for GBS colonization from mother to infant varied from 35% 
(England) to 69% (Brazil). However, only 1-2% of the neonates born from non-treated 
GBS-positive women develop GBS sepsis (Baker and Edwards, 1995). Recently, it has 
been estimated that, of 140 million live births in 2015, there were 21.3 million (UR, 
16.4–27.0 million) infants exposed to maternal GBS colonization at delivery (Seale et 
al., 2017). 
Women who are vaginally colonized during pregnancy are at risk for ascending 
infection or transmission of GBS to the newborn during delivery. Ascending infection 
is a widely accepted route by which vaginal bacteria move from the vagina, through the 
cervix, and into the uterus and penetrate gestational tissues (Figure 1). Once GBS has 
invaded the amniotic cavity, or come into contact with the placenta, there is the potential 
for chorioamnionitis or inflammation of the placental membranes that is frequently 
associated with preterm births and stillbirths (Romero, 2014) (Figure 2). The bacterial 
and host determinants that promote GBS vaginal colonization, ascending infection, and 
adverse perinatal outcomes are poorly understood (see next section). 
In addition to asymptomatic carriage, GBS can also cause maternal infections, 
including urinary tract infections, vulvovaginitis, cervical dysplasia, endometritis, intra-
amniotic infection and wound infections (Figure 2). Recently, the first review assessing 
invasive maternal GBS disease found an incidence of 0.38 (95% CI, .28–.48) per 1000 
pregnancies and 0.23 (95% CI, .09–.37) per 1000 maternities in high-income contexts 
(Hall et al., 2017). This maternal incidence is lower than the incidence of neonatal GBS 
disease (0.42 [95% CI, .30–.54]) in developed countries (Madrid et al., 2017), but it is 
likely to be an underestimate due to underreporting and/or low case ascertainment. 
Anyway, the risk of mortality and morbidity for women with maternal GBS disease 
appears low in the developed region (case fatality risk, 0.19% [95% CI, –0.25% to 
0.62%]) (Hall et al., 2017). 
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Figure 1. Ascending GBS infection. GBS vaginal colonization increases the risk 
of ascending infection during pregnancy. Ascending GBS infection during pregnancy 
involves bacterial trafficking from the vagina, ultimately leading to bacterial invasion of 
placental membranes (chorion and amnion), the amniotic cavity, and the fetus. GBS 
expresses a number of virulence factors that promote vaginal colonization, adhesion and 
invasion of host cells, and for either activation or suppression of inflammatory 
responses. These factors increase the risk of ascending infection, fetal injury, or preterm 
birth. Source: Vornhagen et al. (2017). 
II.2.3. Risk factors for maternal GBS colonization, transmission of GBS from 
mother to baby, neonatal GBS colonization or GBS neonatal disease 
Numerous maternal, obstetric and neonatal factors have been associated with or 
identified as risk factors for maternal GBS colonization, transmission of GBS from 
mother to baby, neonatal GBS colonization or neonatal disease with GBS (both EO and 
LO). Although some of these have provided useful insights into the pathophysiology of 
perinatal GBS disease, many of them are interrelated, studies have produced 
contradictory results and relatively few factors are sufficiently robust or clinically 
relevant enough to guide prevention strategies. 
The gastrointestinal tract is the primary reservoir of GBS and the source of vaginal 
colonization in women. Local hygiene or sexual practices can increase the risk for 
vaginal colonization. Other factors associated with maternal colonization include 
ethnicity (women of black race), use of tampons or intrauterine devices, obesity, absence 
of lactobacilli in the gastrointestinal flora and preterm delivery (Parry et al., 1998; 
Schuchat, 1999; Oddie and Embleton, 2002). GBS bacteriuria during pregnancy is 
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associated with heavy colonization, a further risk factor for perinatal transmission 
(Persson et al., 1985; Kessous et al., 2012). Mothers with GBS bacteriuria demonstrate 
a higher incidence of adverse obstetric outcomes: habitual abortion, intrauterine growth 
restriction, preterm labour, chorioamnionitis and premature rupture of membranes 
(Kessous et al., 2012). Factors associated with an increased risk of neonatal colonization 
include maternal colonization, male sex, black race, prolonged rupture of membranes, 
prematurity, low levels of maternal anti-GBS antibodies and intrapartum fever.  
II.2.4. Neonatal disease by GBS 
GBS disease is not restricted to newborns, but its greatest impact, both in terms of 
severity and incidence, is in the neonatal period and up to the first 90 days of life. Early 
onset (EO) GBS disease is usually defined as infection presenting in the first six days of 
life and accounts for approximately 60–70% of all GBS disease. As stated above, GBS 
serotypes Ia, II, III and V are responsible for most EO disease (Harrison et al., 1998; 
Zaleznik et al., 2000; Weisner et al., 2004). Maternal carriage of GBS in the 
gastrointestinal and/or genital tracts is a pre-requisite for EO disease, vertical 
transmission occurring during or just prior to birth. In developed countries an estimated 
20–30% of pregnant women are colonized with GBS (Bergeron et al., 2000; Jones et al., 
2006b), approximately 50% of their babies become colonized and 1% progress to 
develop invasive disease. Disease may occur rapidly; signs are evident at birth or within 
12 h in over 90% of cases (98% within the first 12 h) and presentation is typically with 
pneumonia or sepsis (Heath et al., 2004). In contrast, late-onset (LO) disease is caused 
predominantly by serotype III, is acquired perinatally, nosocomially or from community 
sources, and in up to 50% of cases presents with meningitis (Easmon et al., 1981; 
Hastings et al., 1981; Weisner et al., 2004; Heath et al., 2004). Cases occurring later in 
infancy than 90 days are also described, but rare, and generally associated with extreme 
prematurity (Schuchat et al., 1990; Zangwill et al., 1992; Lin et al., 2003; Verani et al., 
2010; Stoll et al., 2011). 
The burden of neonatal GBS disease can be defined in terms of its incidence, 
morbidity and mortality. Multistate, population-based, active surveillance in the USA in 
1990 identified an EO disease rate of 1.4 per 1000 live births and a LO rate of 0.4 per 
1000 births (Zangwill et al., 1992). This equated to 7600 cases and 310 deaths per year 
in the USA. Both EO and LO GBS disease occurred at significantly higher rates amongst 
African-American compared to Caucasian infants, as well as amongst low-birthweight 
or preterm infants (Schuchat et al., 1990; Zangwill et al., 1992). In the UK, a multi-
center study carried out between 1977 and 1978 recorded an incidence of invasive GBS 
disease in infants < 2 months of age of 0.3 cases per 1000 live births (Stringer et al., 
1981). Through the late 1990s studies from different centers in England reported 
incidence figures ranging from 0.6 to 1.2 cases per 1000 live births (Moses et al., 1998; 
Bignardi et al., 1999; Beardsall et al., 2000). In 2000–2001, national surveillance was 
enhanced; the overall incidence was 0.72 per 1000 live births (95% confidence interval 
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0.66–0.78), 0.47 per 1000 (0.42–0.52) for EO disease and 0.25 per 1000 (0.21–0.28) for 
LO disease (Heath et al., 2004). Regional variation was marked; the incidence in 
Scotland was 0.42 per 1000 whilst in Northern Ireland it was 0.9 per 1000 live births. 
 
Figure 2. Maternal, fetal and infant disease oucomes after a GBS infection; 
source: Lawn et al. (2017).  
As with other studies, infants of low birthweight (<1500 g) were shown to have 
the highest rates of GBS disease (Heath et al., 2004). National population-based 
surveillance studies have defined the incidence <3 months of age in a number of 
developed countries including Portugal (2001–2005, 0.54/1000), Finland (1985–1994, 
0.76/1000) and Germany (2001–2003, 0.47/1000) (Le Doare and Heath, 2013).  
Hospital based surveillance studies (which may be biased towards higher risk 
pregnancies) have generally yielded higher incidences such as in Australasia (EO GBS 
(<48 h of age): 2/1000 in 1991–1993, 1.3/1000 in 1993–1995, 0.5/1000 in 1995–1997) 
(Isaacs and Royle, 1999) and Spain (EO GBS (<3 days of age): 1.1/1000, 1996–1997; 
0.7/1000, 2000–2001) (López Sastre et al., 2005). Edmonds et al. recently conducted a 
systematic review to define the current global incidence of GBS disease in infants under 
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3 months (Edmon et al., 2012). The analysis was confined to data since the year 2000 
and estimated an overall incidence of 0.53 (0.44–0.62) in the European region, 0.67 
(range 0.54–0.80) in the Americas and 0.15 (range−0.03 to 0.07) in Australasia.  
GBS disease is also associated with significant morbidity and mortality. GBS 
meningitis, in particular, results in long term neurodevelopmental impairment. Bedford 
et al. (2001) described 5-year neurodevelopmental outcomes following an acute episode 
of neonatal meningitis in 98 children, of whom 13% had severe, 17% moderate and 18% 
mild disability at 5 years. Overall 50% of those with GBS meningitis had 
neurodevelopmental impairment at 5 years of age. A recent small series from the USA 
has shown similar rates of sequalae (up to 44% with moderate–severe impairment) 
(Libster et al., 2012). 
Case fatality rates for GBS disease are estimated at between 9% in Oxford (1990–
1996) (Moses et al., 1998) and 15% in London (1990–1999) (Mifsud et al., 2004), with 
a UK national figure of 10% in 2000–2001 (Heath et al., 2004). In the USA between 
1993 and 1998 the quoted case fatality rates for EO and LO disease were 4.7% and 2.8% 
respectively (Schrag et al., 2000). Case fatality rates were significantly higher in 
premature infants (<33 weeks gestation) 15.2% vs. 6.4% for term infants (>37 weeks 
gestation), relative risk of 6.7 in EO GBS (21, 39). Other national studies have revealed 
case fatality rates of 6.6% in Portugal, 4.3% in Germany and 8% in Finland (Le Doare 
and Heath, 2013). Overall current case fatality rates by region as estimated in the 
Edmond meta-analysis are 0.07 (range 0.04–0.1) in Europe and 0.11 (0.06–0.16) in the 
Americas (Edmon et al., 2012). 
II.2.5. Mechanisms for GBS infection during pregnancy  
It is long known that GBS vaginal colonization during pregnancy is associated 
with increased rates of neonatal infection (Hoogkamp-Korstanje, et al., 1982), recurrent 
maternal colonization (Cheng et al., 2008), early-term birth (weeks 37–38, and 6 days 
of gestation) (Mitchell et al., 2013), preterm birth (weeks 14–36, and 6 days of gestation) 
(Lawn et al., 2010), and stillbirth (Monari et al., 2013). GBS is thought to be transmitted 
from person to person via multiple routes, including fecal–oral, sexual, and vertical 
transmission (Manning et al., 2004). In the same woman, the close proximity of the 
vagina and rectum likely enables GBS trafficking from intestinal microbiota into the 
vagina. Once GBS enters the vagina, colonization requires the bacteria to overcome a 
number of challenges, including: physical barriers created by the mucus and epithelial 
layers, low environmental pH, antimicrobial peptides, antibodies, microbicidal immune 
cells, and a vaginal microbiome dominated by lactobacilli.  
How a non-motile bacterium, such as GBS, manages to ascend into the uterus 
while evading host responses is not completely understood. The process of ascending 
infection is challenging to study, as in vitro models are unsuitable, and in vivo models 
are limited in their ability to recapitulate human pregnancy (McDuffie and Gibbs, 1994; 
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De Clercq et al., 2013). Despite these limitations, a number of animal models, including 
pregnant mice and non-human primates, have been developed to study the mechanisms 
of ascending GBS infection (Ancona and Ferrieri, 1979; Adams Waldorf et al., 2011; 
Randis et al., 2014; Kolar et al., 2015; Vornhagen et al., 2016; Boldenow et al., 2016; 
Kothary et al., 2017), shedding new light on these complicated processes. While studies 
using these models have revealed a novel insight into the role of virulence factors that 
contribute to ascending infection, more research is needed to fully understand the 
process of ascending GBS infection and adverse neonatal outcomes.  
The host immune response evoked in the placenta in response to GBS infection is 
a key determinant of perinatal outcome, microbial invasion of the amniotic cavity 
(MIAC), and fetal injury. A variety of fetal and maternal cells within the placental 
membranes are capable of pathogen recognition for initiating and sustaining an 
inflammatory response; these include amniotic epithelial cells, fetal macrophages, 
decidual macrophages, decidual NK cells, and neutrophils (Singh et al., 2005; Duriez, 
et al., 2014; Boldenow et al., 2015; Whidbey et al., 2015; Boldenow et al., 2016). While 
a severe infection leading to early preterm birth is typically associated with MIAC, an 
inflammatory response confined to the placenta even in the absence of MIAC is also 
sufficient to induce preterm labor in some cases (Adams Waldorf et al., 2011). 
Interestingly, intra-amniotic administration of cytokines, such as tumor necrosis factor-
alpha (TNF-α) and inter-leukin (IL)-1b alone (i.e., without any bacteria), can induce 
preterm labor in pregnant nonhuman primates (Sadowsky et al., 2006), and IL-1a, IL-
1b, IL-6, and IL-8 drive infection-associated preterm birth in humans (reviewed by 
Cappelletti et al., 2016). Thus, placental inflammation induced by bacterial infection is 
likely a critical component of infection-associated preterm birth. Also, bacterial 
suppression of placental immune responses could contribute to MIAC, leading to 
stillbirths. A better under-standing of the mechanisms by which in utero GBS infections 
drive preterm births or stillbirths may lead to the development of new interventions to 
reduce the burden of disease. Key bacterial and host factors that have been identified to 
influence GBS colonization and perinatal infection are described in the next section.  
II.2.6. Bacterial factors that promote GBS vaginal colonization, ascending 
infection, and preterm birth  
II.2.6.1. GBS adhesins to extracellular matrix (ECM) proteins 
As an opportunistic commensal constituting a part of the intestinal and vaginal 
physiologic microbiota, GBS colonization, persistence, translocation, and invasion of 
host barriers are largely dependent on their adherence abilities to host cells and ECM 
(Singh et al., 2012; Landwehr-Kenzel and Henneke, 2014). Functionally characterized 
adhesins mediating GBS adherence and/or invasion within the host are the fibrinogen-
binding proteins (Fbs), the laminin-binding protein (Lmb), the group B streptococcal 
C5a peptidase (ScpB), the streptococcal fibronectin-binding protein A (SfbA), and the 
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GBS immunogenic bacterial adhesin (BibA). In addition, surface-protruding structures 
comprised of multiples genes like pili are considered as essential adhesins in promoting 
GBS colonization, persistence, biofilm production, and central nervous system invasion. 
Major adhesins mediating GBS interaction with host cells are depicted in Figure 3.  
Figure 3. Major adhesins mediating S. agalactiae (GBS) interaction with host cells. 
Source: Shabayek and Spellerberg (2018). 
Up to date, five Fbs have been characterized in GBS; FbsA (Schubert et al., 2004), 
FbsB (Gutekunst et al., 2004), the serine-rich repeat glycoproteins Srr1 and Srr2 (Seo et 
al., 2012, 2013), and recently FbsC or BsaB (Buscetta et al., 2014; Jiang and Wessels, 
2014). In general, invasive GBS isolates display stronger fibrinogen-binding abilities in 
comparison to colonizing ones (Rosenau et al., 2007). FbsA was mainly shown to 
promote adherence (Schubert et al., 2004) whereas FbsB was shown to be required for 
invading human cells (Gutekunst et al., 2004). Srr1 and Srr2 were reported to mediate 
invasion of microvascular endothelial cells (Seo et al., 2012, 2013). Additionally, Srr1 
was demonstrated to promote vaginal colonization and persistence, since a Srr1-
deficient mutant displayed reduced persistence in a mouse GBS vaginal colonization 
model (Sheen et al., 2011). FbsC was recently characterized to promote invasion of 
epithelial and endothelial barriers. FbsC deletion mutant of GBS displayed a drastic 
reduction in abilities for adherence, invasion and biofilm formation. Besides, virulence 
abilities of FbsC deletion mutant were impaired in murine infection models (Buscetta et 
al., 2014). Interestingly, the fibrinogen-binding abilities of the hypervirulent CC17 
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clones are mainly attributable to FbsB more than FbsA. Deletion mutants 
of fbsB displayed 78–80% reduction in their binding abilities vs. 49–57% as encountered 
with fbsA deletion mutants of CC17 strains (Al Safadi et al., 2011). Accordingly, the 
relative transcription level of fbsB was up to 12.7-fold higher than fbsA gene in CC17 
stains (Al Safadi et al., 2011). Moreover, Srr2 was highly expressed and exclusively 
detected in ST-17, however, Srr1 was absent (Seifert et al., 2006; Seo et al., 2013). 
Furthermore, CC17 strains are devoid of FbsC. The fbsC gene is not adequately 
expressed in CC17 strains because of a lineage-dependent frameshift mutation (Buscetta 
et al., 2014). 
In addition to the Fbs family, the Lmb adhesin appears to have a pronounced role 
in bacterial tropism of the central nervous system. Spellerberg et al. (1999) reported 
Lmb to be essential for GBS colonization of damaged epithelium and subsequent 
translocation into the bloodstream. This role was later confirmed by Tenenbaum et al. 
(2007) as they demonstrated mutation of the lmb gene to result in a dramatic reduction 
in GBS invasion of the brain microvascular endothelial cells. In consistence, Al Safadi 
et al. (2010) displayed higher expression levels of Lmb in GBS strains associated with 
meningitis in comparison to other isolates whereas the expression levels of other ECM-
binding proteins, such as ScpB mediating fibronectin binding ability, remained 
unchanged. 
ScpB or the group B ScpB is a surface associated serine protease that both 
interrupts complement activation through splitting the neutrophil chemoattractant C5a 
and mediates bacterial binding to fibronectin (Chmouryguina et al., 1996; Bohnsack et 
al., 1997; Cheng et al., 2002; Lindahl et al., 2005). The fibronectin binding ability 
conferred by the scpB gene appears to be involved in cellular adherence and invasion. 
In frame deletion mutation of scpB gene significantly reduced invasion of human 
epithelial cells in vitro (Cheng et al., 2002). Strikingly, scpB and lmb genes were found 
to be encoded on a composite transposon where the scpB gene is positioned directly 
upstream of the lmb gene. The scpB-lmb intergenic region has been described as a hot 
spot for integration of the GBS mobile genetic elements GBSil and IS1548 which are 
located in the promoter region of the lmb gene (Franken et al., 2001; Granlund et al., 
2001; Luan et al., 2003, 2005; Broker and Spellerberg, 2004). Al Safadi et al. (2010) 
reported a marked increase in the transcription levels of lmb gene for invasive GBS 
isolates carrying IS1548 in the scpB-lmb intergenic region associated with an increased 
laminin binding ability. However, no influence was observed on the scpB gene. Deletion 
mutation of IS1548 revealed IS1548 to act as an lmb gene up-regulator when compared 
to the wild-type parent strains. Interestingly the ability of GBS to colonize human 
mucosal surfaces seems to be closely linked to the presence of this composite transposon 
carrying scpB and lmb. In a large percentage of bovine strains, the encoded genes are 
absent while the presence in human colonizing strains, as well as invasive strains, is 
close to 100% (Franken et al., 2001; Sørensen et al., 2010; Rato et al., 2013). 
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More recently, a novel GBS fibronectin binding protein has been identified (Mu 
et al., 2014). It was designated as streptococcal fibronectin-binding protein A (SfbA) 
and reported to be highly conserved in GBS mediating cellular invasion but not 
adherence. SfbA was shown to be directly involved in fibronectin binding and human 
brain microvascular endothelial cells invasion. When expressed in recombinant non-
pathogenic Lactococcus lactis, fibronectin binding ability was significantly greater in 
comparison to a SfbA negative control strain. The investigation also demonstrated SfbA 
to be primarily involved in brain microvascular endothelial cells invasion. Infection of 
mice with sfbA mutants resulted in a reduced ability to breach the blood brain barrier 
and subsequent meningitis. This is supported by a study showing SfbA to be crucial for 
invasion of astrocytes which are physically associated with the brain endothelial cells 
(Stoner et al., 2015). Furthermore, SfbA contributes to GBS invasion of vaginal and 
cervical epithelial cells and hence may take part in GBS colonization and niche 
establishment in the vagina (Mu et al., 2014). Another fibronectin binding protein was 
described in 2014 (Jiang and Wessels, 2014), BsaB or the bacterial surface adhesin of 
GBS is a fibronectin and laminin-binding protein which is involved in GBS binding to 
epithelial cells and in biofilm formation. Deletion of bsaB gene and a cotranscribed 
upstream region significantly abrogated GBS adherence to VK2 vaginal epithelial cells 
in vitro and immobilized fibronectin. However, genome and sequence analysis revealed 
BsaB and FbsC as identical proteins encoded by the same gene (Buscetta et al., 2014). 
The obtained results are in agreement with those of Jiang and Wessels (2014), except 
that FbsC or BsaB was found to mediate GBS attachment to fibrinogen instead of 
fibronectin. Hence, BsaB was renamed to FbsC. 
The multitude of GBS adhesins allowing attachment to different ECM, stresses 
the importance of this step in GBS pathogenesis, which was confirmed in different in 
vivo models. In this regard, fibrinogen binding may play an especially important role as 
demonstrated by the presence of numerous fibrinogen binding proteins. These may 
represent a kind of “backup” system in cases where the primary fibrinogen adhesin was 
rendered non-functional. 
II.2.6.2. GBS adhesins to cellular targets 
Besides adherence to ECM, the adhesion to host cells plays an important role in 
the pathogenesis of GBS. An essential adhesin in this context is the GBS immunogenic 
bacterial adhesin (BibA). It is a cell wall-anchored protein which is well-conserved in 
GBS and is involved in bacterial binding to human epithelial cells (Santi et al., 2007, 
2009). A knockout mutant displayed impaired adherence capacity to the lung, intestinal, 
and cervical epithelial cells (Santi et al., 2007). Overexpression of BibA resulted in 
increased adherence to human epithelial cells in recombinant wild-type strains harboring 
a bibA plasmid (Santi et al., 2007). In addition, BibA was reported to aid GBS survival 
in human blood through interfering with the classic complement pathway by binding the 
C4-binding protein and by conferring anti-phagocytic activity against opsonophagocytic 
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killing by human neutrophils (Santi et al., 2007, 2009). A total of four variants of BibA 
(I, II, III, and IV) were described in GBS (Brochet et al., 2006; Santi et al., 2007, 2009). 
Interestingly, variant IV, which was found to be highly similar to the bovine BibA 
counterparts, was exclusively associated with ST-17 strains (Lamy et al., 2006; Santi et 
al., 2009). Thus, BibA seems to be a multifactorial virulence factor in regard to GBS as 
a pathobiont. It contributes to GBS mucosal colonization and adherence to host cells and 
then confers resistance to phagocytic killing at a stage when the switch to invasive GBS 
infection has occurred. 
The GBS hypervirulent adhesin (HvgA) is a novel cell wall anchored protein that 
is specific for the hypervirulent clone ST-17. It was first described (Tazi et al., 2010) as 
being strongly associated with ST-17 causing neonatal meningitis in LO disease. It was 
suggested to promote meningeal tropism in neonates through efficient intestinal 
colonization and subsequent translocation across the intestinal and the blood brain 
barriers. Bypassing intestinal colonization by intravenous infection resulted in a 
significant decrease in the amount of bacteria reaching the central nervous system. HvgA 
was required for intestinal colonization in orally infected mice for meningitis 
development. In addition, HvgA was found to mediate GBS adherence to intestinal 
epithelial cells, choroid epithelial cells and microvascular endothelial cells (Tazi et al., 
2010). Clones expressing HvgA exhibited greater adherence abilities than non-
expressing ones. HvgA thus contributes to colonization as well as invasion of 
hypervirulent clones (Tazi et al., 2010). 
II.2.6.3. GBS pili 
Pili are also crucial for GBS adhesion. Different from their Gram-negative 
counterparts, pili in GBS have been shown to be primarily involved in epithelial cell 
colonization, biofilm formation, translocation, and invasion. Pili are cell-wall anchored 
appendages extending from the bacterial surface. They contain covalently linked 
multimeric motifs that are composed of three pilin proteins, the pilus shaft backbone 
protein (BP) or PilB subunits, and the two ancillary proteins AP1, AP2 located at the 
pilus tip (PilA subunit, the pilus-associated adhesin) and pilus base (PilC subunit, the 
pilus anchor), respectively, (Dramsi et al., 2006; Rosini et al., 2006; Maisey et al., 
2007, 2008; Cozzi et al., 2015). While PilB has been shown to be involved in bacterial 
invasion and paracellular translocation mediating resistance to phagocytic killing and 
virulence, PilA was found contributing to cellular adherence and colonization (Dramsi 
et al., 2006; Krishnan et al., 2007; Maisey et al., 2007, 2008; Pezzicoli et al., 2008; Sheen 
et al., 2011). Three pilus variants named PI-1, PI-2a, PI-2b were reported in GBS 
representing two pilus islands (PI) where PI-2a and PI-2b are variants of the pilus island 
2 (PI-2). All characterized GBS strains harbored at least one variant or a combination of 
two pilus islands (Rosini et al., 2006; Margarit et al., 2009; Springman et al., 2014). PI-
1 pili were also found to play an important role in evasion of innate immunity 
mechanism. They diminished macrophage-mediated phagocytic killing of GBS by 50% 
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with no influence on complement-promoted opsonophagocytic killing by neutrophils 
(Jiang et al., 2012). Strikingly, PI-1 pili do not appear to contribute to bacterial adhesion 
to lung, vaginal or cervical epithelial cells (Jiang et al., 2012). The PI-2a pili were found 
to have a specific involvement in adherence and biofilm formation and not PI or PI-2b 
(Konto-Ghiorghi et al., 2009; Rinaudo et al., 2010). The PI-2b protein, however, was 
demonstrated to increase the intracellular survival in macrophage (Chattopadhyay et al., 
2011). In addition, a special role for pilus type 2b has been suggested in promoting strain 
invasiveness and bacterial host cell interactions. Mutants of pilus 2b possess less 
adherence and invasion capacities for epithelial and endothelial cells (Lazzarin et al., 
2017). Pilus 2b was further identified as important for infection and penetration of the 
blood brain barrier. These results are supported by an investigation of the distribution of 
pilus islands among GBS strains belonging to ST lineages of human and bovine origin 
(Springman et al., 2014). In addition, the distribution of pili islands appears to determine 
the capacity for colonization or invasive infections. Invasive GBS were more likely to 
carry a combination of PI and one of the PI-2 variants in comparison to maternal 
colonizing isolates. Moreover, GBS causing invasive neonatal disease including all CC-
17 strains were harboring PI-1 plus PI-2b. Earlier genomic studies showed pilus type 2b 
to be conserved in the ST-17 hypervirulent clone (Brochet et al., 2006). Interestingly PI-
2b pilus variants are almost exclusively present in bovine GBS isolates. These bovine 
strains mostly lack PI-1, unlike the human isolates which commonly encode the pilus 
PI-1 in association with one of the PI-2 variants (Springman et al., 2014). 
II.2.6.4. Biofilm formation 
Colonization and persistence in different host niches is dependent on the 
adherence capacity of GBS to host cells and tissues. This then facilitates bacterial cell 
aggregation and formation of sessile communities known as biofilms. Bacterial biofilms 
represent well-known virulence factors with a vital role in persistence and chronic 
infections. In the host environment, bacteria are often protected from the immune system 
by building sessile colonies embedded in an extracellular matrix of polysaccharides 
representing the biofilm. For GBS the bacterial capsule and type IIa pili have been 
demonstrated to play an important role in biofilm formation (Konto-Ghiorghi et al., 
2009; Xia et al., 2015). Host environmental conditions are crucial determinants in 
developing bacterial biofilms (Costerton et al., 1999; Lewis, 2005; Nobbs et al., 2009; 
Rosini and Margarit, 2015). Contradictory data are available concerning the 
environmental cues favoring biofilm communities in GBS (Rosini and Margarit, 2015). 
As a normal inhabitant of the vagina, acidic pH seems to be optimal for GBS 
colonization. Early investigations reported enhanced GBS adherence to vaginal 
epithelial cells under low pH in comparison to neutral pH (Zawaneh et al., 1979; Tamura 
et al., 1994). In line with these observations, a significantly higher biofilm production 
of colonizing GBS isolates from pregnant women was demonstrated at pH 4.5 vs. pH 7 
(Ho et al., 2013). Similarly, enhanced biofilm formation of GBS was shown under acidic 
pH conditions in comparison to neutral pH with the strongest biofilm producing GBS 
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isolates belonged to the ST-17 sequence type. In respect to GBS origins, higher 
frequencies of strong biofilm producers were found among neonatal strains in 
comparison to colonizing strains (D’Urzo et al., 2014). However, a recent investigation 
reported invasive GBS belonging to CC17 and CC19 lineages as weak biofilm formers 
while GBS isolated from asymptomatic carriers were found to be strong biofilm 
producers (Parker et al., 2016). One possible explanation for this discrepancy is the 
experimental set up of the study since GBS biofilm formation was tested at neutral pH 
conditions and not under acidic pH. Furthermore, the presence of human plasma was 
shown to promote GBS biofilm formation (Xia et al., 2015). 
In summary, biofilms allow long-term bacterial persistence and protect bacteria 
from recognition by the immune system. For GBS low pH and the presence of plasma 
appear as crucial environmental factors through controlling the expression of bacterial 
surface-associated structures, such as pili and the capsule, which are both involved in 
promoting bacterial biofilm formation. 
II.2.6.5. Hemolytic pigment  
GBS is a b-hemolytic bacterium, and the hemolytic property of GBS is important 
for infection and immune evasion. Hemolytic activity of GBS is due to the ornithine 
rhamnolipid pigment (hereafter referred to as ‘hemolytic pigment’ or ‘pigment’) 
(Whidbey et al., 2013), which is produced by the genes of the cyl operon (Pritzlaff et al., 
2001). Transcription of cyl genes, and therefore production of the hemolytic pigment, is 
negatively regulated by the CovR/S two-component system (also known as CsrR/ S) 
(Lamy et al., 2004; Jiang et al., 2005; Whidbey et al., 2013). Consequently, deletion of 
covR/S renders GBS hyperhemolytic and hyperpigmented (Lamy et al., 2004; Jiang et 
al., 2005; Whidbey et al., 2013). Conversely, deletion of the cylE gene, which encodes 
an N-acyltransferase necessary for pigment production (Whidbey et al., 2013), renders 
GBS nonpigmented and nonhemolytic (Pritzlaff et al., 2001; Whidbey et al., 2013). 
Identification of hemolytic, hyperhemolytic and nonhemolytic GBS strains in human 
cases allowed for a greater understanding of the role of hemolysin in GBS infection.  
The hemolytic pigment promotes GBS penetration of human placenta 
(chorioamniotic membranes) and induces loss of barrier function in human amniotic 
epithelial cells (Whidbey et al., 2013). Furthermore, hyperpigmented GBS strains were 
isolated from either the amniotic fluid or chorioamniotic membranes of women in 
preterm labor (Whidbey et al., 2013). Randis et al. (2014) also noted decreased bacterial 
dissemination, fetal injury, and preterm birth in mice that were vaginally inoculated with 
non-hemolytic GBS (i.e., GBS lacking cylE). Recently, it has been shown that the 
increased hemolytic pigment expression accelerated GBS invasion of the amniotic 
cavity with significant uterine contractions and inflammatory responses indicative of 
preterm labor in a nonhuman primate model (Boldenow et al., 2016). Although infection 
with hyperpigmented GBS induced the formation of neutrophil extracellular traps 
           II. Introduction 
31 
 
(NETs) in chorioamniotic membranes of nonhuman primates (Boldenow et al., 2016), 
these GBS strains were resistant to the antimicrobial activity of NETs, likely through 
increased pigment-mediated antioxidant activity (Liu et al., 2004). Formation of NETs 
in response to GBS infection was also observed in murine models of colonization (Carey 
et al., 2014) and ascending infection (Kothary et al., 2017). Collectively, these studies 
indicate a role for the hemolytic pigment in promoting GBS dissemination in uterine, 
placental, and fetal tissues during pregnancy.  
The GBS hemolytic pigment also affects vaginal colonization. Absence of the 
hemolytic pigment reduced the ability of GBS to successfully colonize the vagina, 
possibly due to increased susceptibility to neutrophil clearance (Randis et al., 2014; 
Carey et al., 2014). Surprisingly, hyperpigmented GBS also exhibited decreased vaginal 
colonization in mice (Patras et al., 2013; Gendrin et al., 2015; Patras and Doran, 2016), 
likely due to increased pigment-mediated stimulation of neutrophil (Patras et al., 2013) 
and mast cell (Gendrin et al., 2015) inflammatory pathways. Consistent with these 
observations, hyperpigmented strains of GBS were rarely isolated from rectovaginal 
swabs of asymptomatic pregnant women (Gendrin et al., 2015). These results emphasize 
the role of vaginal immune responses in pathogen colonization.  
Apart from immune cells, pH regulates GBS gene expression and therefore 
influences vaginal colonization. For instance, the GBS CovR/S system responds to pH 
wherein increased CovR/S regulation was observed under low (acidic) pH (Santi et al., 
2009; Cumley et al., 2012; Park et al., 2012). Changes in pH also influence GBS 
adhesion (Tamura et al., 1994; Park et al., 2012), survival (Borges et al., 2012), and 
biofilm formation (Ho et al., 2013; D’Urzo et al., 2014). Of note, high vaginal pH and a 
non-lactobacilli-dominated vaginal microbiome (Ravel et al., 2011) were associated 
with a higher incidence of GBS vaginal colonization (Hickman et al., 1999; Kwatra et 
al., 2016) and neonatal disease (Lin et al., 2003; Weston et al., 2011; Peltier et al., 2012) 
in women of African descent. These studies indicate that GBS responds to 
environmental cues, such as pH, and even utilizes regulatory systems such as CovR/S to 
temporally control virulence factor expression (e.g., hemolytic pigment) during 
pregnancy-associated infections. As such, this makes the GBS pigment an intriguing 
target for vaccine development.  
II.2.6.6. Hyaluronidase  
The GBS hyaluronidase, known as HylB, promotes vaginal colonization (Kolar et 
al., 2015). HylB is secreted by GBS and specifically targets and degrades host hyaluronic 
acid (Gochnauer and Wilson, 1951; Baker and Pritchard, 2000). Hyaluronic acid is an 
extracellular matrix glycosaminoglycan composed of repeating disaccharide units (N-
acetyl- D-glucosamine-D-glucuronic acid) and is important for cell migration, cell 
signaling, regulation of inflammation, and the prevention of ascending infection 
(Mahendroo, 2012; Akgul et al.,  2014). GBS HylB degrades host hyaluronic acid into 
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its disaccharide components, which are immunosuppressive as they bind to TLR2/TLR4 
receptors and block signaling (Kolar et al., 2015). Deletion of HylB led to increased 
clearance of GBS from the mouse vagina (Kolar et al., 2015). Similarly, GBS lacking 
HylB was less able to ascend from the vagina to the uterus and was diminished for its 
ability to invade fetal tissues and cause preterm birth (Vornhagen et al., 2016). By 
contrast, uterine tissue infected with HylB-proficient GBS showed decreased levels of 
inflammatory cytokines such as TNF-a, IL-6, and IL-8, leading to bacterial ascension 
(Vornhagen et al., 2016). Thus, suppression of key inflammatory responses also plays 
an important role in GBS infection-associated fetal injury.  
II.2.6.7. Other virulence factors  
Recent studies have described a role for extracellular membrane vesicles (MVs) 
in the weakening of placental membranes (Surve et al., 2016). GBS MVs contained 
multiple virulence factors, including: (i) HylB; (ii) CAMP factor (Christine, Atkins, 
Munch-Peterson factor; Christie et al., 1944), a secreted pore-forming protein (Lang and 
Palmer, 2003) that may amplify (Jurgens et al., 1987), but is not essential for, GBS 
virulence (Hensler et al., 2008); (iii) IgA-binding protein, with the ability to bind human 
IgA (Kvam et al., 1992) for host immune evasion (Nordstrom et al., 2011), and (iv) 
multiple enzymes that may regulate ECM degradation (Surve et al., 2016). Intra-
amniotic administration of GBS MVs in pregnant mice caused significant damage to 
choriodecidual tissues and stimulated leukocytic infiltration and inflammation, leading 
to membrane weakening (Surve et al., 2016). The specific role played by each virulence 
factor in the context of MVs remains unknown. MV weakening of choriodecidual 
membranes represents a novel mechanism of GBS fetal injury.  
II.2.7. Host determinants of GBS vaginal colonization, ascending infection, 
and preterm birth 
II.2.7.1. Vaginal colonization 
Evasion of the host immune response is essential for successful vaginal 
colonization. GBS vaginal immunity is mediated by its ability to resist many physical 
and cellular barriers, including the luminal mucus layer, vaginal epithelia, and immune 
cells in the vagina. Recent work, using animal models, has provided new information 
regarding the host immune response to GBS vaginal colonization (Patras et al., 2013; 
Carey et al., 2014; Patras et al., 2015; Gendrin et al., 2015). Vaginal immune responses 
to GBS are largely mediated by neutrophils (Patras et al., 2013; Carey et al., 2014; Patras 
et al., 2015), mast cells (Gendrin, C. et al., 2015), and macrophages (Carey et al., 2014) 
(Figure 4). The role of NK cells and dendritic cells in GBS colonization is not known. 
Multiple soluble inflammatory cytokines and chemokines have been identified as 
important for reducing GBS vaginal colonization and include IL-1b, IL-6, IL-8, IL-17, 
IL-23, and histamine (Patras et al., 2013; Carey et al., 2014; Patras et al., 2015). 
Currently, the mucosal T cell response to GBS colonization is ill-defined. Studies have 
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shown that IL-17 and IL-17+ cells play an important role in clearance of a hyperadherent 
and invasive GBS strain from the vagina (Patras et al., 2015), suggesting that the Th17 
differentiation pathway is important for controlling persistent GBS colonization. 
Similarly, another study found cytokines involved in Th1, Th2, and Th17 differentiation 
pathways as important for decreased colonization (Carey et al., 2014); however, T cells 
were not directly identified as being important in either study.  
II.2.7.2. Infection of placental membranes  
Many studies have focused on GBS infection of the placental membranes 
(chorioamnion) in order to understand how GBS penetrates these barriers and induces 
chorioamnionitis. GBS is able to adhere to and invade both chorionic and amniotic 
epithelial cells (Winram et al., 1998). Adherence and invasion to these cells are mediated 
by several factors: (i) IagA, a glycosyltransferase that helps anchor lipoteichoic acid to 
the cell surface (Doran et al., 2005); (ii) the hemolytic pigment and its regulator CovR/S 
(Whidbey et al., 2013); and (iii) quorum sensing mediated by genes in the rgf operon 
(Parker et al., 2017). GBS has also been shown to induce secretion of multiple cytokines 
and defensins from placental membranes ex vivo, including TNF-a, IL-1a, IL-1b, IL-6, 
and IL-8 (Flores-Herrera et al., 2012; Boldenow et al., 2013; Boldenow et al., 2015). 
Inflammation is stimulated either through pattern-recognition receptor (PRR) sensing of 
GBS antigens (Boldenow et al., 2015) or by pigment-mediated activation of nuclear 
factor-kβ (NF-kβ) (Whidbey et al., 2013). An important family of PRRs that mediate 
placental membrane immunity are the Siglecs (Brinkman-Van der Linden et al., 2007¸ 
Ali et al., 2014), a family of cell-surface sialic acid-binding lectins that regulate innate 
and adaptive immune function (Crocker et al., 2007). GBS is able to bind Siglecs 
through the sialic acid capsule or b-protein to suppress immune cell activation (Carlin et 
al., 2007; Carlin et al., 2009; Ali et al., 2014) and placental membrane inflammation (Ali 
et al., 2014), potentially leading to increased rates of GBS-associated preterm birth and 
stillbirth.  
II.2.7.3. Fetal injury  
GBS invasion of the fetus in utero leads to a variety of adverse outcomes, 
including tissue damage, inflammation, lung and brain injury, pneumonia, meningitis, 
sepsis, and fetal death. GBS can invade multiple fetal organs, including the lung, blood, 
liver, spleen, and gastrovascular cavity. Fetal tissue damage has been observed in the 
presence and absence of bacterial invasion, which may be due to inflammation in the 
gestational tissues and amniotic fluid. GBS invasion of fetal tissues induces 
inflammation and fetal death (Monari et al., 2013; Randis et al., 2014; Whidbey et al., 
2015; Vornhagen et al., 2016), and in the case of the hemolytic pigment, this involved 
induction of the NLRP3 inflammasome (Whidbey et al., 2015). 
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Figure 4. Interaction of GBS with innate immune cells during genital infection. 
Source: Vornhagen et al. (2017). 
GBS stimulates the NLRP3 inflammasome in a number of immune cells, such as 
dendritic cells (Costa et al., 2012), macrophages (Whidbey et al., 2015), and neutrophils 
(Mohammadi et al., 2016), which contribute to in vivo inflammation. Interestingly, fetal 
injury is not entirely dependent on bacterial invasion of fetal tissues. Fetal lung injury 
can also be caused by GBS-induced chorioamnionitis without bacterial invasion (Adams 
Waldorf et al., 2011). Also, increases in amniotic fluid cytokines contribute to fetal lung 
injury (Adams Waldorf et al., 2011) and dysregulation of fetal lung development 
(Adams Waldorf et al., 2015). Moreover, intra-amniotic administration of MVs leads to 
significantly increased rates of fetal damage and preterm birth (Surve et al., 2016). These 
studies suggest that fetal injury can occur during transient or limited infection, and 
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further emphasizes the importance of developing therapeutics that prevent vaginal 
colonization and ascending infection. 
II.2.8. Preventive measures: intrapartum antibiotic prophylaxis (IAP) 
The relevance of GBS as agent of neonatal infections prompted the finding of 
strategies for its eradication from the intestinal and genitourinary mucosal surfaces of 
pregnant women (Puopolo et al., 2005). Chlorhexidine vaginal treatment, with or 
without neonatal wash, reduced GBS bacterial load but showed no impact on EOD 
(Stade et al., 2004). Induction of labor with intravenous oxytocin may be preferable for 
GBS positive women with prelabor rupture of membranes at term as infections are 
reduced. However, the most commonly used prevention intervention is intrapartum 
chemoprophylaxis with antibiotics to mothers with known GBS colonization. To date, 
four approaches have been recommended for the prevention of neonatal GBS infections: 
(a) a risk-based strategy; (b) a screening- (vaginal/rectal GBS cultures) based strategy; 
(c) a combined risk/screening-based strategy; and (d) a combined risk/screening-based 
strategy using the PCR test (Akker van Marle, 2005).  
In 1976, chemoprophylaxis was first proposed for reducing maternal GBS 
colonization in labor to reduce neonatal disease (Ablow et al., 1976). Non-randomized 
studies showed that intravenous ampicillin given during labor to GBS positive women 
could significantly reduce neonatal GBS colonization, and a non-significant reduction 
in GBS neonatal invasive disease was reported (Yow et al.,  1979; Allardice et al., 1982). 
In 1992, the first guidelines for GBS prevention were published in the US (AAP, 1992; 
ACOG, 1992). Since then numerous guidelines with different recommendations have 
been published by various organizations (AAP, 1997; ACOG, 1996; CDC, 1996; SOGC, 
1997; CDC, 2002; RCOG, 2003; SOGC, 2004; CDC, 2010; Alós Cortés, et al., 2013; 
Money, 2013), often based on studies of poor quality. Some authors and organisms have 
claimed a temporary association between the introduction of GBS screening guidelines 
and a decline in the GBS EO disease rate (CDC, 2005; CDC, 2007). The incidence of 
invasive EO GBS disease decreased from 1.8 cases/1,000 live births in the early 1990s 
to 0.3 cases/1,000 live births in 2010 (Andreu et al., 2003). In contrast, no reduction in 
rates of LO GBS disease has been observed since then (CDC, 2007). Currently in the 
USA and other countries with a GBS screening-based strategy, penicillin is the drug of 
choice for intrapartum prophylaxis given every 4 h intravenously until the baby is born. 
Information on whether intrapartum ampicillin is preferable to penicillin for GBS 
colonized women is lacking (Ohlsson and Shah, 2013). 
However, the same literature has been interpreted differently by different scientists 
and professional organizations and this have relevant implications for clinical practice. 
In the three studies investigating the effects of intrapartum antibiotics versus no 
treatment for GBS-colonized women, risks of bias for one or more key domains in the 
study methodology and execution were identified and such risks were high enough to 
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affect the interpretation of the results (Ohlsson and Shah, 2009; Ohlsson and Shah, 2013; 
Ohlsson and Shah, 2014). In fact, these reviews based on Cochrane’s guidelines have 
concluded that there is no valid information from these biased trials to inform clinical 
practice.  
The conclusion of Cochrane’s reviews on this issue is that intrapartum 
chemoprophylaxis to reduce perinatal GBS infections are not supported by conclusive 
evidence from well designed and conducted randomised controlled trials (Ohlsson and 
Shah, 2009): 
“Women, men and children of all ages can be colonized with Group B 
streptococcus (GBS) bacteria without having any symptoms; About one in 2000 newborn 
babies have Group B streptococcus bacterial infections, usually evident as respiratory 
disease, general sepsis, or meningitis within the first week. The baby contracts the 
infection from the mother during labor. Giving the mother an antibiotic directly into a 
vein during labor causes bacterial counts to fall rapidly, which suggests possible 
benefits but pregnant women need to be screened. Many countries have guidelines on 
screening for GBS in pregnancy and treatment with antibiotics. However, very few of 
the women in labor who are GBS positive give birth to babies who are infected with GBS 
and antibiotics can have harmful effects such as severe maternal allergic reactions, 
increase in drug-resistant organisms and exposure of newborn infants to resistant 
bacteria, and postnatal maternal and neonatal yeast infections. 
This review finds that giving antibiotics is not supported by conclusive evidence. 
The review identified four trials involving 852 GBS positive women. Three trials, which 
were around 20 years old, compared ampicillin or penicillin to no treatment and found 
no clear differences in newborn deaths although the occurrence of early GBS infection 
in the newborn was reduced with antibiotics. Maternal colonization with group B 
streptococcus (GBS) during pregnancy increases the risk of neonatal infection by 
vertical transmission. Administration of intrapartum antibiotic prophylaxis (IAP) 
during labor has been associated with a reduction in early onset GBS disease 
(EOGBSD). However, treating all colonized women during labor exposes a large 
number of women and infants to possible adverse effects without benefit. All cases of 
perinatal GBS infections are unlikely to be prevented even if an effective vaccine is 
developed. 
Intrapartum antibiotic prophylaxis appeared to reduce EOGBSD, but this result 
may well be a result of bias as we found a high risk of bias for one or more key domains 
in the study methodology and execution. There is lack of evidence from well designed 
and conducted trials to recommend IAP to reduce neonatal EOGBSD. Ideally the 
effectiveness of IAP to reduce neonatal GBS infections should be studied in adequately 
sized double-blind controlled trials. The opportunity to conduct such trials has likely 
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been lost, as practice guidelines (albeit without good evidence) have been introduced in 
many jurisdictions” 
It should be noted that the guidelines have changed many times, indicating that 
they are not based on clear evidence informing best clinical practice (Ohlsson and Shah, 
2014).  
Possibly, the strongest argument supporting that introduction of GBS screening 
and IAP is not associated to the reduction of EOS by GBS is the fact that the rate has 
declined similarly, at least, in some European countries in which GBS screening strategy 
was not adopted. As an example, the UK National Screening Committee examined the 
issue of strategies for the prevention of EOS GBS disease in November 2008 and 
recommended that routine screening using bacteriological culture or near-patient testing 
techniques should not be introduced into UK practice (UK National Screening Comité, 
2012). The latest update of the guidelines from the Royal College of Obstetricians and 
Gynaecologist regarding GBS do not recommend routine bacteriological screening of 
all pregnant women for antenatal GBS carriage (RCOG, 2012). Previously, an analysis 
of the cases of GBS sepsis occurred in UK and Ireland among the ~800,000 neonates 
born in a year (with ~198.000 GBS-colonized women) revealed that 840 GBS-positive 
women should be treated to avoid a single neonatal GBS sepsis (Heath et al., 2004). This 
fact was considered unacceptable in the frame of the current antibiotic resistance 
epidemics. 
II.2.9. Adverse effects of IAP 
The first critical review of randomized controlled trials of intrapartum 
chemoprophylaxis of perinatal GBS infections identified numerous methodological 
flaws (Ohlsson, 1992). In addition, such strategy for GBS management in pregnancy has 
been questioned (Yudin et al., 2006). Therefore, a Cochrane review adopting high-
quality methodology was justified. In the first Cochrane review on the efficacy of IAP 
to eradicate GBS colonization, Ohlsson and Shah (2009) considered that it was 
important to know if intrapartum antibiotics do more good than harm in trying to reduce 
mortality and morbidity from neonatal GBS infections. As stated above, most women 
colonized with GBS are asymptomatic, so screening is necessary if these women are to 
be identified. However, of the women in labor who are GBS positive, very few will give 
birth to babies who are infected with GBS. Hence, giving intravenous antibiotics to all 
women in labor who are GBS positive will put a large number of women and babies at 
risk of adverse effects unnecessarily. These adverse effects include potentially fatal 
anaphylaxis, increase in drug-resistant organisms and the medicalization of labor and 
the neonatal period (RCOG, 2003). Severe allergic reaction to antibiotics has been 
reported among mothers giving birth (Berthier et al., 2007; Jao et al., 2006). 
However, the biggest concerns are the increasing rates of antibiotic resistance 
among clinically relevant microorganisms and the impact of IAP on the acquisition, 
II. Introduction 
38 
 
composition and development of the infant microbiota. In the words of Blaser (2016): 
“Anti-infectives, including antibiotics, are essentially different from all other drugs; they 
not only affect the individual to whom they are given but also the entire community, 
through selection for resistance to their own action. Thus, their use resides at the 
intersection of personal and public health. Antibiotics can be likened to a four-edged 
sword against bacteria. The first two edges of the antibiotic sword were identified 
immediately after their discovery and deployment in that they not only benefit an 
individual in treating their infection but also benefit the community in preventing the 
spread of that infectious agent. The third edge was already recognized by Alexander 
Fleming in 1945 in his Nobel acceptance speech, which warned about the cost to the 
community of antibiotic resistance that would inevitably evolve and be selected for 
during clinical practice. We have seen this cost mount up, as resistance curtails or 
precludes the activities of some of our most effective drugs for clinically important 
infections. But the fourth edge of the antibiotic sword remained unappreciated until 
recently, i.e., the cost that an antibiotic exerts on an individual's own health via the 
collateral damage of the drug on bacteria that normally live on or in healthy humans: 
our microbiota. These organisms, their genes, metabolites, and interactions with one 
another, as well as with their host collectively, represent our microbiome. Our 
relationship with these symbiotic bacteria is especially important during the early years 
of life, when the adult microbiome has not yet formed”. 
The incidence of postnatal maternal and neonatal bacterial and yeast infections 
may increase with the use of intrapartum antibiotics (Edwards et al., 2002; Dinsmoor et 
al., 2005; Barcaite et al., 2008). The ever evolving nature of the mechanisms conferring 
antibiotic resistance is particularly worrying since the selective pressure exerted by 
antibiotics may favour that certain bacteria (E. coli, Klebsiella spp., Proteus spp., 
Serratia spp., group A and group viridans streptococci, S. aureus, S. epidermidis, 
Clostridium difficile, etc.) with the potential to cause neonatal sepsis occupy the 
ecological niche of GBS (Schrag et al., 2006; Chung et al., 2007). Parallel, the potential 
spread of penicillin-resistant GBS strains is also worrying and, in fact, an increase in 
such a resistance has already been observed among GBS (Chu et al., 2007; Dahesh et 
al., 2008).  
II.2.10. Adverse effects of IAP on the acquisition of the infant microbiota and 
potential alternatives (vaccines, probiotics) 
The process of acquisition and establishment of the microbiota in the neonate is 
one of the most important phenomena for the later health of the individual (Renz et al., 
2012; Sommer and Bäckhed, 2013). This process contribute to developmental 
programming of epithelial barrier function, gut homeostasis, angiogenesis, innate and 
host adaptive immune functions. Additionally, the microbiota have developmental 
effects in other organs elsewhere in the body (Claus et al., 2008; Björkholm et al., 2009) 
and deep consequences in systemic metabolism and neuroendocrinology (Neuman et al., 
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2015). The functional development of the brain is of particular interest because it has 
been shown to be highly susceptible to modulation during perinatal life (Diaz Heijtz et 
al., 2011; Mayer et al., 2014). As an example, there seems to be an association between 
common neurodevelopmental disorders, such as autism and schizophrenia, and 
microbial pathogen infections during the perinatal period (Finegold et al., 2002; Bilbo 
et al., 2005; Mittal et al., 2008). 
Recent animal studies have demonstrated that the early neonatal period is the most 
important moment for reaching the microbiota-induced host-homeostasis; if the 
microbiota is absent during this critical period of life the homeostatic state of the 
individual will not be reached, even if the microbiota is restored at a later life stage 
(Hansen et al., 2012; Olszak et al., 2012; Cox et al., 2014). Thus, alterations in the 
microbiota development during this sensitive initial period may increase the risk of 
disease in later life. Indeed, human studies have shown that early microbiota alterations 
precede the development of disease (Kalliomaki et al., 2001; Kalliomaki et al., 2008). 
Therefore, the first weeks of the infant life may constitute a unique window of 
opportunity for microbiota modulation towards the establishment of a healthy microbial 
profile and later health. 
The microbial colonization of the intestine starts with facultative anaerobes which 
contribute, by lowering the intestinal redox-potential, to the later establishment of strict 
anaerobic microorganisms, such as Bifidobacterium, Bacteroides or Clostridium 
(Wopereis et al., 2014). During the first months of life there is a significant presence of 
Actinobacteria and, in many cases, Proteobacteria (Turroni et al., 2012; Arboleya et al., 
2012; Bergström et al., 2014; Arboleya et al., 2015) which is in contrast to the 
dominance of Bacteroidetes and Firmicutes during adulthood (Arumugan et al., 2011; 
Human Microbiome Consortium, 2012). Several factors influence the early colonization 
and its further development in the infant, including gestational age at birth (Barrett et 
al., 2013; Arboleya et al., 2015; Ruiz et al., 2016), mode of delivery (Dominguez-Bello 
et al., 2010; Jakobsson et al., 2014), feeding strategies (Yatsunenko et al., 2012; Backhed 
et al., 2015; Gómez et al., 2016) and, of course, the use of perinatal antibiotics (Fouhy 
et al., 2012; Faa et al., 2013; Arboleya et al., 2015; Moles et al., 2015). The neonatal 
colonization process has been recently reviewed by Milani et al. (2017) 
It has been long known that antibiotics are responsible for dysbiosis processes in 
the human microbiota, leading to antibiotic-associated diarrhea and gastroenteritis, 
urogenital, and oral infections. It is becoming evident that antibiotherapy during 
pregnancy, intrapartum, and lactation alters the maternal microbiota, a fact that may 
have negative consequences for infant health (Murk et al., 2011; Soto et al., 2014).  
Perinatal antibiotic use affects the gut microbiota development during the critical 
first weeks of life (Arboleya et al., 2016; Cotten, 2016). The composition of the gut 
microbiota of neonates whose mothers received IAP has been described as aberrant in 
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comparison with that of non-treated neonates (Tanaka et al., 2009; Aloisio et al., 2016). 
The detrimental impact of perinatal antibiotics, mainly IAP, on early life microbiota may 
involve a lasting effect on the individual physiology (Cox et al., 2014). The use of 
antibiotics may influence microbiota-host crosstalk during the neonatal period, which 
may have profound consequences for later health (Faa et al., 2013). Actually, perinatal 
antibiotics exposure has been reported to increase the risk of later disease such as allergy 
(Droste et al., 2000; Kozyrskyj et al., 2007; Kummeling et al., 2007; Russell et al., 2012; 
Chu et al., 2015). An increased risk of asthma exacerbation and hospitalization, 
requiring inhaled corticosteroids, in children if mothers used antibiotics during 
pregnancy, supports a role for bacterial ecology in pre- or perinatal life for the 
development of asthma (Stensballe et al., 2013). 
Studies of antibiotic-induced microbiome alterations and downstream effects on 
the developing immune system have increased our understanding of the mechanisms 
underlying the associations between antibiotics and adverse outcomes. The emergence 
of resistant microorganisms and recent evidence linking antibiotic practice variations 
with health outcomes has led to the initiation of antibiotic stewardship programs (Cotten, 
2016).  
Given that the estimated use of IAP is over 30% of total deliveries (van Dyke 
tal al., 2009), greater attention should be paid to its potential impact upon the gut 
microbiota. This impact should be considered as a factor in the decision on whether 
or not to administer IAP. In the frame of the current antibiotic resistance epidemics, 
preventive exposure of an important percentage of mothers and infants to antibiotic 
may be unacceptable in the future. In other words, the use of IAP for the prevention 
of EOS by GBS may turn out to be an interim strategy rather than a final solution 
(Edwards, 2008). 
Availability of effective antibiotics has revolutionized public health and has been 
responsible for enabling countless advancements in medical care (Spellberg et al., 2008). 
For example, antibiotics have been critical to the development of advances in surgery 
and of myeloablative therapies for cancer and to the transplantation of both solid organs 
and hematopoietic stem cells. Effective antibiotics have also been critical for advanced 
medical treatment of patients with trauma and battlefield injuries, as well as myocardial 
infarctions, strokes, and other illnesses that require intensive care with catheters, 
hyperalimentation, and mechanical ventilation. Ironically, the very advances in medical 
care enabled by effective antibiotic therapies have, in turn, created enormous 
populations of increasingly immunocompromised hosts, who develop infections caused 
by increasingly resistant microbes that require treatment with newer, more powerful 
antibiotics. Meanwhile, an equally alarming decline has occurred in the research and 
development of new antibiotics to deal with the threat. 
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We are in the midst of an emerging crisis of antibiotic resistance for microbial 
pathogens throughout the world (Alanis, 2005). Epidemic antibiotic resistance has been 
described in numerous pathogens in varying contexts, including—but not limited to—a 
global pandemic of methicillin-resistant S. aureus (MRSA) infection, the global spread 
of drug resistance among common respiratory pathogens, including S. pneumoniae, 
Mycobacterium tuberculosis, and epidemic increases in multidrug-resistant (and, 
increasingly, truly pan-resistant) Gram-negative bacilli (Spellberg et al., 2008). 
Infections caused by these and other antibiotic-resistant microbes impact clinicians 
practicing in every field of medicine. Given their breadth of effect and significant impact 
on morbidity and mortality, multidrug-resistant microbes are considered a substantial 
threat to public health worldwide. Therefore, biological markers unambiguously 
associated to a risk of neonatal GBS disease are required. 
In addition, it would be advisable to develop alternative strategies. Since the 
1930’s, important efforts have been made in order to obtain effective anti-GBS 
vaccines (Johri et al., 2006). Human isolates of GBS express a capsular polysaccharide 
(CPS) which is a major virulence factor that helps the organism evade host defense 
mechanisms. Clinical trials of conjugated vaccines prepared with purified CPS types Ia, 
Ib, II, III, IV, V, and VII have demonstrated that these preparations are safe and 
immunogenic (Paoletti et al., 2000). However, these preparations do not offer protection 
against other GBS serotypes such as VI and VIII, which are prevalent in some parts of 
the world. Further advances in GBS vaccine development are likely through using the 
newer -omics technologies (Johri et al., 2006). A GBS maternal immunization program 
will reduce some adverse pregnancy outcomes and intrapartum infections in the mother 
in addition to early- and late-onset infections in infants. The development of GBS 
vaccine has been reviewed by Heath (2016) and Madhi and Dangor (2017). 
Even if an effective vaccine to prevent GBS infections is developed in the future, 
a need for alternative strategies is still likely to be present as all women will not be 
immunized and the vaccine may not be effective in women giving birth preterm. In this 
context, the isolation, selection and characterization of safe probiotic strains with the 
ability to antagonize and, eventually, eradicate GBS from maternal and infant 
mucosal surfaces is a very attractive target. This has been the objective of this PhD 
Thesis. 
II.3. PROBIOTICS 
In recent years, scientific and clinical advances in the field of probiotics have 
allowed the development and commercialization of some products duly contrasted. In 
parallel, the demand for probiotics by consumers increasingly aware of the close 
relationship between our microbiota and health has also increased. Unfortunately, some 
companies have taken advantage of this situation to apply the term "probiotic" to 
products that do not fit into this concept and/or whose presumed benefits lack any 
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scientific basis. This misuse, intentional or not, has been favored by the absence, until 
the beginning of the 21st century, of an international consensus on the methodology to 
evaluate the efficacy and safety of these products. 
In 2001, a FAO/WHO joint commission of experts recognized the need to 
establish guidelines for the evaluation of the efficacy and safety of probiotics 
(FAO/WHO, 2001). The commission proposed a definition of the term probiotic that, 
since then, has been the most widely accepted worldwide: "live microorganisms that, 
when administered in adequate amounts, confer a health benefit on the host". In 2002, 
another joint working group of FAO and WHO developed guidelines with the minimum 
requirements necessary for a product to receive the name of probiotic (FAO/WHO, 
2002). The documents derived from the work of both committees and the International 
Scientific Association for Probiotics and Prebiotics (ISAPP) (Hill et al., 2014) are key 
references to know what currently understood by probiotic.  
The probiotic definition is inclusive of a broad range of microbes and 
applications, whilst capturing the essence of probiotics (microbial, viable and 
beneficial to health). The definition differentiates live microbes used as processing 
aids or sources of useful compounds from those that are administered primarily for 
their health benefits. Evidence of a health benefit is required for a probiotic, at either 
a strain-specific or group level, depending on the nature of the benefit. Probiotics can 
have different means of administration, target host species (humans and animals), 
target populations, target sites (gut and beyond), efficacy end points and regulatory 
categories. Dead microbes, microbial products, microbial components do not come 
under the probiotic classification (Hill et al., 2014) (Figure 5). 
 
Figure 5. Overall framework for probiotic products. Source: Hill et al. (2015). 
The distinction between commensal microorganisms and probiotics is also 
inferred from this definition. Although commensals in the gut are often the source of 
probiotic strains, until these strains are isolated, characterized and a credible case 
presented for their health effects, they cannot be called 'probiotics'. In the years that 
have passed since the definition was proposed, numerous lines of research have 
challenged the limits of the probiotic concept, from live cultures present in fermented 
foods to fecal microbiota transplants (FMT). The term has also been clearly misused, 
for example, on products such as mattresses, shampoos, disinfectants and aftershave, 
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for which maintenance of viability and efficacy of the microbes used are not 
established.  
Use of the term probiotic has been restricted in some countries of the European 
Union because it is deemed misleading to consumers in the absence of approved 
health claims. It is now evident that different interpretations of the term probiotic are 
creating notable concerns for major stakeholders with respect to the translation of a 
large body of research on probiotics to probiotic-containing foods that can benefit 
consumers. The objectives of the different stakeholders in the probiotic field are 
described in Figure 6; notably, all the stakeholders' objectives are compatible. 
Importantly, all parties involved in the probiotic field must work toward a common 
goal so that society benefits from the scientific advances in the field of probiotic 
research. 
The process that goes from the initial selection of strains to the commercialization 
of an effective probiotic for a specific target is not easy. Of the thousands of strains 
isolated each year due to their presumed probiotic potential in laboratories around the 
world, very few go into a stage of industrial development and much less those that get a 
hole in the shelves of a pharmacy or food establishment. The main aspects that should 
be taken into account in the (sometimes, long and winding) path that a strain must follow 
from its initial isolation until its commercialization are reviewed in the next sections. 
 
Figure 6. Objectives of stakeholders in the probiotic field. Source: Hill et al. 
(2015). 
 
II. Introduction 
44 
 
II.3.1. Identification of probiotic microorganisms  
The identification of an isolate at the species and strain levels is an essential 
requirement for any isolate that is intended to be commercialized. The allocation of an 
isolate to one species or another is not banal since the risk assessment according to the 
European Food Safety Authority (EFSA) is much simpler for those which, based on a 
history of safe use, enjoy the Qualified Presumption of Safety (QPS) status (EFSA, 
2013). The QPS list is reviewed periodically, incorporating new taxonomic units if the 
available data so guarantee. Consequently, it is likely that in the future, genera and 
species will be included (e.g.: Roseburia spp., Faecalibacterium prausnitzii...) that have 
not been used to date as probiotics but that have been linked with clear effects beneficial 
for health by several studies on the human microbiome. 
Like any other discipline, the taxonomy of bacteria and yeasts is constantly 
evolving and species determination must be carried out (and, eventually, reevaluated) 
with the most adequate state-of-the-art methodology. Although phenotypic tests 
(carbohydrate fermentation, enzymatic activities ...) were very useful when there were 
no other alternative methods, they are currently not valid for the identification of species 
since their resolution capacity is clearly insufficient; in fact, the inheritance of the use 
of inadequate identification methods is the main cause of mislabeling of probiotic 
products (Huys et al., 2006). 
Phenotypic tests were quickly replaced by various molecular techniques, based on 
fingerprinting or the sequencing of various genes. Among them, partial or complete 
sequencing of the 16S rRNA gene has practically become the standard method of 
identification. However, this approach has some drawbacks, such as the existence of 
non-contrasted sequences in the databases (EMB/GenBank/DDBJ) or its inability to 
discriminate between closely related (sub)species, such as those that fall within the 
Lactobacillus plantarum group or the Lactobacillus paracasei group. In such cases, the 
use of housekeeping genes, such as pheS, rpoA, atpD, tuf, groEL or recA, or their 
combination with the 16S rRNA gene, offers a greater discriminatory capacity. In any 
case, it is unacceptable to prolong the use of obsolete or confusing nomenclature on the 
labels of the products, although there are examples in this regard in the current probiotic 
market (eg: Lactobacillus biphidus instead of Bifidobacterium bifidum; Lactobacillus 
sporogenes instead of Bacillus coagulans).  
The identification of an isolate at the strain level is equally relevant. The ability to 
identify a specific strain in a given biological sample or food matrix, or to differentiate 
it among other probiotics or among the members of the native microbiota of a host, is 
essential since it enables traceability in laboratory tests, in clinical trials, in 
epidemiological studies (including possible involvement in adverse effects) and 
throughout the production and marketing process. On the other hand, it is usual for the 
company interested in a strain to want to protect it by means of a patent that covers its 
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possible applications. To do this, the company will have to deposit the strain in a 
reference collection, such as the Spanish Type Culture Collection (CECT), under the 
conditions of the Budapest Treaty. In this case, the ability to differentiate the strain is a 
useful tool to detect possible illegal use by third parties.  
Identification at the strain level is also desirable if there are beneficial effects 
specifically associated with a specific strain. In many documents it is considered that the 
health effects demonstrated for a specific microbial strain can not be extrapolated or 
attributable to other strains of the same species; However, this is an aspect that should 
be reviewed since some effects (and the mechanisms that sustain them) are widely 
distributed among species belonging to different genera (production of organic acids, 
competitive exclusion of pathogens ...), others are frequent among the different strains 
of the same species and, finally, others are more rare (neurological or endocrinological 
effects ...) and can only be associated with a few strains within a given species (Hill et 
al., 2014) (Figure 7). 
 
Figure 7. Possible distribution of mechanisms among probiotics at the strain or 
species levels. Source: Hill et al. (2014). 
Despite the availability of various genotyping techniques, pulsed-field gel 
electrophoresis (PFGE) is still considered the one of choice to differentiate strains, 
without forgetting that the presence of plasmids and megaplasmids may be associated 
with properties that differentiate a strain against to similar ones of the same species. The 
complete genome sequence (including the extrachromosomal elements) is the best 
possible information for the identification of a species and strain, as well as providing 
very valuable information about its safety, functionality and technological properties. At 
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present, functional genomics already facilitates the selection of strains for specific 
applications and will be a common approach in the near future (Douillard and de Vos, 
2014).  
II.3.2. Strain safety 
The evaluation of the safety of probiotics is obviously an essential requirement in 
the selection process that begins, as mentioned above, with a correct taxonomic 
identification. The microorganisms used as probiotics include yeasts (Saccharomyces 
cerevisiae) and bacteria from different genera (Lactobacillus, Streptococcus, 
Enterococcus, Pediococcus, Bifidobacterium, Propionibacterium, Bacillus, 
Escherichia), some of which are part of the native microbiota of the hosts to which they 
are directed and others not. On the other hand, probiotics have been used in a wide range 
of situations, including healthy people, healthy people but in a special situation (babies, 
pregnant or lactating women, elderly...) and people with different types of pathologies 
and severities. Consequently, the safety assessment must take into account, among other 
factors, the microorganism in question, the form of administration, the level of exposure, 
the health status of the host and the physiological functions that they can perform 
(Sanders et al., 2010). 
The cases in which it has been possible to establish a relationship between the 
consumption of a probiotic and an adverse effect are very scarce and have affected 
people with serious underlying diseases or with an altered intestinal barrier. This low 
epidemiological incidence is especially noteworthy considering the wide use of this type 
of products (Cannon et al., 2005; Boyle et al., 2006). For example, the risk of infection 
by Lactobacillus is approximately one case per 10 million people while, in general, the 
risk of lactobacilemia is considered as "unequivocally insignificant" (Salminen et al., 
2002; Borriello et al., 2003; Bernardeau et al., 2008). In such cases, the species most 
implicated to date have been Lactobacillus rhamnosus (Rautio et al., 1999; Mackay et 
al., 1999), Saccharomyces cerevisiae var. boulardii (usually associated with the 
presence of central venous catheters) (Hennequin et al., 2000), and Bacillus subtilis 
(Oggioni et al., 1998; Spinosa et al., 2000). 
The fact that no side effects have been observed (and indeed beneficial effects) in 
the vast majority of clinical trials in which probiotics have been administered to 
immunocompromised hosts, including people positive for human immunodeficiency 
virus (HIV), very low or extremely low weight preterm infants of elderly patients, 
confirms the low pathogenicity of probiotics, even in situations favorable for infections 
by opportunistic microorganisms (Bernardeau et al., 2006; Trois et al., 2008; AlFaleh 
and Anabrees, 2013; Moles et al., 2015) 
Despite this, the issue of safety is essential in people with serious diseases, 
especially after observing that the administration of a multi-species probiotic to patients 
with acute pancreatitis was associated with a higher mortality than the control group 
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(16% vs. 6%) (Besselink et al., 2008). An analysis of patient subgroups revealed that the 
probiotic had beneficial effects in moderately ill patients but negative in critical ones. 
No translocation of any of the strains contained in the probiotic product was observed 
in the systemic circulation and everything seems to indicate that the adverse effects 
(higher rate of intestinal ischemia and mortality) were due to an excess of oxidative load 
on a redox system that was already very altered, causing an increase in damage induced 
by oxidative stress and ischemia (Ammori, 2003). 
In theory, probiotics could produce four types of adverse effects: (1) infectivity or 
pathogenicity; (2) production of undesirable metabolites; (3) excessive 
immunostimulation or immunosuppression in sensitive individuals; and (4) possibility 
of transmission of genes that confer resistance to antibiotics. 
II.3.2.1. Pathogenicity 
To date, no gene has been unequivocally related to pathogenicity in Lactobacillus 
or Bifidobacterium genera, including isolates associated with sepsis or other adverse 
effects (Vesterlund et al., 2007). The factors that have been proposed to explain their 
involvement in infections include their adhesion to the host cells (which would facilitate 
its translocation), the degradation of mucins (which provides metabolites for its growth), 
the hydrolase activity of bile salts (which facilitates its survival in the intestinal 
environment) or the resistance to the innate defense mechanisms. However, these are 
characteristics that, in general, contribute to the colonization of mucosal surfaces and, 
as such, are shared by a large part of the natural microbiota. 
The process of infection and invasion involves a first contact or adhesion between 
the bacterial cells and the epithelial cells, a translocation through the intestinal 
epithelium, and an indiscriminate proliferation that can end up in a liver abscess, an 
endocarditis or a sepsis. For this reason, it has been suggested that the potential for 
adhesion and translocation of a strain may be a part of the safety assessment of 
probiotics. However, these are clearly controversial issues. In fact, adhesion capacity 
has been considered as a possible probiotic characteristic since it can promote the 
colonization of the target epithelium, the improvement of neuro-immunological 
interactions, the occupation of receptors (to the detriment of pathogens), and the 
strengthening of the intestinal barrier (Huys et al., 2013). 
Translocation also has numerous nuances; on the one hand, there is an "infectious" 
bacterial translocation, which implies a high translocation rate, which is usually 
associated with pathogenic bacteria (enteroinvasive strains of E. coli, L. monocytogenes 
...), which usually coincides with an alteration of the intestinal barrier and/or of the 
immune system, and which leads to a pathological situation; on the other hand, 
"controlled" translocation constitutes a selective and highly regulated physiological 
process that happens continuously in healthy individuals, which implies a low rate of 
translocation and is fundamental for the homeostasis of an individual (Rodríguez, 2014). 
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Therefore, the fact that a strain is capable of translocating in a controlled manner is not 
only a reason to reject a strain but could even constitute a relevant probiotic property. 
In any case, there are many doubts about the validity of in vitro tests to predict the 
adhesion and translocation in vivo of a strain since, depending on the physiological state 
of the bacteria, the different types of tests, the different cell lines used and the differences 
between laboratories, the results for the same strain can vary considerably. 
In contrast to lactobacilli and bifidobacteria, numerous virulence factors 
(hemolysin, gelatinase, DNase ...) have been described in the genus Enterococcus, and 
especially in the species Enterococcus faecalis and Enterococcus faecium (Eaton and 
Gasson, 2001), although there is no consensus on a procedure or method that 
differentiates the pathogenic from the non-pathogenic strains. Currently, they are not 
included in the QPS list so, like other microorganisms in the same situation, the 
evaluation of their safety should be done demonstrating the absence of virulence factors 
in a strain by strain basis. In the case of the Bacillus species used as probiotics and 
included in the QPS listing (eg: B. coagulans, B. pumilus, B. subtilis), the absence of 
toxigenic activity (absence of Hbl and Nhe genes and of cytotoxicity) is required (Duc 
et al., 2004; ISAPP, 2003). 
II.3.2.2. Production of D-lactate 
In the past, some authorities considered that the production of the D (-) isomer of 
lactic acid was a property to be taken into account for the evaluation of the safety of 
probiotics, especially for use in children. However, from the scientific point of view, it 
is a property practically irrelevant to determine the safety of an isolate since many of the 
native species of the human gastrointestinal tract, including some widely used as 
probiotics in pediatrics (eg: Lactobacillus reuteri), produce D-lactic acid. It is also 
widely accepted that the ingestion of yogurt, which contains high concentrations of this 
isomer due to the activity of Lactobacillus delbrueckii subsp. bulgaricus, does not pose 
a risk to children's health. In this sense, everything seems to indicate that there is no 
reason to avoid the use as probiotics of human autochthonous lactobacilli on the basis 
of the lactic acid stereoisomers that they produce (ISAPP, 2003). In fact, to date, no case 
of acidosis has been described by D-lactic acid in any healthy human being, regardless 
of age. Clinical trials, in which probiotic D-lactate-producing strains have been 
administered to full-term and premature infants, have revealed no signs of acidosis, even 
after daily administration during the first 12 months of life (Connolly and Lönnerdal, 
2004; Connolly et al., 2005). 
II.3.2.3. Production of biogenic amines 
Biogenic amines (BA) are low molecular weight nitrogen compounds that are 
formed mainly by decarboxylation of amino acids and that exert essential physiological 
functions for living beings. However, the decarboxylation of some amino acids, carried 
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out by certain microorganisms, can cause the presence of high concentrations of BA 
(histamine, tyramine ...) in food. For this to happen, it is important that the raw material 
contains a high protein load and that adequate conditions for intense proteolysis are 
given. These conditions occur in certain fermented foods when the fermentation is 
directed by lactic bacteria with aminoacyl-decarboxylase activity, a property that 
depends on the strain and not on the species (Fernández and Álvarez, 2005). 
It should be noted that there are people especially sensitive to BA because the 
enzymes responsible for its detoxification, monoamine oxidase (MAO) or diamino 
oxidase (DAO), are not functional, either because of genetic problems or because of the 
presence of inhibitors, such as alcohol or some antidepressant drugs. Therefore, it is 
difficult to establish the toxic levels for each of the BAs since it depends on the 
effectiveness of the detoxification systems and, therefore, varies from one individual to 
another. For this reason, the inability to synthesize BA must be included in the selection 
criteria of starter cultures and also of those probiotics that are going to be transported 
through food where the conditions for their formation can be foreseen. 
II.3.2.4. Resistance to antibiotics 
The rise of antibiotic (multi)resistant bacteria represents a serious threat to Public 
Health. Consequently, the possible presence of transmissible genes that can confer this 
phenotype to the bacteria of the host's microbiota (including those potentially 
pathogenic) is a very relevant aspect in the evaluation of the safety of the bacteria that 
are to be used as probiotics. However, it should be noted that no in vivo assay 
demonstrating the transfer of this type of genes from a probiotic strain to any member 
of the indigenous autochthonous microbiota has been published up to date. 
The determination of antibiotic resistance seems a relatively simple test but, 
traditionally, trials involving bifidobacteria and lactic acid bacteria (except enterococci) 
have faced standardization difficulties. It is currently considered that it should be 
performed according to internationally accepted procedures such as, for example, the 
most up-to-date version of the Clinical and Laboratory Standards Institute (CLSI) guide. 
The criteria proposed by Klare et al. (2005, 2007) for this type of bacteria are also widely 
used. 
Antibiotic resistance is part of the safety evaluation scheme proposed by EFSA to 
determine the QPS status of a strain (EFSA, 2012). To do this, EFSA indicates the 
antibiotics that should be considered depending on the genus or species to be evaluated 
and provides cut off values. With some exceptions, this approach requires the 
determination of the minimum inhibitory concentration (MIC) against ampicillin, 
vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, 
tetracycline and/or chloramphenicol. When a strain is resistant to an antibiotic, the type 
of resistance must be determined. There is “intrinsic resistance” when this property is 
inherent to all strains of a species while it is “acquired” when a strain of a species 
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typically sensitive to an antibiotic shows resistance to it. In this second case, it is 
necessary to present genetic data that explain the cause of the resistance since it can be 
due to mutations in endogenous genes or by acquisition of exogenous transmissible 
genes (tetW, tetM, tetS, ermB ...) (Ammor et al., 2007; Devirgiliis et al., 2011; van 
Reenen and  Dicks, 2011) 
In this context, the criterion of the EFSA (2012) is as follows: (a) the horizontal 
transmission potential of the intrinsic resistances is minimal, so bacteria that carry them 
can be used in food; (b) the potential for horizontal transmission of the acquired 
resistances due to chromosomal mutations is low so that, in general, such bacteria can 
also be used in foods; (c) bacteria that carry acquired resistance as a consequence of the 
incorporation of genetic elements (and, especially, mobile genetic elements: plasmids, 
transposons ...) are those that have the greatest potential of horizontal transmission, so 
they should not be used in foods; (d) avoid using any strain if genetic information about 
the nature of a demonstrated resistance is not available; and (e) the presence of 
resistances does not convert a lactobacillus or a bifidobacterium strain into a pathogenic 
microorganism. 
II.3.2.5. Negative effects on the immune system 
The safety assessment of probiotics should also consider their impact on 
immunologically immature or immunocompromised hosts. All microorganisms, both 
autochthonous and allogenic (http://www.sepyp.es/es/wiki), exert an impact on the 
immune system. The autochthonous microbiota is crucial for the development and 
maintenance of the physiology and homeostasis of the mucous membranes and epithelia 
that they inhabit, places that act as a highly selective barrier and organ of communication 
between the luminal environment and the host (O'Hara and Shanahan, 2006); in fact, a 
failure in this interaction it can contribute to the development of inflammatory, 
metabolic or infectious pathologies. 
In this context, the fact that, in many cases, the mechanisms by which probiotics 
exert their action are still not well known is a drawback to predict the immunological 
safety of a probiotic intervention. Whether a probiotic exerts immunostimulatory or 
immunosuppressive effects (which may be protective or harmful) depends on the 
interactions between the microbial signals, the genetic basis of the host and the 
environmental conditions. Several studies have shown that certain probiotic bacteria 
stimulate the proliferation and activity of immune cells, increasing the effectiveness of 
the response to pathogens. In contrast, other probiotics are effective against chronic 
inflammations and allergies through the suppression of effector cells and the induction 
of tolerance mechanisms (Kalliomaki et al., 2003; Kruis et al., 2004). Knowledge of the 
relationships between structure (genotype, phenotype) and the functions of probiotics in 
target populations will limit the risk of inducing adverse immunological effects in a host. 
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II.3.2.6. Safety of excipients 
The safety assessment of a probiotic should take into account the excipients used 
in the formulation of the final products. As an example, cases of children who have 
suffered anaphylactic reactions due to exposure to cow's milk proteins used as excipients 
have been described (Moneret-Vautrin et al., 2006; Lee et al., 2007) In this sense, 
probiotic products must comply with the regulations in force regarding the declaration 
of allergens in the labeling. With regard to clinical trials, it is important to include allergy 
or excipient intolerance among the exclusion criteria. 
II.3.2.7. Tests and models for the evaluation of safety 
There are numerous types of in vitro, ex vivo and in vivo assays to assess the safety 
of probiotics. In general, all are useful to have more information when selecting the 
safest strains, although those based on simple phenotypic tests and the use of cell 
cultures have, to a greater or lesser extent, the disadvantage of not adequately reflecting 
the complex interactions that are established in a living being. Animal testing has 
traditionally been considered an essential part of evaluating the safety of anything that 
is intended to be administered to humans. For this purpose, a wide range of species 
belonging to different zoological classes have been used, highlighting, among all of 
them, the rat model. However, animal models are also subject to controversy because of 
the inherent ethical connotations and because frequently the safety data obtained are not 
directly extrapolated to the human species (Sanders et al., 2010) Therefore, it is desirable 
that the animal model be selected for its ability to predict what may happen in a person, 
which implies that their anatomy and physiology, including their development, 
metabolic processes, immune system responses and the composition of the microbiome, 
are as similar as possible to ours. In this sense, the pig is the ideal model (Pang et al., 
2007), despite the fact that it poses problems of cost and space, which often make it 
necessary to opt for other species. 
To date, studies of acute, subchronic and chronic oral toxicity of probiotics in 
standard models (eg, healthy rats) have shown no adverse effects even when 
administered at high doses (up to 10,000 times greater) than those normally consumed 
in humans) during a prolonged period of time (Ishibashi and Yamazaki, 2001; Reid et 
al., 2003; Sanders et al., 2010).  Due to this low or no pathogenicity, some authors have 
resorted to the use of animals which are immunosuppressed or genetically predisposed 
to suffer from certain pathologies in order to evaluate the safety of probiotics although 
this strategy has also been questioned because of the difficulty of extrapolating the 
results to a real situation. Another alternative that has been used to try to force the 
pathogenicity of probiotics is its administration by unusual routes (intravenous, 
intraperitoneal ...). Again, these approaches are difficult to validate since the results 
obtained can not be extrapolated to what happens when the same strain is administered 
orally (Ishibashi and Yamazaki, 2001). Globally, although the different in vitro, ex vivo 
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and animal models assays can provide useful information during the process of selection 
of strains, the only data that allow assessing the safety of a probiotic in a direct way are 
those obtained in the course of phase 1, 2 and 3 human clinical trials, properly designed 
and specifically directed to the target population. 
II.3.3. Functionality 
Similar to the safety assessment, there are also numerous in vitro, ex vivo and in 
vivo tests to detect those strains that have relevant functional properties. To a greater or 
lesser extent, all are useful to have as much information as possible when scrutinizing 
the strains with the greatest probiotic potential, but in practice, most of the in vitro and 
ex vivo tests do not allow guarantee the functionality of probiotic microorganisms in a 
host. Again, it will be clinical trials (phase 2 and 3) that determine whether a probiotic 
exerts the beneficial effect that was expected on the target population (Holzapfel et al., 
1998). 
From the functional point of view, the selection criteria usually include, on the one 
hand, a series of prerequisites for the strain to reach its place of action at an adequate 
concentration (normal inhabitant of the target host, resistance to transit through the 
digestive system, capacity of adhesion to epithelial cells ...) and, on the other hand, 
properties that could be associated with a beneficial effect in a host (production of 
antimicrobial substances, competitive exclusion of pathogens, stimulation of mucin 
synthesis, production of short chain fatty acids, synthesis of specific bioactive 
compounds, neutralization or detoxification of carcinogens and abiotic contaminants, 
immunomodulation, endocrinomodulation, neuromodulation ...). Among the last type of 
properties, some mechanisms might be widespread among commonly studied 
probiotic genera; others might be frequently observed among most strains of a 
probiotic species; others may be rare and present in only a few strains of a given 
species. Evidence is accumulating on a cross-section of probiotic strains that suggest 
some generalizations can be made beyond strain-specific effects (Figure 7). 
II.3.3.1. Prerequisites 
Traditionally it was recommended that probiotic strains had to be originally 
isolated from samples of the same species to which they were to be administered, based 
on the belief that strains of human origin would implant or colonize the human 
gastrointestinal epithelium more easily than strains isolated from samples belonging to 
other species (Holzapfel et al., 1998; Ouwehand et al., 1999). However, the report of the 
aforementioned FAO/WHO working group concluded that there is no defined criterion 
for the term "human origin" (FAO/WHO, 2002) since, in many cases, it is 
extraordinarily difficult, if not impossible, know the ultimate origin of a strain (human, 
animal, vegetable, food ...) even though it has been isolated, for example, from a sample 
of human feces. It also pointed out that there are several examples of probiotic strains 
that belong to allochthonous species but with beneficial effects well documented in 
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humans. For all these reasons, it concluded that, globally, the property "human origin" 
does not constitute a relevant criterion in the selection of probiotics for its use in our 
species. 
In order for orally administered probiotic strains to exert their beneficial effects, 
they must be able to withstand the environmental conditions existing during transit 
through the digestive system (saliva, gastric acidity, bile, pancreatic secretion ...), taking 
into account that the composition of the different secretions, the time of gastric emptying 
or the intestinal motility can vary depending on the age and health status of the host. To 
determine the resistance, in vitro methods, such as acidification and/or the addition of 
bile salts to the culture medium, the use of gastrointestinal secretions obtained from 
healthy individuals or the use of more sophisticated dynamic models such as those 
developed by the TNO in the Netherlands (Marteau et al., 1997), have been proposed. 
The survival of probiotics during transit can also be studied in vivo using intestinal 
intubation techniques and biopsies of the colon or analyzing their presence in the feces 
of people or animals that have ingested them, resorting to molecular techniques that 
allow discriminate between members of the host's indigenous microbiota. 
An important factor for the survival of probiotic bacteria is the substrate or matrix 
with which they are transported and, in fact, the results obtained in culture media can 
not be extrapolated to what happens when the strains are transported through food or 
encapsulated (Saxelin et al., 1993; Saxelin et al., 1995; Charteris et al., 1998). Systems 
that allow the maximum protection of probiotic strains during their passage through the 
stomach and duodenum have been developed in the last years, so that this criterion does 
not imply a real limitation. The same is applicable for the administration of probiotics 
by other classical (vaginal) or emerging routes (ophthalmologic eye drops, ear solutions, 
skin applications,..) in relation to the specific conditions of each ecosystem. 
II.3.3.2. Probiotic properties  
The functional properties by which a probiotic is selected can be as broad as our 
imagination, technology or budget can allow. For this reason, the intention of this section 
is not to offer a complete catalog of potentially probiotic characteristics but to highlight 
the diversity and complexity of the existing alternatives. Ideally, it would be necessary 
to know what a probiotic is desired for and what population it is intended to apply; in 
this way, they would be selected through the most appropriate tests to highlight the 
properties that are considered most relevant to achieve the final objective. 
As discussed above, adhesion to epithelial cells is a controversial property. 
However, for many authors it remains a key characteristic for a strain to colonize a 
mucosa and exert a probiotic effect, which can range from the competitive exclusion of 
pathogens (by competing for the same receptors) to complex neuroimmunological 
interactions, through induction of the biosynthesis of antimicrobial peptides or mucins 
by the epithelial cells. Various surface proteins, including mucus-binding proteins, and 
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some specific structures, such as the pili described in some strains of L. rhamnosus, are 
involved in the adhesion process. Self-aggregation phenomena can substantially 
increase the colonization capacity in those ecosystems in which probiotics have a short 
residence time. Another relevant property of some probiotic strains is to coaggregate 
with certain pathogens and, consequently, prevent their access to mucous membranes. 
The antimicrobial effect of the congregation is particularly intense when the same strain 
is capable of producing antimicrobial substances (organic acid, hydrogen peroxide, 
bacteriocins, reuterin ...) that inhibit the pathogen in question (Boris et al., 1998). 
The integrity of the mucous membranes is influenced by many factors, including 
changes in permeability, mucin composition, oxidative stress or the relationship between 
the production of new epithelial cells and the rate of apoptosis of damaged or aged 
epithelial cells. Several studies have demonstrated the ability of some probiotics to 
maintain or improve intestinal barrier function by modifying the expression of proteins 
that are part of the occlusion zones (occludin ZO-1, claudin-1, claudin-4,...), the 
modification of the monosaccharide composition of the mucins, the increase in the 
thickness of the mucus layer, the inhibition of apoptosis processes and/or the promotion 
of cell differentiation and cytoprotective activities, including reduction of oxidative 
stress (Howarth and Wang, 2013). 
The lymphoid tissue associated with the mucous membranes represents the 
majority of the immune system and its interaction with the microbiota constitutes one of 
the pillars of health. In fact, the processes of dysbiosis of the endogenous microbiota 
alter the immune responses and contribute to the appearance of infectious, inflammatory 
and (auto)immune diseases. Therefore, it is not surprising that the immunomodulation 
capacity is one of the activities that have been most associated with probiotics. In this 
regard, the effect of various strains on the different components of both innate (NK cells, 
dendritic cells, macrophages, epithelial cells...) and adaptive or acquired (Th1, Th2, 
Th17, Treg, Tc and B) immunity, including the proliferation and gene expression of 
various populations of cells of the immune system and the production of a broad 
spectrum of immunoglobulins, cytokines, chemokines, and growth factors has been 
repeatedly reported (Hardy et al., 2013).  
However, the selection process must take into account that the type of immune 
response associated with a probiotic (immunoactivation, immunodeviation, 
immunoregulation, immunosuppression) can be positive or negative depending on the 
state of the host. Consequently, to modulate an immunopathy for the benefit of the host, 
one must have as much knowledge as possible about the mechanisms responsible for the 
pathology and about the responses that can be expected from the probiotic. Therefore, 
the strain must be carefully selected depending on the population to which it is directed. 
Neuromodulation is one of the most promising effects in the field of probiotics. 
The human gastrointestinal tract contains a very complex nerve network, called the 
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enteric nervous system, whose main objective is the regulation of physiological 
functions and the modulation of communication between the intestine and the central 
nervous system, both upstream (bowel-brain) and downstream (brain-gut) (Mayer, 
2011). This communication system is known as the "gut-brain axis" and serves as 
coordination between the brain, the gastrointestinal tract, the endocrinological system 
and the immune system. Alterations in the bowel-brain axis are usually associated with 
certain psychiatric (from anxiety and depression to autism) and intestinal (irritable bowel 
syndrome) pathologies and the presence of an aberrant microbiota in individuals who 
suffer them (Critchfield et al., 2011; Saulnier et al., 2013). In this sense, it is considered 
that probiotics can have an important impact for these populations although, again, it 
will be necessary a careful selection of the strains (interaction with nervous receptors, 
effects in the biosynthesis and metabolism of neurotransmitters,...) and studies that 
reveal the magnitude, mechanisms and clinical relevance of the possible beneficial 
effects. 
There is a broad and growing spectrum of phenotypic tests to manifest probiotic 
properties through in vitro procedures. In addition, the availability of a functional 
genome analysis using new generation sequencing technologies and the rest of the –
omics approaches have revolutionized the discovery of potentially probiotic properties 
within a strain (Saulnier et al., 2011; Tu et al., 2014). Such powerful techniques allow a 
detailed analysis of genes involved in colonization, persistence, interaction and signaling 
within the human host and, consequently, a rapid selection of strains with very specific 
properties. 
II.3.3.3. In vivo assays 
Currently, in vivo assays offer the advantage of being able to apply a wide range 
of techniques (from –omics to the advanced imaging techniques, including biochemical 
techniques, molecular microbiology and cell biology) to try to elucidate the mechanisms 
of action and identify markers related to the beneficial effects (and, eventually, the 
possible adverse effects) of a probiotic. 
The use of animal models allows the study of samples, tissues and organs that, for 
ethical reasons, it is impossible to access in human clinical trials, so they are still 
essential to determine action mechanisms and biomedical markers. The range of animal 
models used to date to demonstrate the functionality of probiotics in vivo is very broad, 
both in animal species (including nematodes, insects, amphibians, fish, birds and 
mammals) and in types of animals within a specific species (breeds, pathophysiological 
states, germ-free animals, animals with a microbiota or "humanized" immune system, 
knock-out animals,...). 
Despite its undoubted usefulness, there are many anatomical and physiological 
differences (metabolic processes, immunological and endocrine responses, composition 
of the microbiome ...) between animal models and the human species; therefore, it will 
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be the human clinical trials the ones that finally determine the efficacy of the probiotic 
for the chosen target. Previously, descriptive human studies comparing samples of 
healthy people and people with different pathologies are extremely useful in determining 
the markers to be included in clinical trials. The definition of probiotic contains the word 
"benefit" and, in this sense, the objective of clinical trials is to determine scientifically 
if it actually occurs and its magnitude. 
The clinical trials in which efficacy is evaluated are typically those of phase 2 and 
phase 3. The phase 2 studies evaluate the efficacy of a probiotic against a placebo, 
preferably in a double-blind format, and collect the possible adverse effects. The 
desirable result would be a biological and statistically significant improvement in one or 
more of the following aspects: well-being or quality of life, reduction in disease risk, 
faster recovery from a disease, milder symptomatology during a disease and/or increase 
in recurrence times. More clinical evidence derived from this type of studies is needed 
for probiotics (species, strain, formulation, dose, specific application for which they 
have shown efficacy) to gain credibility among consumers and, especially, among the 
medical community, regardless of whether or not are marketed in the form of food or 
drug presentations. 
Phase 3 studies evaluate the efficacy of a probiotic versus the standard therapy 
used to prevent or treat a particular disease (Arroyo et al., 2010). In general, they are 
randomized trials in which the sample size must be carefully calculated and they should 
include possible adverse effects and incidents, an assessment of the risk: benefit ratio 
and a series of controls to check the quality of the trial. It would be desirable to carry 
out more phase 3 studies to encourage the use of probiotics in the prevention and 
treatment of diseases in those cases in which they can replace or complement 
conventional medicines. Currently, there are several factors that make more and more 
doctors consider the possibility of using probiotics as an alternative to certain 
medications, among which the growing number of (multi)resistance to antibiotics among 
pathogenic microorganisms is probably the most important one. 
The FAO and WHO working group recommended publication in internationally 
recognized scientific or medical journals, both for documentation proving the probiotic 
nature of a strain (including evidence from clinical trials) and for those cases in which 
negative results are obtained (FAO/WHO, 2002) 
II.3.4. Technological aspects 
The fact that a bacterial strain grows well under laboratory conditions (small 
volumes, complex culture media...) does not mean that the same will happen in industrial 
conditions. In this sense, companies that commercialize or wish to commercialize 
probiotics face two important technological challenges: (1) the need to obtain a very 
high bacterial biomass in an economically viable way; and (2) the need for the 
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concentration of bacteria necessary to exert the beneficial effect to remain viable until 
the end of the shelf life of the product (Rodríguez, 2015). 
Both aspects are related to the physiological characteristics of each strain, so 
conditions must be established case by case. In addition, viability also depends on the 
format in which the bacteria are to be administered since, for example, the shelf life of 
refrigerated dairy probiotic products is significantly shorter than that of lyophilized 
products sold with a medicinal presentation (capsules, powder ...). At the same time, 
there are several parameters (concentration of oxygen, humidity, storage temperature ...) 
and formats (microencapsulation, coatings ...) that play an important role in the stability 
of the product. In any case, it is inevitable that a greater or lesser rate of bacteria will die 
or be damaged during the productive process or the storage of the probiotic product and, 
in this sense, companies usually resort to the initial overdose of the probiotic, in such a 
way that keep the effective dose at the end of its useful life. 
Companies that are dedicated to the development of probiotics (including 
industrial scaling and feasibility studies) usually organize their work in the form of 
stages with an increasing degree of difficulty in which it is absolutely necessary that the 
objectives of a phase be achieved in order to be able to move on to the next one. The 
first stage usually consists of: (a) the deposit of the stock in the bank of the company 
and the verification of its identity (species); and (b) evaluation of its fermentative 
capacity (production, ropyness, morphology ...) on a small scale in mini-bioreactors or 
mini-fermenters that simulate the conditions of the plant fermenters (temperature, pH, 
agitation ...). 
The second phase involves scaling to pilot plant productions to evaluate 
productivity before and after the lyophilization process and the study of stability after 
three months. In general, the objective is for the product to be stable (loss ≤ 0.2 log cfu) 
in a mixture of cellulose (or other excipient) packed in foil pouches stored at a constant 
water activity (<0.2) and at a temperature of 25 °C. In the next phase, the workflow is 
determined so that the probiotic enters into the production phase. After the first 
production, the price is defined on the basis of the product profile (cfu/g) and the 
analytical validation of the mixture is completed. The final goal is the release of the 
product while long-term stability studies (two years) continue, both in refrigeration and 
at room temperature (~25ºC). In general, it is intended that the production process allows 
having a product with a high concentration (> 5 × 1010 cfu/g) which, once dosed in the 
final containers, has a prolonged useful life at room temperature (>2 years). In cases 
where it is not possible, the product must be kept refrigerated until its sale. 
In any case, it is essential to apply the principles of the HACCP system (Hazard 
Analysis and Critical Control Points) and good manufacturing practices to ensure that 
probiotic products reach the consumer with a quality as highest as possible. The quality 
control should consider the presence of the strains at the appropriate concentration, their 
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viability and stability and the possible contamination of the final product with other 
microorganisms, using the most appropriate dependent and independent culture 
techniques in each case (Huys et al., 2013). It is advisable that the companies that 
commercialize probiotics make controls of the products of the competition within the 
framework of the protection of patented strains. 
When a company introduces a probiotic into the market, it should ensure that the 
product is well labeled. In this regard, the expert committee of the FAO/WHO (2012) 
recommended that the label of any product containing probiotics include the following 
information: (1) genus, species and strain; (2) minimum dose of viable microorganisms 
at end of life; (3) necessary amount of product that must be consumed to achieve the 
effective dose; (4) beneficial effect(s); (5) storage conditions; and (6) information to 
contact with the customer service.  
II.3.5. Commercial aspects 
The opinion of the commercial department of a food or pharmaceutical company 
is essential when making a decision about the industrial development and the eventual 
placing on the market of a probiotic. The functions of this department include, among 
others, market studies (which allow detecting those needs of consumers that may be 
profitable), the promotion and advertising of the product, sales and post-sales service. 
Normally, these are activities that involve constant interaction with the production, 
financial and human resources departments. 
In general, three figures are usually identified in relation to the purchase decision: 
the prescriber (professional who recommends the product and whose opinion is valued 
by the consumer, for example, doctor or pharmacist), the buyer (the person who acquires 
the product but that does not have to coincide with the consumer, for example, parents 
who buy a probiotic indicated for infant colic), and the consumer. On the other hand, it 
is important to know the market segmentation, either by sex (for example, probiotics for 
vaginal infections or for mastitis), by age (for example, pediatric probiotics), by level of 
income, etc. 
Marketing campaigns basically focus, as in any other type of product, on different 
elements: the characteristics of the product (including the packaging), its price, 
distribution or availability and after-sales service. Normally, the life cycle of a product 
includes the stages of introduction or launching (a new product to the market, sales occur 
but the balance may become negative since it involves a significant promotion expense), 
growth (the product begins to be known, sales experience strong growth and profits too), 
and maturity (the speed of sales growth begins to stabilize and profits do the same). 
Eventually, there may be a stage of decline or saturation (considerable drop in sales and 
profits), in which you can try to relaunch the product by introducing some innovation. 
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The determination of the price can be based on the costs, on the elasticity of the 
demand, on the prices fixed by the competition for similar products, etc. In general, the 
probiotic products available in pharmacies and parapharmacies are not covered by the 
public health system so they usually have a high final cost (~ € 1/capsule, sachet or 
ovule). This fact prevents a relatively high percentage of potential users to have access 
to them, especially when prolonged treatment is required. In the future, the greater 
availability of results based on well-designed clinical trials and certain regulatory 
changes could change the situation. 
The distribution policy allows the product to be in the right place at the right time 
to be purchased by the consumer. In general, the process that the product follows since 
it leaves the production chain until it reaches the customer is as follows: product storage, 
physical distribution, billing and collection. The distribution channel is any of the means 
(food establishments, pharmacies, parapharmacies ...) that are used to get products to go 
the way from the producer to the consumer. There are several ways to promote the 
product, including advertising, sales promotion, public relations and merchandising or 
advertising at the place of sale. 
Finally, the interaction between the researchers and clinicians who isolated and 
evaluated the probiotic strain(s) and the company that commercializes it is very 
important, especially in relation to the support that the former can offer in presentations 
in meetings, congresses and specialized publications or in the form of informative 
information for a wider audience. 
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S. agalactiae (GBS) is a bacterial specie that is often present in the microbiota of 
the human gastrointestinal and genitourinary tracts of healthy hosts. The GBS 
colonization rate oscillates between 15 and 40% among fertile women, with a mean 
value of 18% worldwide (Russell et al., 2017). However, under certain circumstances S. 
agalactiae can cause infections both in adults, especially pregnant women, 
immunocompromised people and elderly people, and, particularly, in infants (Le Doare 
and Heath, 2013). In fact, this microorganism is one of the leading causes of EOS and 
LOS, which are associated with significant morbidity and mortality. EOS usually 
reflects transplacental or ascending infections from the maternal genitourinary tract, 
whereas LOS has been generally linked to the postnatal nosocomial or community 
environments. 
 Because of the involvement of S. agalactiae in LOS, there is an interest in 
eradicating this microorganism from the gastrointestinal and genitourinary tracts of 
pregnant women. In the last decades, intrapartum antibiotic prophylaxis (IAP) has been 
the most common preventive strategy in developed countries. National strategies for 
targeting pregnant women for IAP include either risk-based or screening-based 
approaches. Risk factors include intrapartum fever above 38ºC, premature (before 37 
weeks of gestation) or prolonged (>18 h) rupture of membranes, a previous infant 
affected by GBS disease and S. agalactiae bacteriuria (≥10 cfu/ml). On the other hand, 
universal screening involves the collection of recto-vaginal swab at late pregnancy (35-
38 week of pregnancy) and the subsequent administration of IAP to positive-women and 
to those with an unknown status. However, even strict and universal implementation of 
IAP guidelines does not eliminate early onset disease by GBS disease while IAP has no 
impact on late onset GBS infection where the burden of disease is also substantial. 
As a method to eradicate GBS neonatal infections, the IAP strategy is not devoid 
of controversy. Some Cochrane’s reviews on this issue have concluded that the efficacy 
of IAP to reduce perinatal GBS infections are not supported by conclusive evidence 
from well designed and conducted randomized controlled trials (Ohlsson and Shah, 
2009; Ohlsson et al., 2013; Ohlsson et al., 2014). A major drawback of the universal 
screening strategy is that, as stated above, most women colonized with GBS are 
asymptomatic and, among GBS-positive women, very few will give birth to babies who 
are infected with GBS. Hence, giving intravenous antibiotics to all GBS-positive 
pregnant women during delivery will put a large number of women and babies at risk of 
the adverse effects of antibiotics unnecessarily. These adverse effects include 
anaphylaxis and allergic reactions. However, the biggest concerns are the increasing 
rates of antibiotic resistance among clinically relevant microorganisms and, particularly, 
the impact of IAP on the acquisition, composition and development of the infant 
microbiota. 
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Given the limitations in IAP strategies, alternatives are required. Vaccines, in 
particular, hold great promise but no GBS vaccine is currently available since vaccine 
development targeting this bacterial species also faces some relevant limitations. But, 
even if an effective vaccine to prevent GBS infections is developed in the future, a need 
for alternative strategies is still likely to be present as all women will not be immunized 
and the vaccine may not be effective in women giving birth preterm. In this context, the 
isolation, selection and characterization of safe probiotic strains with the ability to 
antagonize and, eventually, eradicate GBS from maternal and infant mucosal 
surfaces is a very attractive target. This has been the general objective of this PhD 
Thesis. 
 The partial objectives of the PhD Thesis were the following: 
 1. Analysis of the bacterial diversity and the presence of GBS in vaginal and 
fecal samples of pregnant and non-pregnant healthy women. Isolation of lactobacilli 
strains from the biological samples. 
 2. Characterization of the preselected lactobacilli strains by in vitro assays 
targeting both potential probiotic properties against GBS and safety (antimicrobial 
activity against GBS strains, co-aggregation with GBS strains, adhesion to mucin and 
intestinal and vaginal cells, resistance to the transit through a gastrointestinal tract-like 
environment, production of biogenic amines, mucin degradation, antibiotic resistance 
profile, etc).  
 3. In vivo (rat model) assessment of acute and chronic toxicities of the 
Lactobacillus strain selected because of its highest probiotic potential to eradicate GBS 
on the basis of the activities carried out to achieve the partial objective 2.  
 4. Clinical trial to evaluate the ability of the selected Lactobacillus strain for the 
eradication of GBS colonization in pregnant women.  
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IV.1. ASSESSMENT OF THE VAGINAL MICROBIOTA OF GBS-
POSITIVE AND GBS-NEGATIVE NON-PREGNANT AND PREGNANT 
WOMEN 
IV.1.1. Participating women 
A total of 54 fertile women (30 non-pregnant and 24 pregnant women), aged 25-
35, participated in this study. All volunteers gave written informed consent to the 
protocol, which had been approved (protocol 10/017-E) by the Ethical Committee of 
Clinical Research of Hospital Clínico San Carlos, Madrid (Spain). All non-pregnant 
women provided 4 vaginal exudate samples, which were collected at days 0, 7, 14 and 
21 of their menstrual cycles. Pregnant women provided a single sample which was 
collected at week 35-37 of pregnancy. All women claimed to be completely healthy. 
IV.1.2. Microbial isolation, enumeration and identification 
Samples were diluted in peptone water and spread onto Columbia Nalidixic Acid 
(CNA), Mac Conkey (MCK), Sabouraud Dextrose Chloramphenicol (SDC), 
Gardnerella (GAR) and Mycoplasma agar plates (BioMerieux, Marcy l'Etoile, France) 
for selective isolation and quantification of the main agents involved in vaginal 
infections. They were also spread onto agar plates of MRS (Oxoid, Basingstoke, UK) 
supplemented with either L-cysteine (0.5 g/L) (MRS-C) or horse blood (5%) (MRS-B) 
for isolation of lactobacilli. All the plates were incubated for 48 h at 37ºC in aerobic 
conditions, with the exception of the MRS-C and MRS-B ones, which were incubated 
anaerobically (85% nitrogen, 10% hydrogen, 5% carbon dioxide) in an anaerobic 
workstation (DW Scientific, Shipley, UK). Parallel, all the samples were submitted to 
an enrichment step in Todd Hewitt broth (Oxoid, Basignstoke, UK) to facilitate the 
isolation of S. agalactiae in CNA plates. 
Initially, identification of the bacterial strains (at least one isolate of each colony 
morphology per medium and per sample) was performed by sequencing a 470 pb 
fragment of the 16S rDNA gene PCR amplified using the primers pbl16 (5’-
AGAGTTTGATCCTGGCTCAG-3’) and mbl16 (5’-
GGCTGCTGGCACGTAGTTAG-3’) (Kullen et al., 2005). The PCR conditions were 
as follows: 96 ºC for 30 s, 48 ºC for 30 s and 72 ºC for 45 s (40 cycles) and a final 
extension at 72 ºC for 4 min. The amplicons were purified using the Nucleospin 
Extract II kit (Macherey-Nagel, Düren, Germany) and sequenced at the Genomics Unit 
of the Universidad Complutense de Madrid, Spain. The resulting sequences were used 
to search sequences deposited in the EMBL database using BLAST algorithm and the 
identity of the isolates was determined on the basis of the highest scores (>99%). 
Identification of yeasts and confirmation of the initial 16S rDNA-based bacterial 
identifications was performed by MALDI-TOF (VITEK MS, BioMerieux). Briefly, a 
IV. Materials and Methods 
 
68 
 
portion of a bacterial colony (~1 µL) was directly spotted onto a MALDI sample plate. 
Then, it was overlaid with 1 µL of a saturated solution of α-cyano-4-hydroxycinnamic 
acid in acetonitrile (28%), and allowed to dry at room temperature. For each isolate, a 
mean spectrum was constructed with at least 50 m/z spectra profiles and used for the 
identification by comparison with the spectra contained in the Myla database 
(Biomerieux). Identification was defined as a 99-100% match to the species-specific m/z 
values in the database. Identification of S. agalactiae isolates was also confirmed by 
using a latex agglutination test (Streptococcal grouping kit, Oxoid), following the 
instructions of the manufacturer. 
Those isolates identified as belonging to the genus Lactobacillus were preserved 
for further studies. For such purpose, a MRS-C broth culture of each isolate was mix 
with glycerol (15%, v/v) and kept at -80ºC until required. A total of 89 different 
Lactobacillus strains were isolated from the vaginal swabs and submitted to Random 
Amplification of Polymorphic DNA (RAPD) genotyping in order to avoid duplication 
of isolates. RAPD profiles were obtained using primer OPL5 (5’-ACGCAGGCAC-3’), 
as described by Ruiz-Barba et al. (2005). Lactobacillus strains were routinely cultured 
in MRS-C medium at 37 °C under aerobic conditions. When required, they were grown 
in anaerobiosis as described above.  
IV.2. IN VITRO ASSESSMENT OF THE ACTIVITY OF THE 
LACTOBACILLI STRAINS AGAINST GBS AND THEIR POTENTIAL 
MECHANISMS OF ACTION 
IV.2.1. Antimicrobial activity against S. agalactiae strains 
 An overlay method (Magnusson and Schnürer, 2001) was used to determine the 
ability of the lactobacilli strains to inhibit the growth of 12 different S. agalactiae strains. 
Among them, 6 strains had been isolated from blood or cerebrospinal fluid in clinical 
cases of neonatal sepsis (Hospital Universitario Ramón y Cajal, Madrid, Spain) while 
the remaining 6 ones had been isolated from vaginal samples of pregnant women (our 
own collection). It was performed using MRS agar plates, on which the lactobacilli 
strains were inoculated as approximately 2 cm-long lines and incubated at 37ºC for 48 
h. The plates were then overlaid with the indicator S. agalactiae strains vehiculated in 
10 ml of Brain Heart Infusion (BHI, Oxoid) broth supplemented with soft agar (0.7%), 
at a concentration of ~104 colony-forming units (cfu)/ml. The overlaid plates were 
incubated at 37ºC for 48 h and, then, examined for clear zones of inhibition (> 2 mm) 
around the lactobacilli streaks. All experiments assaying inhibitory activity were 
performed in triplicate. 
 
 
                                IV. Materials and Methods 
 
 
69 
 
IV.2.2. Production of bacteriocins 
The Lactobacillus strains were grown in MRS broth at 37ºC until early stationary 
phase (A620 ~1.0). The culture was centrifuged at 12000  g for 10 min at 4ºC, and the 
supernatant was neutralized to 6.2 with 1 M NaOH, heated at 100ºC for 5 min and filter-
sterilized through 0.22 μm-pore-size filters (Millipore, Bedford, USA). The 
bacteriocinogenic activity of the cell-free supernatants was determined by an agar well 
diffusion assay. Aliquots (100 μl) of the supernatants were placed in wells (7-mm 
diameter) cut in cooled BHI agar plates previously seeded (105 cfu/ml) with the S. 
agalactiae indicator strains. The plates were kept at 4ºC for 2 h and, then, incubated 
under optimal conditions for growth of the indicator.  
IV.2.3. Production of hydrogen peroxide 
Hydrogen peroxide production by the lactobacilli strains was initially tested 
following the procedure described by Song et al. (1999). MRS agar plates supplemented 
with 0.25 mg/ml of tetramethylbenzidine (TMB; Sigma, St. Louis, USA) and 0.01 
mg/ml of horseradish peroxidase (HRP, Sigma) were inoculated with the strain and 
anaerobically incubated for 2 days at 37ºC. HRP is known to oxidize TMB in the 
presence of hydrogen peroxide to form a blue pigment in the H2O2-producing colony. 
Parallel, the hydrogen peroxide was also measured by a modification of the quantitative 
method of Yap and Gilliland (2000). The strain was anaerobically grown in 10 ml of 
MRS broth for 24 h at 37ºC. The cells were harvested by centrifugation at 12000 × g for 
10 min at 4ºC, washed twice with potassium phosphate buffer (50 mM, pH 6) and 
resuspended in 9 ml of the same buffer supplemented with 5 mM glucose. The cell 
suspension (0.5 ml) was inoculated into a tube containing 9 ml of the glucose-containing 
buffer. After an incubation at 37ºC for 24 h in aerobiosis, the cells were removed by 
centrifugation at 12000 × g for 10 min at 4ºC and the supernatants were assayed for 
hydrogen peroxide. Briefly, 5 ml of supernatant were mixed with 100 µL of 1% aqueous 
ø-dianisidine (Sigma), and 1 ml of 0.001% aqueous HRP. The tubes were incubated for 
10 min at 37ºC and the reaction was stopped by adding 0.2 ml of 4 N HCl. Absorbance 
readings (A400 nm) were determined and peroxide content was quantified by comparing 
the values obtained with those of a H2O2 standard curve. In the H2O2 assays, 
Lactobacillus acidophilus CECT 903T and Lactobacillus gasseri CECT 5714 were used 
as a positive control. 
IV.2.4. Production of lactic acid 
Lactic acid production by the Lactobacillus strains was determined in MRS broth 
(pH 6.2). One percent inoculum’s from an overnight MRS culture was used and 
incubation proceeded for 24 h at 37ºC anaerobically. Cells were removed by 
centrifugation at 12000 × g for 5 min and the concentration of L- and D-lactic acid in 
the supernatants was quantified using an enzymatic kit (Roche Diagnostics, Mannheim, 
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Germany), following the manufacturer’s instructions. The pH values of the supernatants 
were also measured. All these assays were performed in triplicate and the values were 
expressed as the mean ± SD. L. salivarius CECT 5713 was used as a positive control 
(high production of L-lactic acid in MRS broth) (Martín et al., 2006). 
IV.2.5. Co-aggregation between the lactobacilli and the S. agalactiae strains 
Coaggregation assays were designed based on previously reported methods (Reid 
et al., 1990). Bacterial suspensions were adjusted to an A600 of 0.6. Aliquots of 10 ml of 
each of the Lactobacillus strains were independently mixed with 10 ml of each of the S. 
agalactiae strains and incubated at 37°C for 4 h and 16 h. The suspensions were then 
observed under a phase-contrast microscope after Gram staining. 
IV.2.6. Broth co-cultures of the lactobacilli and the S. agalactiae strains  
To test the anti-S. agalactiae activity of the lactobacilli in a broth assay format, 
tubes containing 20 ml of MRS broth were co-inoculated with 1 ml of a Lactobacillus 
strain culture (7 log10 cfu/ml) and 1 ml of a S. agalactiae strain (7 log10 cfu/ml). 
Subsequently, the cultures were incubated for 6 h at 37°C in aerobic conditions. 
Immediately after the co-inoculation and after the incubation period, aliquots were 
collected, serially diluted and plated on MRS-C plates and CHROMagar StrepB agar 
plates (CHROMagar, París, France) for selective enumeration of lactobacilli and 
streptococci, respectively. Correct taxonomic assignment was confirmed by MALDI-
TOF analysis as described previously.  
IV.3. IN VITRO ASSESSMENT OF OTHER PROBIOTIC PROPERTIES 
OR PRERREQUISITES OF THE LACTOBACILLI STRAINS  
IV.3.1. Survival after transit through an in vitro gastrointestinal model 
The survival of the strains was tested in an in vitro model of the human stomach 
and small intestine based on that described by Marteau et al. (1997) with the 
modifications included by Martín et al. (2005). Aliquots (25 ml) containing 
approximately 109 cfu/ml of the strain tested was diluted in 5 ml of a sterile electrolyte 
solution containing 6.2 g/l of NaCl, 2.2 g/l of KCl, 0.22 g/l of CaCl2, and 1.2 g/l of 
NaHCO3 to simulate the in vivo dilution by host saliva. Then, 5 ml of porcine gastric 
juice was added and the mixture was incubated at 37ºC with agitation. The pH curve in 
the stomach-resembling compartment was controlled to reproduce the values found in 
monogastrics after yogurt consumption (Conway et al., 1987): pH 5.0 at initiation, pH 
4.1 at 20 min, pH 3.0 at 40 min, and pH 2.1 at 60 min.  
Fractions were successively taken from this compartment at 20, 40, 60, and 80 
min, in a manner that simulates the normal gastric emptying (Marteau et al. 1997). After 
adjusting their pH to 6.5 ± 0.2 with 1 M NaHCO3, they were mixed with 10 ml of a 
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sterile electrolyte solution containing 5 g/l of NaCl, 0.6 g/l of KCl, 0.3 g/l of CaCl2, 4% 
of porcine bile, and 7% of pancreatin (Sigma), which simulates the content of the 
duodenal juice. After 120 min of successive exposure to these conditions, bacterial 
survival was determined by plating the samples onto MRS agar plates, which were 
anaerobically incubated at 37ºC for 48 h. L. salivarius CELA2 was used as a positive 
control because of its high resistance to gastrointestinal-like conditions (Martín et al., 
2009). All these assays were performed in quadruplicate and the values were expressed 
as the mean ± SD. 
IV.3.2. Adherence assays to intestinal and vaginal epithelial cells 
The adherence of lactobacilli to HT-29 and Caco-2 cells was examined as 
described by Coconnier et al. (1992). Routinely, cells were grown in DMEM medium 
(PAA, Linz, Austria) containing 25 mM glucose, 1 mM sodium pyruvate and 
supplemented with 10% heat-inactivated (30 min, 56ºC) fetal calf serum, 2 mM L-
glutamine, 1% non-essential amino acid preparation, 100 U/ml penicillin and 100 mg/ml 
streptomycin. For the adherence assays, HT-29 and Caco-2 were cultured to confluence 
in 2 ml of medium devoid of antibiotics. Approximately 10 days post-confluence, 1 ml 
of the medium was replaced with 1 ml of Lactobacillus suspension (108 cfu/ml in 
DMEM). The inoculated cultures were incubated for 1 h at 37ºC in 5% CO2. Then, the 
monolayer was washed five times with sterile PBS, fixed with methanol, stained with 
Gram stain and examined microscopically. The adherent lactobacilli in 20 random 
microscopic fields were counted for each test. L. rhamnosus GG and Lactobacillus casei 
imunitass were used as positive and negative controls because of their high and low 
adhesive potential, respectively (Martín et al., 2005).  
Adherence to vaginal epithelial cells collected from healthy premenopausal 
women was performed as described previously (Boris et al., 1998).  
IV.3.3. Adherence to and/or degradation of mucin   
The adhesion of the lactobacilli strains to mucin was determined according to the 
method described by Cohen and Laux (1995) with some modifications. Briefly, 100 μl 
of a solution (1 mg/ml) of porcine mucin (Sigma) in HEPES-buffered Hanks salt 
solution (HH) were immobilized in polystyrene microtiter plates (Maxisorp; Nunc, 
Roskilde, Denmark) after overnight incubation at 4ºC. The wells were washed twice 
with 250 μl of HH. Parallel, bacteria were grown overnight at 37ºC in MRS broth and 
the bacterial pellets from 1 ml fractions were obtained by centrifugation and washed 
with HH. Then, 10 μl of 10 mM carboxyfluorescein (Sigma) were added to the pellets 
and the bacterial suspensions were incubated for 20 min at 37ºC. Subsequently, the 
bacterial cells were washed 3 times with HH and, finally, resuspended in 1 ml of HH. 
Then, a suspension of 50 μl of the fluorescent-labelled bacteria (~ 5107 cfu) was added 
to each well. After incubation for 1 h at 37ºC, the plates were washed twice with 250 μl 
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of HH to remove unattached cells, and incubated for 1 h at 60ºC in the presence of 50 μl 
of 1% sodium dodecyl sulphate (SDS)-0.1 M NaOH to release and lyse bound 
microorganisms. Fluorescence was measured in a fluorescence microplate reader (Tecan 
Austria GMBH, Salzburg, Austria). Adhesion was assessed as the percentage of the 
fluorescence retained in the wells after the washing steps when compared to that present 
in the labelled bacterial aliquots originally added to the wells. L. reuteri CR20 was used 
as a positive control (strong adherence to mucin) (Martín et al., 2009). The assays were 
performed in duplicate. 
The potential of the lactobacilli strains to degrade gastric mucin (HGM; Sigma) in 
vitro was evaluated in duplicate following the procedure developed by Zhou et al. 
(2001).  
IV.3.4. Antibiotic resistance/susceptibility 
Minimum inhibitory concentrations (MICs) of the 16 antibiotics included in this 
study (gentamicin, kanamycin, streptomycin, neomycin, tetracycline, erythromycin, 
clindamycin, chloramphenicol, ampicillin, penicillin, vancomycin, virginiamycin, 
linezolid, trimethoprim, ciprofloxacin and rifampin) were determined by a microdilution 
method using VetMIC plates for lactic acid bacteria (National Veterinary Institute of 
Sweden, Uppsala, Sweden), as described previously (Langa et al., 2012). The plates 
were incubated at 37°C for 48 h and MIC was defined as the lowest concentration at 
which no growth was observed. MICs values were compared with the microbiological 
cut-off parameters established by the European Food Safety Authority (EFSA, 2012) for 
Lactobacillus species. 
IV.3.5. Prophage induction  
 In order to discard the presence of phages compromising strain viability, 
prophage induction was carried as described previously (Langa et al., 2012). 
Exponential cultures of the lactobacilli strains (A600~0.4) were treated with 0.25, 0.5 
(minimal inhibitory concentration; MIC), and 1 µg/ml mitomycin C (final 
concentration), and incubation was continued for up to 5 h. Aliquots of the supernatants 
were placed on lawns of presumably susceptible L. salivarius strains growing in soft 
MRS (0.75% agar) supplemented with 1% haemoglobin, 10 mM CaCl2 and 10 mM 
MgSO4, placed on top of plates with the same medium (1.5% agar). After incubation for 
24 h, the generation (or not) of lysis plates was recorded. 
IV.3.6. Production of biogenic amines 
Initially, the ability to form biogenic amines (tyramine, histamine, putrescine and 
cadaverine) was assessed using the decarboxylase broth and the method described by 
Bover-Cid and Holzapfel (1999). The precursor amino acids (tyrosine, histidine, 
ornithine and lysine, respectively) were purchased from Sigma. The lactobacilli strains 
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were streaked onto the different decarboxylase medium plates and incubated for 4 days 
at 37ºC under aerobic and anaerobic conditions. A positive result was indicated by a 
change of the medium colour to purple in response to the pH shift caused by the 
production of the more alkaline biogenic amine from the amino acid initially included 
in the medium.  
Parallel, the lactobacilli strains were grown for 24 h in MRS broth supplemented 
with 10 mM tyrosine (M17T), 13 mM of histidine (M17H) or 20 mM agmatine (M17A) 
for the detection of tyramine, histamine and putrescine production, respectively. The 
supernatants were filtered through a 0.2 μm pore diameter membrane, derivatyzed and 
analyzed by thin layer chromatography (TLC) following the conditions described by 
García-Moruno et al (2005).  
In addition, the presence of the tyrosine decarboxylase gene (tdcA), histidine 
decarboxylase gene (hdcA) and agmatine deiminase cluster (AgdDI) was checked by 
specific PCR using methods described previously (Le Jeune et al., 1995; Lucas and 
Lonvaud-Funel, 2002; Ladero et al., 2012). 
IV.4. IN VIVO ASSESSMENT OF THE SAFETY OF L. salivarius V4II-90 
IN A RAT MODEL 
Globally, L. salivarius V4II-90 was the strain that showed the best results as a 
candidate for future clinical trials. Subsequently, its potential acute and chronic oral 
toxicity was evaluated; in addition, the potential translocation of this strain to blood and 
some organs was also investigated. 
IV.4.1. Acute and repeated doses (4-weeks) oral toxicity studies 
Wistar male and female rats (Charles River Inc., Marget, Kent, UK) were 
acclimated for 7 days prior to study initiation with an evaluation of health status. The 
rats were individually housed in polycarbonate cages with sawdust bedding and 
maintained in environmentally controlled rooms (22 ± 2ºC and 50% ± 10% relative 
humidity) with a 12 h light–dark cycle (light from 08.00 to 20.00 h). Food (A03 rodent 
diet, Scientific Animal Food and Engineering, Villemoisson-sur-Orge, France) and 
water were available ad libitum. The rats were 56-days old at the initiation of treatment. 
Acute (limit test) and repeated dose (4 weeks) studies were conducted in 
accordance with the European Union guidelines. Both studies were undertaken in 
accordance with the ethics requirements and authorized by the Official Ethical 
Committee of the Complutense University. 
In the acute (limit test) study, 24 rats (12 males, 12 females) were distributed into 
two groups of 6 males and 6 females each. After an overnight fast each rat received skim 
milk (500 μl) orally (control group or Group 1), or a single oral dose of 1  1010 cfu of 
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L. salivarius V4II-90 dissolved in 500 μl of skim milk (treated group or Group 2). Doses 
of the test and control articles were administered by gavage. Animals were checked for 
clinical signs and mortality twice a day (a.m. and p.m.). At the end of a 14 days 
observation period, the rats were weighed, euthanized by CO2 inhalation, exsanguinated, 
and necropsied. 
The repeated doses (4 weeks) (limit test) study was conducted in 48 rats (24 males, 
24 females) divided in four groups of 6 males and 6 females each (control group or 
Group 3; treated group or Group 4; satellite control group or Group 5; and satellite 
treated group or Group 6). Rats received a daily dose of either skim milk (Groups 3 and 
5) or 1  109 cfu of L. salivarius V4II-90 dissolved in 500 μl of skim milk (Groups 4 
and 6) orally once a day over 4 weeks. Doses of the test and control articles were 
administered by gavage. Animals were dosed at approximately the same time each day 
(approximately 4–6 h into light cycle). Food but not water was withheld from 4 h before 
until 2 h after control and test article administration. Animals were checked for clinical 
signs and mortality twice a day (a.m. and p.m.). All rats of the Groups 3 and 4 were 
deprived of food for 18 h, weighed, euthanized by CO2 inhalation, exsanguinated, and 
necropsied on Day 29. All animals of the satellite groups (Groups 5 and 6) were kept a 
further 14 days without treatment to detect delayed occurrence, or persistence of, or 
recovery from toxic effects. All rats of the Groups 5 and 6 were deprived of food for 18 
h, weighed, euthanized by CO2 inhalation, exsanguinated, and necropsied on Day 42. 
IV.4.2. Animal observations  
All animals were observed twice daily for general appearance, behaviour, sings of 
morbidity and mortality (once before treatment and once daily thereafter). Rats were 
observed for their general condition and the condition of the skin and fur, eyes, nose, 
oral cavity, abdomen and external genitalia, evaluated for respiration rate and palpated 
for masses. Behavioural parameters checked were abnormal movements (tremor, 
convulsion, muscular contractions), reactions to handling and behaviour in open field 
(excitability, responsiveness to touch and to sharp noise), changes in ordinary behaviour 
(changes in grooming, head shaking, gyration), abnormal behaviour (autophagia, 
backward motion) and aggression. Body weight, body weight gain and food and water 
consumption were measured daily and at the end of the observation periods the rats were 
examined by necropsy, and the weights of the organs recorded. 
IV.4.3. Clinical test parameters 
Blood samples for haematology and clinical chemistry evaluation were collected 
from the retro-orbital plexus from animals under light anaesthesia induced by CO2 
inhalation after 14 days observation period in the acute oral study and alter 4 weeks of 
treatment and 14 days of recovery for the repeated dose 4 weeks safety study. EDTA 
was used as an anticoagulant for haematology samples and sodium citrate was used as 
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an anticoagulant for clinical chemistry. Food was withheld for approximately 18 h 
before blood collection, and samples were collected early in the working day to reduce 
biological variation; water was provided ad libitum. 
Clinical pathology parameters (haematological and clinical biochemistry) were 
evaluated. Most haematology variables were measured with a Coulter/CELL-DYN 3500 
whole blood automated analyzer (Abbott, Chicago, IL). Blood cell smears were 
observed with an Olympus Microscopy BX41 (Olympus, Tokyo, Japan). 
Clinical chemistry parameters were evaluated with a spectrophotometer Konelab 
PRIME 30 (Thermofisher Scientific Inc. Waltham, MA, USA) and special biochemistry 
parameters with a clinical chemistry analyzer AU640 (Olympus, Tokyo, Japan). 
Coagulation parameters were analyzed with a coagulation analyzer Coatron M1 (Teco 
Medical Instruments, GMBH, Neufahrn, Germany). 
IV.4.4. Anatomical pathology  
All rats were euthanized by CO2 inhalation and necropsied. The necropsy included 
a macroscopic examination of the external surface of the body, all orifices, the cranial 
cavity, the brain and spinal cord, the nasal cavity and paranasal sinuses, and the thoracic, 
abdominal, and pelvic cavities and viscera. Descriptions of all macroscopic 
abnormalities were recorded. Samples of the following tissues and organs were collected 
from all animals at necropsy and fixed in neutral phosphate-buffered 4% formaldehyde 
solution: adrenal glands, brain, heart, ileum, jejunum, caecum, colon, duodenum, 
rectum, stomach, oesophagus, trachea, kidneys, liver, lungs, pancreas, spleen, skin, 
testicles with epididymes, ovaries with oviducts, bone marrow, thymus, thyroid and 
parathyroid glands, seminal vesicles, urinary bladder and uterus. The organ: body weight 
ratios were calculated. All organ and tissue samples for histopathological examination 
were processed, embedded in paraffin, cut at an approximate thickness of 2 to 4 mm, 
and stained with hematoxylin and eosin. Slides of all organs and tissues listed above 
were collected from all animals of the control and treated groups. 
IV.4.5. Isolation of L. salivarius V4II-90 from feces and vaginal swabs samples 
Once the rats were euthanized a sample of colon content and a vaginal swab was 
collected from each animal. These samples were diluted and inoculated onto MRS-C 
agar plates. Isolates identified as L. salivarius by MALDI-TOF were submitted to 
pulsed-field gel electrophoresis (PFGE) genotyping (Arroyo et al., 2010), and their 
profiles were compared with that of L. salivarius V4II-90.  
IV.4.6. Bacterial translocation 
Bacterial translocation was analysed in blood, liver and spleen. blood (50 μl) were 
cultured in de Man, Rogosa, Sharpe (MRS) agar medium and incubated at 37ºC during 
IV. Materials and Methods 
 
76 
 
48 h anaerobically. Tissue samples were homogenized in buffered peptone water (1 
g/ml) and 100 μl of the resulting homogenates were cultured on MRS agar as previously 
mentioned. After 48 h, the plates were checked for the presence of lactobacilli. Positive 
growth on MRS agar plates was defined by the presence of even a single colony. 
IV.4.7. Total liver glutathione (GSH) concentration  
A portion of 100 mg of liver from each mouse were homogenized in a 7.5% 
trichloroacetic acid solution and homogenates were centrifuged at 3,000  g for 10 min 
at 4ºC. Total glutathione concentration was measured in the supernatants using a 
colorimetric commercial kit (OxisResearch, Portland, OR). Briefly, 40 μl of the 
homogenates or the standards were added to each well of a microtiter plate, together 
with 40 ml of a reducing agent (tris[2-carboxyethyl] phosphine in HCl), 40 ml of a 
chromogen (1-methyl-3-chloro-7-trifluoromethylquinolinium methylsulfate in HCl) and 
40 ml of color developer (NaOH). After an incubation at room temperature and in the 
dark for 30 min, optical density was measured at 415 nm using a microplate 
spectrophotometer (Bio-Rad Laboratories, Hercules CA).  
IV.4.8. Statistical analysis (for toxicity studies) 
All data are expressed as means ± standard error of the mean (SEM) of the 
determinations. Differences between control and treated groups were evaluated with a 
one-way analysis of variance (ANOVA) followed by Dunnett’s test, and differences 
were considered significant at P < 0.05. 
IV.5. DESIGN OF A PCR ASSAY FOR SPECIFIC AND SENSITIVE 
DETECTION OF S. agalactiae IN BIOLOGICAL SAMPLES  
IV.5.1. In silico design of GBS-specific primers 
In order to design GBS species-specific primers, 16S rRNA gene sequences from 
various bacterial species (S. agalactaie and taxonomically-related species) available in 
the Genbank database were analyzed and compared using the programs Emma and 
Showalign, included in the free open source software analysis EMBOSS (The European 
Molecular Biology Open Software Suite).  
IV.5.2. Conventional and Real-Time PCR assays: specificity and detection 
limit 
All reactions were set up using the CFX Connect and CFX96 Touch™ Real-Time 
PCR Detection Systems (Bio-Rad Laboratories, Inc, Hercules, CA, USA). The reaction 
volume for conventional PCR was 25 μL, and 10 μL for real-time PCR amplification. 
Each run contained a negative control (deionized sterile water) and a positive control 
(100 or 25 ng of DNA from S. agalactiae DSMZ 2134). In the real-time assay the 
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determination of a PCR positive result and the specificity of the reaction was based on 
the melting curve. The melting temperature (Tm), which is specific for each amplicon, 
depends on various factors including the amplicon length and the nucleotide sequence. 
The specificity of the primers designed was tested using DNA obtained from a 
panel of 6 S. agalactiae strains, 10 strains of other streptococcal species, and 21 strains 
of species belonging to related genera. All strains were analyzed in duplicate.  
To check the detection limit of this PCR approach, the DNA extracted from pure 
culture of S. agalactiae DSMZ 2134, obtained from the German Collection of 
Microorganism and Cell Cultures (DSMZ), was used to prepare 10-fold dilution series 
with a bacterial population ranging from 2 to 9 log10 cfu, as determined by plate 
counting.  
IV.5.3. Efficiency   
The DNA extracted from vagino-rectal swab samples provided by female 
volunteers was analyzed in order to evaluate the applicability of the conventional and 
real-time PCR assay to the detection of S. agalactiae colonization in women. Both PCR 
approaches were compared with a conventional culture approach and GBS identification 
by MALDI-TOF, as explained above. All samples were analyzed in duplicate. 
In the real-time PCR assay the presence or absence of GBS DNA in a sample was 
defined using a cut-off Ct value equal to 38.64 (the mean value less twice the standard 
deviation) of the non-target species and non-template controls). DNA from S. agalactiae 
was considered present if a Ct value < 38.64 was obtained. 
IV.6. EFFICACY OF L. salivarius V4II-90 TO ERADICATE GBS FROM 
THE INTESTINAL AND VAGINAL TRACTS OF PREGNANT WOMEN: 
CLINICAL TRIAL  
IV.6.1. Design of the trial    
A total of 87 pregnant women (69 rectal and/or vaginal GBS-positive women; 18 
rectal and vaginal GBS-negative women at the start of the intervention), aged 25-36, 
participated in this study. All met the following criteria: a normal pregnancy and a 
healthy status. Women ingesting probiotic supplements or receiving antibiotic treatment 
in the previous 30 days were excluded. All volunteers gave written informed consent to 
the protocol (10/017-E), which had been approved by the Ethical Committee of Clinical 
Research of Hospital Clínico San Carlos Madrid (Spain).  
Volunteers were distributed into 3 groups (1 probiotic and 2 placebo groups). All 
the volunteers in any of the probiotic groups (n = 55) were GBS-positive and consumed 
a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 cfu of L. salivarius V4II-
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90). Probiotic subgroup (n = 25) started the intervention at pregnancy weeks 26, 
respectively. Placebo subgroup 1 (n=14) included GBS-positive women (pregnancy 
week ranging from 19 to 30) that were going to receive intrapartum antibiotic 
prophylaxis (IAP) because they had a previous baby that suffered a GBS sepsis. Placebo 
subgroup 2 (n=18) included GBS-negative women (pregnancy week ranging from 14 to 
26). Women in both placebo subgroups received a daily sachet containing 50 mg of the 
excipient used to carry the probiotic strain. In all cases, the intervention lasted from the 
start of the intervention to week 38, when recto-vaginal GBS screening was performed 
not only in our laboratory but, also, in those of the hospitals in which the respective 
women were going to deliver their babies. Probiotic- and excipient-containing sachets 
were kept at 4ºC throughout the study. All volunteers were provided with diaries to 
record compliance with study product intake. Minimum compliance rate (% of the total 
treatment doses) was set at 86%. 
IV.6.2. Collection and GBS analysis of the samples 
Rectal and vaginal exudates samples were collected periodically during the trial. 
They were serially diluted and plated on Granada (Biomerieux; isolation of haemolytic 
GBS, which appear as orange colonies), and CHROMagar StrepB (CHROMagar; for 
isolation of haemolytic and non- haemolytic GBS, which appear as purple colonies) agar 
plates. Correct taxonomic assignment was confirmed by MALDI-TOF and latex 
agglutination analyses, as described previously.  
Parallel, and to avoid sensitivity-related problems, two strategies were used: (a) 
DNA was extracted from the samples and submitted to the PCR assays described above; 
(b) a subset of samples was submitted to a GBS enrichment step in Todd-Hewitt broth 
(Oxoid). After 24 h at 37ºC, the broth cultures were spread on CHROMagar StrepB agar 
plates. 
IV.6.3. Statistical analysis  
 Microbiological data were recorded as CFU/ml and transformed to logarithmic 
values before statistical analysis. Two-way ANOVA was used to investigate the effect 
of individual (woman) and sampling time on the semiquantitative S. agalactiae counts 
in vaginal swabs. Statistical significance was set at P< 0.05. Statgraphics Centurion XVI 
version 17.0.16 (Statpoint Technologies Inc, Warrenton, Virginia) was used to carry out 
statistical analyses. 
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V.1. ASSESSMENT OF THE VAGINAL MICROBIOTA OF GBS-
POSITIVE AND GBS-NEGATIVE FERTILE WOMEN (NON-PREGNANT AND 
PREGNANT) 
A total of 54 fertile women (30 non-pregnant women and 24 pregnant women), 
aged 25-35, participated in this study. All volunteers gave written informed consent to 
the protocol, which had been approved (protocol 10/017-E) by the Ethical Committee 
of Clinical Research of Hospital Clínico San Carlos Madrid (Spain). In relation to non-
pregnant women, 4 vaginal exudates samples were collected within a menstrual cycle 
(days 0, 7, 14 and 21). Pregnant women provided a single simple in week 35-37 of 
pregnancy. All women claimed to be completely healthy.  
In all cases, bacterial growth was detected when the samples were inoculated on 
MRS, (2.70-8.08 log10 cfu; mean 5.36 log10 cfu); CNA (3.00-7.92 log10 cfu; mean 
5.13 log10 cfu) and GAR (2.70-8.10 log10 cfu; mean 5.24 log10 cfu) agar plates. 
Globally, similar bacterial groups grew in the three media (data not shown). Growth on 
MCK, SDC or Mycoplasma plates was only detected in a few percentage of samples 
(from 0% in Mycoplasma plates to ~40% in SDC plates). 
S. agalactiae could be isolated from both non-pregnant (~25%) and pregnant 
(~20%) women. Candida albicans and other yeasts were isolated from, approximately, 
7 and 36% of the non-pregnant and pregnant women, respectively. In both groups, 
Lactobacillus were the dominant genus since it was detected in 92-93% of the 
participating women. 
In relation to the samples provided by non-pregnant women, a total of 433 isolates 
(including, at least, one representative of each colony and cell morphology) were 
submitted to taxonomical analyses. The genus Lactobacillus was the dominant one (28% 
of the total isolates), followed by Staphylococcus, Enterococcus, Corynebacterium and 
Streptococcus (Table 1). Among the isolates, the main species were L. crispatus (23%), 
L. gasseri (24%), L. salivarius (21%), L. vaginalis (12%), L. plantarum (13%), L. 
coleohominis (5%) and L. jensenii (2%). 
From the samples provided by pregnant women, 120 isolates were submitted to 
taxonomical analyses. Again, the genus Lactobacillus was the dominant one (17% of 
the total isolates), followed by Staphylococcus, Streptococcus, yeasts and Enterococcus, 
(Table 1). Among the isolates, the main species were L. gasseri (41%), L. casei (19%), 
L. salivarius (16%), L. fermentum (8%), L. vaginalis (6%), L. reuteri (5%) and L. 
jensenii (5%). 
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Overall, the dominant bacterial genus was the genus Lactobacillus, present in 
85.71% of the samples from both groups of women (Figure 8). 
Other genera such as Staphylococcus, Streptococcus, Enterococcus and 
Corynebacterium were isolated from the samples of both groups of women (Figure 8). 
In addition, 35.71% of pregnant women had yeast and Gardnerella vaginalis was 
isolated in 7.14%. Regarding samples from non-pregnant women, yeasts were detected 
in a lower percentage of samples (7.14%) and enterobacteria (7%). 
The presence of GBS was detected in 22% of the women in the study. The 
percentage of GBS positive women in the group of pregnant women was lower than that 
of non-pregnant women (19% and 25%, respectively). On the other hand, throughout 
the menstrual cycle, S. agalactiae was isolated with a higher frequency in the menstrual 
phase, being detected in 20% of the samples of EGB-positive women, in comparison 
with the rest of the phases, postmenstrual (5 %), ovulation (15%) and premenstrual 
(10%). However, the presence of EGB in the different phases of the cycle was not 
constant, varying individually. Thus, while in only one woman could be detected 
throughout the cycle (V6), in others it was only detected in two phases of the cycle (V16 
and V20) or, exclusively during the menstrual phase (V2 and V14) (Figure 9). 
 
Table 1. Main genera and species isolated from the vaginal samples provided by the women that participated in the study. 
Non-pregnant women Pregnant women 
Genus/groups  Percentage (%) Main species Genus/groups  Percentage (%) Main species 
Lactobacillus 28 L. crispatus (23%) 
L. gasseri (24%) 
L. salivarius (21%) 
L. vaginalis (12%) 
L. plantarum (13%) 
L. coleohominis (5%) 
L. jensenii (2%) 
Lactobacillus 18 L. gasseri (41%) 
L. casei (19%) 
L. salivarius (16%) 
L. fermentum (8%) 
L. vaginalis (6%) 
L. reuteri (5%) 
L. jensenii (5%) 
Staphylococcus 17 S. epidermidis 
S. hominis 
S. aureus 
Staphylococcus 17 S. epidermidis 
S. hominis 
S. aureus 
Enterococcus 11 E. faecalis Streptococcus 10 S. agalactiae (60%) 
Corynebacterium 7 C. pseudogenitalium 
C. afermentans 
C. aurimucosum  
Yeasts 10 C. albicans 
C. glabrata, 
C. parapsilosis 
Streptococcus 4 S. agalactiae (75%) 
S. sanguinis 
S. anginosus  
Enterococcus 6 E. faecalis 
Others 12 Streptomyces albus  
Dermabacter hominis 
Propionibacterium avidum  
Aerococcus urinae 
Dermacoccus nishinomiyaensis  
Actinomyces neuii  
Roseomonas mucosa 
Facklamia spp. 
Arthrobacter cumminsii  
Brevibacterium sp 
Helcobacillus massiliensis 
E. coli 
Yeasts (C. albicans, C. glabrata, 
C. parapsilosis) 
Others 12 Bifidobacterium spp.(30%) 
Corynebacterium spp. (10%) 
Non-identified 21  Non-identified 27  
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Figura 8.  Frequency of detection of the different bacterial groups in pregnant 
women (A) and non-pregnant women (B). 
0
20
40
60
80
100%
85,71%Lactobacilus 100%Otros géneros
21,42%
0.00
20.00
40.00
60.00
80.00
100.00
Lb
. c
ris
pa
tu
s 
Lb
. s
al
iv
ar
iu
s
Lb
. g
as
se
ri 
Lb
.v
ag
in
al
is
 
Lb
.p
la
nt
ar
um
Lb
. c
ol
eo
ho
m
in
is
 
Lb
. je
ns
en
ii
St
re
pt
oc
oc
cu
s 
ag
al
ac
tia
e
St
re
pt
oc
oc
cu
s 
St
ap
hy
lo
co
cc
us
En
te
ro
co
cc
us
 
Co
ry
ne
ba
ct
er
iu
m
Ot
ro
s
%
 d
e 
m
u
es
tr
as
%
85,71%Lactobacilus 100%
Otros géneros
21,43%
71,43%
A
B
Lactobacillus
Lactobacillus
Other genera
Other genera
V. Results 
 
 
84 
 
 Figure 9. Distribution of lactobacilli throughout the menstrual cycle in each 
woman. 
As stated above, the 89 different lactobacilli strains isolated in this study belonged 
to the following species: Lactobacillus salivarius, Lactobacillus gasseri, Lactobacillus 
vaginalis, Lactobacillus jensenii, Lactobacillus crispatus, Lactobacillus plantarum, 
Lactobacillus colehominis, Lactobacillus casei, Lactobacillus reuteri and Lactobacillus 
fermentum. Among them, a few were selected on the basis of the following criteria: (1) 
absence of S. agalactiae, Gardnella vaginalis, Candida spp., Ureaplasma spp. and 
Mycoplasma spp in the vaginal samples from which the lactobacilli were originally 
isolated; (2) Qualified Presumption of Safety (QPS) status (European Authority of Food 
Safety, EFSA) of the Lactobacillus species, since there was the purpose of using them 
as food supplements; and (3) ability of the strain to grew rapidly in MRS broth under 
aerobic conditions (1 ×106 cfu/mL after 16 h at 37ºC). Only 10 strains (V3III-1, V4II-
90, V7II-1, V7II-62, V7IV-1, V7IV 60, V8III-62, V11I-60, V11III-60 y V11IV-60) met 
all the criteria and, interestingly, all of them belonged to the same species (Lactobacillus 
salivarius). These strains were those selected for further characterization. 
V.2. ISOLATION AND CHARACTERIZACION OF THE SAFETY AND 
EFFICACY AGAINST GBS OF LACTOBACILLI ISOLATED IN THE 
PREVIOUS PHASE  
V.2.1. Antimicrobial activity and production of potential antimicrobial 
compounds 
Initially, the antimicrobial activity of the 10 selected lactobacilli against the S. 
agalactiae strains was determined by an overlay method. Clear inhibition zones (ranging 
from 2 to 20 mm) were observed around the lactobacilli streaks. 
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In relation to the antimicrobials compounds that may be responsible for such 
activity, the concentration of L- and D-lactic acid and the pH of the supernatants 
obtained from MRS cultures of the lactobacilli are shown in Table 2. The global 
concentration of L-lactic acid was similar (~10 mg/mL) in all the supernatants. In 
contrast, D-lactic acid was not detected in the supernatants of the tested strains. In 
addition, all the strains acidified the MRS-broth medium to a final pH of ~4 after 16 h 
of incubation; among them, L. salivarius V7IV-1 showed the highest acidifying capacity 
(final pH of 3.8). 
No bacteriocin-like activity could be detected against the tested S. agalactiae 
strains. Two strains (L. salivarius V4II-90 and V7IV-1) were able to produce hydrogen 
peroxide (7.29 μg/mL ± 0.69 and 7.46 μg/mL ± 0.58, respectively) (Table 2). 
 
V.2.2. Production of biogenic amines 
The L. salivarius strains neither produced biogenic amines nor harboured the 
genes required for the biosynthesis of this type of compounds. 
V.2.3. Co-aggregation between the lactobacilli and the S. agalactiae strains 
The capacity of the lactobacilli strains to form large, well defined co-aggregates 
with S. agalactiae was strain-dependent. Strains V3III-1, V7IV-60 and V11IV-60 
coaggregated with 5 S. agalactiae strains, strains V8III-62, V11I-60 and V11III-60 with 
7, strain V7II-62 with 9 S. agalactiae strains, and strains V4II-90, V7II-1 and V7IV-1 
with 10 S. agalactiae strains (Figure 10). 
 
The initial pH value of MRS broth was 6.2. ND: not detectable. 
 
Table 2. pH and concentrations of L- and D-lactic acid (mg/mL; mean ± SD), and hydrogen peroxide 
(g/mL; mean ± SD) in the supernatants obtained from MRS cultures of the lactobacilli (n=4). 
Strain pH L -lactic acid D-lactic acid Hydrogen peroxide 
L. salivarius V3III-1 4.00 9.66 ± 0.57 Nd Nd 
L. salivarius V4II-90 4.01 10.03 ± 0.60 Nd 7.29 ± 0.69 
L. salivarius V7II-1 4.02 9.82 ± 0.69 Nd Nd 
L. salivarius V7II-62 4.01 9.76 ± 0.54 Nd Nd 
L. salivarius V7IV-1 3.85 10.47 ± 0.58 Nd 7.46 ± 0.58 
L. salivarius V7IV-60 4.02 9.72 ± 0.63 Nd Nd 
L. salivarius V8III-62 4.04 9.91 ± 0.55 Nd Nd 
L. salivarius V11I-60 4.03 9.84 ± 0.43 Nd Nd 
L. salivarius V11III-60 4.07 9.61 ± 0.47 Nd Nd 
L. salivarius V11IV-60 4.03 10.02 ± 0.62 Nd Nd 
L. salivarius CECT 5713 3.93 10.26 ± 0.62 Nd - 
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Figure 10. Strong co-aggregation between L. salivarius V4II-90 (rods) and a S. 
agalactiae strain (cocci chains). 
V.2.4. Broth co-cultures of the lactobacilli and the S. agalactiae strains 
The ability of the lactobacilli strains to interfere or inhibit the growth of four S. 
agalactiae strains was evaluated using MRS broth co-cultures. Co-cultures with S. 
agalactiae seemed not to affect the growth of any of the L. salivarius strains (Table 3). 
In contrast, most of the L. salivarius strains were able to interfere at a higher or lower 
degree with the growth of the different S. agalactiae strains included in this assay. 
Among them, L. salivarius V4II-90 showed the highest ability to inhibit the growth of 
S. agalactiae since the presence of two of the four S. agalactiae strains was not 
detectable in the co-cultures and the concentration of the other two showed a ~2.5 log10 
decrease after an incubation period of only 6 h at 37ºC (Table 3). Interestingly, no viable 
streptococci could be detected when the in the co-cultures were incubated for 24 h (Table 
3). 
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V.3. IN VITRO ASSESSMENT OF OTHER PROBIOTIC PROPERTIES 
OR PRERREQUISITES OF THE LACTOBACILLI STRAINS  
 V.3.1. Survival after transit through an in vitro gastrointestinal model  
The viability of the strains after exposition to conditions simulating those found in 
the gastrointestinal tract varied from ~64% (L. reuteri CR20, L. salivarius V4II-90) to 
30% (L. salivarius V3III-1) (Table 4). 
Table 3. Bacterial counts of the S. agalactiae strains when co-cultured with the L. 
salivarius strains in MRS broth for 0, 6 and 24 h at 37ºC.  
     
L. salivarius (strain) S. agalactiae (strain)  0 h 6 h 24 h 
V3III-1 RC5 7.10 6.44 Nd 
RC6 7.24 7.04 Nd 
V2I-80 7.10 7.04 Nd 
V14I-63 7.27 7.10 Nd 
V4II-90 RC5 7.04 4.48 Nd 
RC6 7.23 Nd Nd 
V2I-80 7.10 4.70 Nd 
V14I-63 7.34 Nd Nd 
V7II-1 RC5 7.15 7.27 Nd 
RC6 7.15 6.70 Nd 
V2I-80 7.04 7.10 Nd 
V14I-63 7.35 5.65 Nd 
V7II-62 RC5 7.24 7.04 Nd 
RC6 6.98 7.49 Nd 
V2I-80 7.35 7.92 Nd 
V14I-63 7.10 6.93 Nd 
V7IV-1 RC5 7.32 7.58 Nd 
RC6 7.34 6.90 Nd 
V2I-80 7.15 7.38 Nd 
V14I-63 7.23 6.04 Nd 
V7IV-60 RC5 7.24 7.32 Nd 
RC6 7.32 8.06 Nd 
V2I-80 7.04 7.15 Nd 
V14I-63 7.35 8.34 Nd 
V8III-62 RC5 7.15 7.90 Nd 
RC6 7.34 7.23 Nd 
V2I-80 7.24 6.90 Nd 
V14I-63 7.20 8.77 Nd 
V11I-60 RC5 7.31 7.44 Nd 
RC6 7.01 6.94 Nd 
V2I-80 7.23 7.07 Nd 
V14I-63 6.93 6.60 Nd 
V11 III-60 RC5 7.27 6.44 Nd 
RC6 6.95 6.88 Nd 
V2I-80 7.28 6.52 Nd 
V14I-63 7.37 6.85 Nd 
V11IV-60 RC5 7.26 6.74 Nd 
RC6 7.42 6.60 Nd 
V2I-80 7.10 6.60 Nd 
V14I-63 7.06 5.32 Nd 
Control cultures 
(no L. salivarius strain) 
RC5 7.20 9.32 9.34 
RC6 7.31 9.20 9.27 
V2I-80 7.04 9.15 9.23 
V14I-63 7.10 9.02 9.15 
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V.3.2. Adherence assays to intestinal and vaginal epithelial cells 
In this study, the lactobacilli strains tested were strongly adhesive to both Caco-2 
and HT-29 cells, with the exception of the negative control strain (L. casei imunitass) 
which showed a low adhesive potential (Table 5). In addition, all showed adhesion to 
vaginal epithelial cells. Among the L. salivarius strains, L. salivarius V4II-90 globally 
displayed the highest ability to adhere to both intestinal and vaginal epithelial cells 
(Table 5). 
V.3.3. Adherence to and/or degradation of mucin 
The lactobacilli strains tested showed a variable ability to adhere to porcine mucin 
(Table 6). Lb. reuteri CR20 (positive control strain) was the strain that showed the 
highest adherence ability followed by L. salivarius V4II-90 and L. salivarius V7IV-1 
(Table 6). None of the strains were able to degrade gastric mucin in vitro. 
V.3.4. Antibiotic susceptibility  
The MIC values of the lactobacilli strains for 16 antibiotics assayed are shown in 
Table 7. All the strains were sensitive to most of the antibiotics tested, including those 
considered clinically relevant antibiotics such as, gentamycin, tetracycline, clindamycin, 
chloramphenicol, and ampicillin, showing MICs equal to, or lower than, the breakpoints 
defined by EFSA (EFSA, 2012). All the strains were resistant to vancomycin and 
kanamycin, which is an intrinsic property of the L.  salivarius at the species level. 
 
Table 4. Percentage (%) of initial lactobacilli (109 cfu/mL) that survived to conditions simulating those of the 
gastrointestinal tract. 
 Gastric-emptying fractiona 
Strain 20 min 40 min 60 min 80 min % Total 
L. salivarius V3III-1 9.4 ± 0.4 12.1 ± 0.5 5.0 ± 0.3 3.7 ± 0.1 30.2 
L. salivarius V4II-90 16.9 ± 0.6 21.3 ± 1.7 16.5 ± 0.9 9.3 ± 0.5 64.3 
L. salivarius V7II-1 14.8 ± 0.4  23.7 ± 2.4 14.3 ± 1.4 7.0 ± 0.4 59.8 
L. salivarius V7II-62 14.3 ± 2.0 12.0 ± 1.3 11.5 ± 0.7 12.7 ± 1.5 50.5 
L. salivarius V7IV-1 13.6 ± 0.8 13.5 ± 1.2 11.9 ± 1.3 9.1 ± 1.4 48.1 
L. salivarius V7IV-60 12.8 ± 1.9 16.3 ± 1.5 10.7 ± 1.2 13.5 ± 1.6 53.3 
L. salivarius V8III-62 7.5 ± 0.6 12.4 ± 1.0 10.8 ± 1.2 10.6 ± 1.4 41.3 
L. salivarius V11I-60 8.2 ± 0.7 11.7 ± 1.4 11.3 ± 1.1 9.6 ± 1.3 40.8 
L. salivarius V11III-60 7.9 ± 0.8 12.0 ± 1.2 10.2 ± 1.3 11.0 ± 1.6 41.1 
L. salivarius V11IV-60 8.5 ± 0.7 12.7 ± 1.3 10.9 ± 0.9 10.2 ± 1.1 42.3 
L. salivarius CELA2 15.4 ± 1.6 25.8 ± 2.9 17.0 ± 2.2 6.2 ± 0.4 64.4 
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Table 5. Ability of the lactobacilli to adhere to HT-29, Caco-2 and vaginal epithelial 
cells.  
Strain HT-29 Caco-2 Vaginal cells 
L. salivarius V3III-1 877.3 ± 303.2 259.1 ± 67.1 + 
L. salivarius V4II-90 905.2 ± 297.0 345.1 ± 72.8 +++ 
L. salivarius V7II-1 900.5 ± 336.2 297.8 ± 84.5 ++ 
L. salivarius V7II-62 911.7 ± 250.9 321.5 ± 80.2 ++ 
L. salivarius V7IV-1 884.0 ± 226.3  252.3 ± 67.1 ++ 
L. salivarius V7IV-60 799.7 ± 210.1 255.9 ± 60.3 ++ 
L. salivarius V8III-62 623.4 ± 200.2 108.7 ± 24.3 + 
L. salivarius V11I-60 593.2 ± 191.5 121.6 ± 22.0 + 
L. salivarius V11III-60 612.4 ± 188.2 153.2 ± 26.7 + 
L. salivarius V11IV-60 601.6 ± 172.0 159.5 ± 23.4 + 
L. rhamnosus GG 912.4 ± 345.0 371.5 ± 67.8 Nd 
L. casei imunitass 127.4 ± 20.9 16.7 ± 7.3 Nd 
The adherent lactobacilli in 20 random microscopic fields were counted for each test 
(n=4). Nd, not determined. 
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V.3.5. Prophage induction  
None of the supernatants obtained from the L. salivarius strains generated phage-
related inhibition halos or plaques of lysis on lawns of any of indicator strains tested in 
this study. 
IV.4. IN VIVO ASSESSMENT OF THE SAFETY OF Lactobacillus salivarius 
V4II-90 IN A RAT MODEL 
V.4.1. Acute oral toxicity in rats  
No abnormal clinical signs, behavioural changes, body weight changes, 
macroscopic findings, or organ weight changes were observed. All animals survived the 
2-week observation period. There were no statistical differences in body weights among 
groups. Similarly, no statistically significant differences in body weight gain, food and 
water consumption were noted. Body weight, daily body weight gain, food and water 
consumption thus were unaffected by the treatment (single oral dose of 1  1010 cfu of 
L. salivarius V4II-90). 
The haematological and clinical chemistry parameters assessed 2 weeks after 
administration of the strain as a single oral dose of 1  1010 cfu were not significantly 
different compared with those of controls (Tables 8 and 9). No treatment-related changes 
were noted. 
There were no statistical differences in organ weight or tissue: body weight ratios 
related to the test strain (data not shown). The L. salivarius V4II-90 preparation was not 
associated with any incidence of macroscopic and microscopic changes. No treatment-
related histopathological changes were observed 2 weeks after administration of the 
Table 7. Minimal inhibitory concentration (MIC, mg /ml) values of 16 antibioticsa to the L. salivarius strains. 
 Antibiotic 
 
Strain 
GEN KAN STP NEO TET ERY CLI CHL AMP PEN VAN VIR LIN TRM CIP RIF 
V3III-1 4 64 32 8 2 0.12 0.5 2 0.5 0.12 >128 0.5 0.5 0.5 2 0.5 
V4II-90 4 256 32 8 2 0.12 0.5 2 0.5 0.12 >128 0.5 1 0.25 4 1 
V7II-1 4 128 32 4 2 0.12 0.5 4 0.5 0.12 >128 0.5 0.5 0.5 2 0.25 
V7II-62 2 128 32 8 2 0.25 0.5 2 0.5 0.25 >128 0.25 1 0.25 2 0.5 
V7IV-1 8 256 32 4 2 0.12 0.5 2 0.5 0.25 >128 0.5 1 0.5 2 0.5 
V7IV-60 8 128 32 8 2 0.12 0.4 4 0.5 0.25 >128 0.5 1 0.5 2 0.5 
V8III-62 8 128 32 2 2 0.25 0.5 4 0.5 0.25 >128 1 1 0.5 2 0.5 
V11I-60 4 128 32 8 2 0.12 0.5 2 0.5 0.25 >128 1 1 0.5 2 0.5 
V11III-60 8 256 32 4 2 0.12 0.5 2 0.5 0.25 >128 0.5 1 0.5 2 0.5 
V11IV-60 4 128 32 8 2 0.12 0.5 2 0.5 0.25 >128 1 1 0.5 2 0.5 
Breakpointb 16 R 64 nr 8 1 1 4 4 nr nr (R) nr nr nr nr nr 
aAbbreviations: GEN, gentamycin; KAN, kanamycin; STP, streptomycin; NEO, neomycin; TET, tetracycline; ERY, erythromycin; CLI, clindamycin; CHL, chloramphenicol; 
AMP, ampicillin; PEN, penicillin; VAN, vancomycin; VIR, virginiamycin; LIN, linezolid; TRM, trimethoprim; CIP, ciprofloxacin; RIF, rifampicin; nr, not required by EFSA. 
R, the species L. salivarius is intrinsically resistant. 
bBreakpoint: microbiological breakpoints (mg /ml) that categorise Lactobacillus salivarius as resistant (microbiological breakpoints are defined as the MIC values that clearly 
deviate from those displayed by the normal susceptible populations; EFSA, 2012). 
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strain as a single oral dose of 1  1010 cfu. Therefore, L. salivarius V4II-90 has a low 
order of acute toxicity and the oral lethal dose (LD50) for male and female rats is higher 
than 1  1010 cfu. 
 
 
V.4.2. Repeated dose (4 weeks) oral toxicity in rats 
No mortality was observed. No treatment-related changes in the general condition 
and external appearance were observed in male and female rats treated with 1  109 cfu 
of L. salivarius V4II-90 daily dose. The development of the animals during the 
experimental period corresponded to their species and age. There was no significant 
difference in body weight or body weight gain among groups treated with L. salivarius 
V4II-90 in comparison to the control groups at any time point of the experimental period. 
All L. salivarius V4II-90-treated groups consumed similar amounts of food and water 
(data not shown) to that of the corresponding control groups.  
All haematology data were within normal limits and differences between groups 
were no observed (Table 10). Clinical chemistry data showed no treatment-related 
alterations at the end of 4-weeks treatment period (Table 11). Individual values and 
group mean values were within the physiologic ranges. After 14 days without treatment 
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to detect delayed occurrence of potential toxic effects, there were no treatment-related 
changes neither in hematological nor in clinical test parameters (Tables 10 and 11; 
satellite control group or Group 5 and satellite treated group or Group 6). 
 
 
The necropsy performed on day 29 after the last dose of L. salivarius V4II-90 
(Group 4) and on day 42 after 14 days without any treatment (Group 6) did not reveal 
any gross pathological changes or any differences in organ weights in comparison to the 
corresponding control groups. Mean organ weights and rate body weight: organ are 
presented in Table 12. After 4-weeks of treatment, there were no treatment-related 
histopathological findings in the organs examined neither in male nor in female rats (data 
not shown). There were also no treatment-related histopathological findings in the 
satellite treated group (Group 6) (data not shown). 
The no-observed-adverse-effect level in this repeated dose (4 weeks) oral toxicity 
study was the dose tested, i.e. 1  109 cfu of L. salivarius V4II-90.  
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V.4.3. Total liver glutathione (GSH) concentration and potential bacteremia 
In order to determine changes in the antioxidant defence because of the probiotic 
treatment, liver GSH concentration was determined. No significant differences in liver 
GSH concentration were observed between control and treated groups (9.54±1.21 vs 
9.37±1.39 mmol/g, P>0.1). This indicates that treatment with L. salivarius V4II-90 did 
not cause oxidative stress to rats and is consistent with the absence of bacteremia since 
no lactobacilli could be isolated from blood, liver or spleen of the rats. It suggests that 
the tested strain do not cause either a local or a systemic infection in rats. 
V.4.4. Isolation of L. salivarius V4II-90 from feces and vaginal swabs samples 
L. salivarius V4II-90 could be isolated from colonic material and vaginal swabs 
samples of all the treated animals (probiotic groups) at the end of the treatment. The 
concentration oscillated between 5  105 and 7  108 cfu/g of colonic material, and 
between 3  103 and 23  106 cfu/g in the vaginal swabs. The strain could not be detected 
in any sample from the placebo group. 
V.5. DESIGN OF PCR ASSAY FOR SPECIFIC AND SENSITIVE 
DETECTION OF S. agalactiae IN THE BIOLOGICAL SAMPLES  
 On the basis of sequence comparison using programs Emma and Showalign, 
primers S.agalacFW1 (5´-GTTTGGTGTTTACACTAGA-´3) and S.agalacRV1 (5´- 
CAATTGCTCCTTTTAAATAACT-´3) were designed for the specific amplification of 
a teorethical 148 bp fragment of the 16S rRNA gene of S. agalactiae (Figure 11).  
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 Figure 11. Design of the primers S.agalacFW1 and S.agalacRV1 
 In conventional PCR, the GBS-specific primer pair (S.agalacFW1 and 
S.agalacRV1) amplified a single 148 bp amplicon from S. agalactiae DNA. Cross-
reactivity was not obtained with DNA from any other species analyzed (Figure 12). 
 
Figure 12. Electroforetic analysis of PCR product of the 148 bp region of 16S 
rRNA gene with the use of primers S.agalacFW1 and S.agalacRV1 obtained from 
Streptococcus peroris DSM 12493 (lane 1); Streptococcus mitis DSM 12643 (lane 2); 
Streptococcus oralis CECT 907 (lane 3); Streptococcus parasanguinis DSM 6778 (lane 
4); Streptococcus bovis DSM 20564 (lane 5); Streptococcus uberis DSM 20564 (lane 
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Lb.plantarum_EF185922122    .....AA..CTG.T---ATTGATT.----.T......----A----.CA--TGATTTAC..-TTGA-GTG...G......T.....-.....A...G..-A........CAGA.............ACC.... 
Ped.pentosaceus_CP000422    .....AA..TCC.TT-AATTGATTATGAC.TA....T----A.TGA.TG--AGATTTTA.C-ACGAAGTG...G............-.....A...G..-.........CAGA..TA.........ACC.... 
Lb.fermentum_EF460496       .....CGT..GCCC--AATTGATT.ATG-.T......----A.CTGAT---TGATTTT.G.-TGCCAACG...G...G........-.....A...A..-.........CAGA.........C...AT..... 
Weissella minor_NR040809    .....CTT..TG.TTCAACTGAT-ATGAA.A......----..GGA.TT--GAAGATGA.CATTGCAAAG...G............-.....A...G..-A.....A...CTT.............AC..... 
Staphy.epidermidis_D83363   ..G..AA.A..C.A----------.----.A......----..CTC.-----------..C.TT------..CG...G........-.....A...G.A-......A...ATA..ACT.........TCG... 
Staphy.aureus_D83357        ..G..AA.G..C.A----------.----AA......----.TCTC.-----------....TT------..CG...G........-.....A...G.A-......A...ATA..ACT.........TCG... 
Staphy.xylosus_D83374       ..G..AA.A..TAA----------.----.A......----..CTT.-----------..A.TT------..CG...G........-.....A...G..-......A...ATA..ACT.........TCG... 
E.faecalis_EF120452         .N.A.GC..TCTTTT--CTCTTCC.----AG.NG...CT-G..CACCTCTAA.TTGTG..AATGTGGGTGN..GCG.G.....G.TT.....A...G..G......A..CATC..T..........AC..... 
E.faecium_DQ672262          .T...--..TCTTTT---TCCACC.----.A......----..CACC----------G..AAAA--GAAG...G............-.....A...G..-.........CATC..AA.........AC..... 
Strep.mitis_AY281078        .....--....A.C--------TT.----.T......---AC.GAGC----------G....--------...T............-.....G...A..-..........CTT..............A..... 
Strep.parasaguinis_AY281087 .....--....A.C--------TT.----.T......---AC.GAGC----------G....--------...T............-.....G...A..-..........CTT..............A..... 
Strep.oralis_DQ232537       .....--....A.C--------TT.----.T......---AC.GAGC----------G....--------...T............-.....G...A..-..........CTT..............A..... 
Strep.oralis_AY281079       .....--....A.---------GA.----.A......----..TTC.----------G....--------...T............-.....G...A..-..........GGT..............A..... 
Strep.infantis_AY485603     .....--....A.---------GA.----.A......----..TTC.----------G....--------...T............-.....G...A..-..........GGT..............A..... 
Strep.peroris_AB008314      .....--....A.---------GA.----.A......----.TCTC.----------G....--------...T............-.....G...A..-..........GGT..............A..... 
Strep.salivarius_AY188352   .....--....A.A--------GA.----.A......----..TTC.T---------G....--------...T............-.....G...A..-..........TGT..............A..... 
Strep.bovis_AB002481        .....--....A.A--------CTT----TA......----.AAAG.T---------G..A.--------...T............-.....G...A..-..........ACT..............A..... 
Strep.agalactiae_AE00948    .....--....G.T--------TT.----.T.T..A.AC--.AGAC.-----------....--------...T............-.....G...A..-..........CAT..............A..... 
Strep.agalactiae_AB596948   .....--....G.T--------TT.----.T.T..A.AC--.AGAC.-----------....--------...T............-.....G...A..-..........CAT..............A..... 
L.lactis_CP002365           ..G..--....A.G--------TT.----.TA....T---AC.GAC.----------G....--------..CA............-.....G...G..-G..T......TTG.........C...AT..... 
Leu.mesenteroides_CP000414  .....CA.A.CGAA---------A.----.T......----A.CTT.C---------AAG..--------...G............-.....A...G.A-C.........CAAG..T.........AT..... 
Bif.bifidum_CP001840        .....GTGATCCATC--------------AA......-----TTGG.GG--------T....--------...G............-....TG...GAC-CG.......CCAG.CTCC..A...G..CC.... 
B.vulgatus_NC009614         ..GG.GCAGC.T.GT------------CTTA......----.AAGGCC----------....GC-----G.CCG...C........-.....A...ATC-C........GTCT.CTCTT...C.G.CT.CT.. 
Consensus                   GAACGnnCTGAnGnnnnnnnnnnnGnnnnGnGCTTGCnnnnTCnnnTnnnnnnnnnnnGATGnnnnnnnnAGTnGCGAACGGGTGAnGTAACnCGTnGGnTAACCTGCCTnnnAGCGGGGGATAACTnTTGGA 
 
                                   210       220       230       240       250       260       270       280       290       300 
                            ----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----|----:----| 
Consensus                   AACGAnAGCTAATACCGCATAAnAnTnnnnAnCnGCATGnTnnnnnnTTGAAAGGTGCnnTTGCnnnATCACTnnnAGATGGACCnGCGTTGTATTAGCT 
Lb.plantarum_EF185922122    ...AGAT...............C.ACTTGG.C.-.....G.CCGAGC.......A..GCT.C.G-CT......TTTG.....T..C...GC......... 
Ped.pentosaceus_CP000422    ...AGAT..........T....C.GAGAAA.C.-.....G.TTTCTT..A....A..GCTC..--CT......TCTG........C...GC......... 
Lb.fermentum_EF460496       ...AGAT...............C.GCGTTGTT.-.....AACAACGC..A....A..GCT.CT.GCT......TCTG........T...G..C....... 
Weissella minor_NR040809    ...A.GT...............T.C.GATA.C.-.....G.TATCAG.......A..GTTC..--CT......AAG......T..C...G.......... 
Staphy.epidermidis_D83363   ...CGG...........G....T.TATTGA.C.-.....G.TCAATAG......AC.GTT....--TG.....TAT.......T.C...CC.C....... 
Staphy.aureus_D83357        ...CGG...........G....T.T.TTGA.C.-.....G.TCAAAAG......AC.GTC....--TG.....TAT.......T.C...C..C....... 
Staphy.xylosus_D83374       ...CGG...........G....C.T.TAGA.C.-.....G.TCTAAAG......A..GTT....--T......TAT.........C...CC......... 
E.faecalis_EF120452         ...AGGG...............C.G.TTTAGC.-.....GCATAAGAG.......C..TT.C.G-GTG..G..GATG........C...G..C....... 
E.faecium_DQ672262          ...AGGT..........T....C.A.CGAA.C.-.....G.TTTGAT........C..TT.C.G-GTG..G..GATG........C...G..C....... 
Strep.mitis_AY281078        .....T................A.G.CGAT.T.-.....A.ATTGAT...........AAA...---......AAG.........T.............. 
Strep.parasaguinis_AY281087 .....T................A.G.CGAC.TT-.....A.ATTGAC...........AAA...---......AAG.........T.............. 
Strep.oralis_DQ232537       .....T................M.G.CGAT.T.-.....A.ATTGAT...........AA....---......AMG.........T.............. 
Strep.oralis_AY281079       .....T................G.G.AGATGTT-.....ACATTTGC..A........AA....---......ACC.........T.............. 
Strep.infantis_AY485603     .....T................C.G.AGAT.T.-.....A.AGCTGC...........AA....---.C....ACC.........T.............. 
Strep.peroris_AB008314      .....T................G.GCAGTTGTT-.....ACAGCTGT..A........AA....---.C....ACC.........T.............. 
Strep.salivarius_AY188352   .....T................C.A.GGATGA.-A....TCATTTAT........G..AA....---TC....ACA.........T.............. 
Strep.bovis_AB002481        .....T................C.GCATTT.A.-C....T.AGATGC........A..AA....---T.....AGT.........T.............. 
Strep.agalactiae_AE00948    .....T................G.G.AATT.A.-A....T.AGTTAT..A.....A..AA....---T.....GTG.........T.............. 
Strep.agalactiae_AB596948   .....T................G.G.AATT.A.-A....T.AGTTAT..A.....A..AA....---T.....GTG.........T.............. 
L.lactis_CP002365           .....AT...............A.ACTTTA.A.-A..A.T.TTAAGT.......A...AA....---......CAA.....AT..C.............. 
Leu.mesenteroides_CP000414  ...AGAT..........A....A.C.TAGTGT.-.....ACACAAAG..A.....C..TTCG..---G....CTAG.......T.C...G..C.....T. 
Bif.bifidum_CP001840        ....GGT.G....G...G..GTTCCACATG.T.-.....-.GATTGTGG.....A.T.T--------...GGCGTGG.....GGTC....CC...C.... 
B.vulgatus_NC009614         ..G..AGAT......AAG..GGC.TCATGAGT.C.....T.CACATGA.T......ATT---------C.GG.AGAC.....GGAT.....CC.....A. 
Consensus                   AACGAnAGCTAATACCGCATAAnAnTnnnnAnCnGCATGnTnnnnnnTTGAAAGGTGCnnTTGCnnnATCACTnnnAGATGGACCnGCGTTGTATTAGCT 
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6); Streptococcus salivarius CECT 805 (lane 7); Streptococcus thermophilus, ATCC 
19987 (lane 8); Streptococcus pneumoniae 0566 (lane 9); Streptococcus dysgalactiae 
DSM 20662 (lane 10). M, Molecular weight marker HyperLader™ IV (Bioline); PC, 
positive control, S. agalactiae, DSMZ 2134; NC, negative control. This figure is a 
reverse image of the agarose gels containing Gel Red™ Nucleic Acid gel Stain 10.000X 
(Biotium). “bp”, base pair. 
The real-time specific system amplified a 148 bp fragment from all the S. 
agalactiae samples analyzed. No homologous product was amplified from any other 
bacterial DNA tested. Threshold cycle (Ct) values between 16.72 and 20.87 were 
obtained from S. agalactiae DNA. The Ct values measured for DNA extracted from non-
target species were 39.82 ± 0.59 (Table 13). Under our experimental conditions, a cut-
off value was establish as follows: Ct values above that corresponding to the mean Ct 
value of all the non-target species and non-template controls minus twice their standard 
deviation (Ct > 38.64) were considered negative for the presence of target DNA. In 
relation to the detection limit of this PCR approach, it was observed that the lower 
percentage of target DNA, the higher Ct values obtained in the real-time PCR with the 
species-specific primers. The detection limit of this assay was lower than 0.005 ng of 
target DNA, which corresponds to Ct value of 34.34 (Figure 13). 
When real biological samples were tested, there was an excellent agreement 
between conventional PCR results and those obtained by culture-based methods (Table 
14). MALDI-TOF and conventional (qualitative) PCR identification were discordant for 
only 1 sample. In addition, two samples that were positive by conventional PCR 
provided a negative result by real-time PCR. Globally, the results obtained indicate that 
the PCR techniques developed in this study have proven to have a high specificity and 
sensitivity, and, therefore, they constitute useful GBS screening methods. 
V.6. EFFICACY OF L. salivarius V4II-90 TO ERADICATE GBS FROM 
THE INTESTINAL AND VAGINAL TRACTS OF PREGNANT WOMEN: 
CLINICAL TRIAL  
 At the inclusion in the study, GBS was detected in both rectal and vaginal swabs 
obtained from 39 women, out of a total of 57 participating women, while the rest of 
women (n = 18) were GBS-negative (Table 15). This last group of GBS-negative 
women, which did not take a L. salivarius strain also had negative GBS cultures from 
rectal and vaginal swabs taken regularly at 28, 32 and 36-38 weeks (Table 15; Figure 
14). A group of GBS-positive women at the start of the study (n = 14) did not receive 
probiotic and the routine screening results for vaginal and rectal GBS at 28, 32 and 36-
38 weeks were found to be all positive (Table 15; Figure 14).  
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Table 13. Specificity of the real-time PCR system (Ct values obtained from 10 ng DNA). 
Scientific name Crossing point (Ct) 
Melting temperature 
(Tm) 
Streptococcus agalactiae DSM 2134 16.77±1.51a 80.00 
Streptococcus agalactiae M57207 18.08±1.14 80.00 
Streptococcus agalactiae M57730 17.97±0.58 80.00 
Streptococcus agalactiae M67018 16.72±0.45 80.00 
Streptococcus agalactiae M6836 19.07±0.81 80.00 
Streptococcus agalactiae M70043 20.87±0.31 80.00 
Streptococcus dysgalactiae DSM 20662 40.00±0.00 None 
Streptococcus peroris DSM 12493 40.00±0.00 None 
Streptococcus mitis DSM 12643 39.01±0.54 None 
Streptococcus oralis CECT 907 40.00±0.00 None 
Streptococcus parasanguinis DSM 6778 40.00±0.00 None 
Streptococcus bovis DSM 20564 38.73±0.51 None 
Streptococcus  uberis DSM 20564 40.00±0.00 None 
Streptococcus salivarius CECT 805 39.83±0.10 None 
Streptococcus termophilus ATCC 19987 40.00±0.00 None 
Streptococcus pneunoniae 0566 40.00±0.00 None 
Bifidobacterium adolescentis HE 005 40.00±0.00 None 
Bifidobacterium animalis subsp. lactis PS17 40.00±0.00 None 
Bifidobacterium  breve CECT 4839 40.00±0.00 None 
Bifidobacterium infantis CECT 4551 40.00±0.00 None 
Bacteroides vulgatus DSM 1447 40.00±0.00 None 
Bacteroides fragilis DSM 2151 40.00±0.00 None 
Leuconostoc citreum CECT 4025 40.00±0.00 None 
Leuconostoc mesenteroides CECT 219 40.00±0.00 None 
Leuconostoc fallax LMG 13177 40.00±0.00 None 
Weissella cibaria CECT 7032 40.00±0.00 None 
Weissella confusa CECT 4707 40.00±0.00 None 
Lactobacillus crispatus DSMZ 20584 40.00±0.00 None 
Lactobacillus delbrueckii  subsp. lactis CECT 282 37.09±1.23 None 
Lactobacillus salivarius CECT 4063 40.00±0.00 None 
Staphylococcus epidermidis CECT 232 40.00±0.00 None 
Staphylococcus aureus CECT 86 40.00±0.00 None 
Lactococcus lactis ATCC 10456 40.00±0.00 None 
Pediococcus pentosaceus CECT 46595 40.00±0.00 None 
Klebsiella pneumoniae subsp. pneumoniae DSM 30104  40.00±0.00 None 
Enterococcus faecium CECT 410 40.00±0.00 None 
Enterococcus faecalis CECT 481 40.00±0.00 None 
a Ct values are expressed as mean ± standard deviation 
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Figure 13. Detection limit of the real-time PCR system, using ten-fold dilution series of S. agalactiae DSMZ 2134 DNA as standard. 
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50 - - 40±0.00 
51 + 148 bp 30.16±1.22 
52 - - 40±0.00 
53 + 148 bp 24.99±1.69 
54 - - 40±0.00 
55 - - 40±0.00 
56 + 148 bp 29.98±1.10 
57 + 148 bp 33.70±1.17 
58 - - 40±0.00 
59 - - 40±0.00 
60 - - 40±0.00 
61 + 148 bp 27.54±1.00 
62 - - 40±0.00 
+ Positive GBS isolation; - Negative GBS isolation/GBS DNA detection. 
a Ct values are expressed as mean ± standard deviation. 
50 - - 40±0.00 
51 + 148 bp 30.16±1.22 
52 - - 40±0.00 
53 + 148 bp 24.99±1.69 
54 - - 40±0.00 
55 - - 40±0.00 
56 + 148 bp 29.98±1.10 
57 + 148 bp 33.70±1.17 
58 - - 40±0.00 
59 - - 40±0.00 
60 - - 40±0.00 
61 + 148 bp 27.54±1.00 
62 - - 40±0.00 
+ Positive GBS isolation; - Negative GBS isolation/GBS DNA detection. 
a Ct values are expressed as mean ± standard devi tion. 
50 - - 40±0.00 
51 + 148 bp 30.16±1.22 
52 - - 40±0.00 
53 + 148 bp 24.99±1.69 
54 - - 40±0.00 
55 - - 40±0.00 
56 + 148 bp 29.98±1.10 
57 + 148 bp 33.70±1.17 
58 - - 40±0.00 
59 - - 40±0.00 
60 - - 40±0.00 
61 + 148 bp 27.54±1.00 
62 - - 40±0.00 
+ Positiv  GBS isol tion; - Neg tive GBS solation/GBS DNA detection. 
a Ct values are expressed as mean ± standard deviation. 
50 - - 40± .0  
51 + 148 bp 30.16±1.22 
52 - - 40± .0  
53 + 148 bp 24.99±1.69 
54 - - 40± .0  
55 - - 40± .0  
56 + 148 bp 29.98±1.10 
57 + 148 bp 33.70±1.17 
58 - - 40± .0  
59 - - 40± .0  
60 - - 40± .0  
61 + 148 bp 27.54±1.00 
62 - - 40± .0  
+ Positive GBS isolation; - Negative GBS isolation/GBS DNA detection. 
a Ct values are expr ssed as m a  ± standard deviat on. 
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 Significantly, the group of GBS-positive women that started using the probiotic 
(109 cfu/daily) since they were enrolled in this study (from 26 weeks) also tested positive 
for GBS at 28 weeks, but an increasing number of GBS-negative results appeared in the 
successive swabs collected until delivery (Table 15; Figure 14). At 30 weeks, culture of 
rectal swabs taken from four women of this group rendered a negative result and the 
number of these samples increased to 18 (72% of the participants) at 38 weeks. Similar 
results were obtained culturing vaginal swabs obtained from this group, although the 
proportion of women testing negative for GBS were always slightly higher when 
analyzing the rectal swabs than in vaginal swabs (Table 15; Figure 14). 
 A more detailed analysis revealed that the GBS absence in rectal and vaginal 
swabs was detected at the same sampling time in 6 participants among women with 
GBS-negative samples (n = 19) (one woman at 35 weeks and five women at 32 weeks). 
The detection of GBS absence was most frequently found for the first time in rectal 
swabs (11 women) than in vaginal swabs (2 women) (Table 16). 
The estimation of the concentration of GBS in vaginal swabs taken regularly up 
to the delivery from all participants is shown in Figure 15. There were no significant 
changes in both GBS-negative women (n = 18) and GBS-positive women (n = 14) 
without oral administration of L. salivarius V4II-90 regarding the semiquantitative 
estimation of GBS. However, the number of vaginal swabs where the GBS could not be 
detected increased in successive sampling times in the group that initially tested positive 
for GBS taking 109 cfu of L. salivarius V4II-90 (n = 25). Furthermore, the change in 
mean bacterial counts for S. agalactiae in those women that tested positive and took the 
L. salivarius strain depended both on women and sampling time, but there was no 
interaction between these two factors (two-way ANOVA; P<0.001). The mean value for 
S. agalactiae counts decreased significantly with the administration time of L. salivarius 
V4II-90 (Figures 14 and 15) from a mean value of 5.14 cfu/mL at 26 weeks (n=25) to 
3.80 cfu/mL at 38 weeks (n=9) (Figure 15). 
Table 15. Qualitative assessment (GBS positive/GBS negative) of Streptococcus agalactiae in rectal and vaginal swabs of participants (N = 57).
Initial 
GBS status
Probiotic
intake
Rectal swabs Vaginal swabs
Negative
(n = 18)
NO week 12-26 28* 32** 36-38 12-26 28* 32** 36-38
GBS positive 0 0 0 0 0 0 0 0
GBS negative 18 17 16 18 18 17 16 18
GBS negative (%) 100 100 100 100 100 100 100 100
Positive NO week 14-17 28** 32* 36-38 14-17 28** 32* 36-38
(n = 14) GBS positive 14 12 13 14 14 12 13 14
GBS negative 0 0 0 0 0 0 0 0
GBS negative (%) 0 0 0 0 0 0 0 0
Positive YES week 26 28 30 32 35 38 26 28 30 32 35 38
(n = 25) GBS positive 25 25 21 12 9 7 25 25 25 15 10 8
GBS negative 0 0 4 13 16 18 0 0 0 10 15 17
GBS negative (%) 0 0 16 52 64 72 0 0 0 40 60 68
*: sample from one participant was mising at this sampling time.
**: sample from two participants were mising at this sampling time.
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Table 16. Comparison of the results obtained for qualitative assessment (GBS positive/GBS negative) of Streptococcus agalactiae in rectal and 
vaginal swabs of participants who tested positive for GBS and received oral administration of L. salivarius V4II-90 (109 cfu/daily) (n = 25). 
 Rectal swab Vaginal swab  Detection of GBS absence in cultured rectal and vaginal swabs 
 week week   For the first time For the first time 
Woman 26 28 30 32 35 38 26 28 30 32 35 38  Simultaneously in rectal swab in vaginal swabs 
3 P P P P P P P P P P P P  -   
9 P P P P P P P P P P P P  -   
10 P P P P P P P P P P P P  -   
17 P P P P P P P P P P P P  -   
18 P P P P P P P P P P P P  -   
21 P P P P P P P P P P P P  -   
15 P P P P P P P P P P P N*    week 38 
24 P P P P P N* P P P P P P    week 38  
6 P P P P P N* P P P P P P    week 38  
5 P P P P N* N P P P P  P  N   week 35  
25 P P P P N N P P P P  N N  week 35   
23 P P P P N N P P P N* N N    week 32 
7 P P P N* N N P P P P  N N   week 32  
12 P P P N* N N P P P P  N N   week 32  
13 P P P N* N N P P P P  N N   week 32  
22 P P P N* N N P  P  P  P  N N   week 32  
16 P P P N N N P P P N N N  week 32   
19 P P P N N N P P P N N N  week 32   
1 P P P N N N P P P N N N  week 32   
4 P P P N N N P P P N N N  week 32   
8 P P P N N N P P P N N N  week 32   
2 P P N* N N N P P P N N N   week 30  
11 P P N* N N N P P P N N N   week 30  
14 P P N* N N N P P P N N N   week 30  
20 P P N* N N N P P P N N N   week 30  
Abbreviations: P: positive; N: negative. *: Only one of the swabs (vaginal or rectal) was negative for GBS at that sampling time. 
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Figure 14. Concentration (CFU/mL) of S.agalactiae (GBS) in vaginal swabs 
taken regularly from A) GBS-negative women (n = 18) without oral administration of 
L. salivarius V4II-90 (109 cfu/daily); B) GBS-positive women (n = 14) without oral 
V. Results 
 
 
102 
 
administration of L. salivarius V4II-90; and C) GBS-positive women (n = 25) in the 
probiotic group (109 cfu of L. salivarius V4II-90 daily). 
 
 
Figure 15. Means concentration (CFU/mL) of S. agalactiae (GBS) in vaginal 
swabs sampled regularly up to the delivery from GBS-positive women taking109 cfu of 
L. salivarius V4II-90 daily. Statistically significant differences between samples taking 
at different sampling times are indicated by letters (Bonferroni post-hoc test). 
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 No adverse effects arising from the intake of L. salivarius V4II-90 were reported 
by any of the women that participated in this study. 
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It is unresolved why GBS establishes as a harmless colonizer in approximately 
10% of infants in the first weeks of life, and overcomes epithelial barriers and cellular 
innate immunity only in less than one in thousand infants to cause LOD. In other words, 
it remains a puzzle which specific factors at the level of mucosal immunity and the local 
microbiome allow GBS to leave its colonizing niche, thus facilitating invasion in the 
individual child. 
At the beginning of life, the developmental lines of the microbiota and of the local 
cellular innate immunity have to run with substantial interdependence. Both areas are 
subject to factors in cis and in trans, i.e., specific bacteria are influenced by the 
microbiota and by host immunity, and host cells are modulated by other host and 
microbial cells (Thaiss et al., 2016). In order to guarantee long-term ecologic stability, 
adaptation on either side of the host–microbe interface is required, both at the population 
level and in the individual cell. The putative contribution of variations in specific innate 
immune genes to neonatal sepsis has recently been discussed (Borghesi et al., 2017). 
The authors suggested that affected children may suffer from yet to be identified minor 
primary immunodeficiency. This is a tempting hypothesis, given the enormous gain in 
knowledge on single gene alterations leading to susceptibility to a narrow spectrum of 
microorganisms. On the other hand, there is no indication for inheritance of a specific 
neonatal sepsis risk. Moreover, LOD typically remains the only “suspicious” episode in 
the individual infection biography. Finally, preterm birth is a well-recognized risk factor 
of GBS sepsis. In preterm infants, several factors impact on the individual co-
development of microbiota and immunity, in particular cesarean section and formula 
feeding, which modify the microbiome (Bokulich et al., 2016; Chu et al., 2017), and 
antibiotic usage, which affects both the microbiome and myeloid cell development 
(Deshmukh et al., 2014; Josefsdottir et al., 2017) 
VI.1. LIMITATIONS OF IAP AS THE STRATEGY TO PREVENT 
NEONATAL GBS INFECTIONS  
The application of universal GBS screening at weeks 35-38 of pregnancy together 
with IAP during delivery as the general rule for prevention of neonatal GBS infections 
seems to be an interim strategy due to three main reasons: (l) lack of actual efficacy to 
reduce the GBS burden, including its inability to prevent mother-to-fetus GBS 
transmission during pregnancy; (2) contribution to raising antibiotic resistances; and (3) 
negative impact on the maternal and infant microbiomes. First of all, recent Cochrane 
reviews have revealed that most of the old randomized controlled trials that supported 
the adoption of national guidelines for universal GBS recto-vaginal screening in 
pregnant women (and IAP of those with a positive result) had severe methodological 
flaws (Ohlsson and Shah, 2009; Ohlsson and Shah, 2013; Ohlsson and Shah, 2014). In 
fact, the reviews were critical of the overall quality of the studies, particularly the high 
risk of bias, no a priori sample size calculation, and the failure to use placebo in the trials 
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against no treatment. The results of these systematic reviews indicated that the use of 
IAP did not significantly reduce the incidence of all-cause neonatal mortality, neonatal 
mortality from GBS infection, or from infections caused by bacteria other than GBS. 
Although the prevalence of GBS infection was reduced with IAP compared to no 
treatment, the reviews concluded that “there is lack of evidence from well designed and 
conducted trials to recommend IAP to reduce EOS by GBS” (Ohlsson and Shah, 2009). 
Recent use of antibiotics was associated with a reduced rate of vaginal GBS colonization 
only when the rectum was not colonized. This observation suggests that either antibiotics 
were ineffective in eradicating rectal GBS or that they were ineffective at eradicating 
vaginal GBS among women who were colonized rectally (Meyn et al., 2009). 
Persistence of GBS colonization with the identical serotype after the use of the 
recommended or per protocol antibiotics has been reported (Gardner et al., 1979). 
VI.2. IAP IN THE CONTEXT OF THE CURRENT ANTIBIOTIC 
RESISTANCE CRISIS IAP  
Secondly, preventive exposure of disproportionally high percentage of mothers 
and infants to antibiotic may be unacceptable in the future in the frame of the current 
antibiotic resistance epidemics. This strategy may be more harmful that beneficial in a 
risk-benefit basis (Michael et al., 2014; Van Boeckel et al., 2014). Antimicrobial 
resistance (AMR) is an increasingly serious threat to global public health. AMR 
develops when a microorganism (bacteria, fungus, virus or parasite) no longer responds 
to a drug to which it was originally sensitive. This means that standard treatments no 
longer work; infections are harder or impossible to control; the risk of the spread of 
infection to others is increased; illness and hospital stays are prolonged, with added 
economic and social costs; and the risk of death is greater—in some cases, twice that of 
patients who have infections caused by non-resistant bacteria. The problem is so serious 
that it threatens the achievements of modern medicine. A post-antibiotic era— in which 
common infections and minor injuries can kill—is a very real possibility for the 21st 
century (WHO, 2014).  
In 1928 a piece of mould fortuitously contaminated a petri dish in Alexander 
Fleming’s Laboratory at St Mary’s Hospital London, and he discovered that 
it produced a substance (penicillin) that killed the bacteria he was examining. 
Within 12 years Fleming and others had turned this finding into a wonder drug 
of its time, which could cure patients with bacterial infections. Further antibiotics were 
discovered and went on to revolutionize healthcare, becoming the bedrock of many of 
the greatest medical advances of the 20th century. Common yet frequently deadly 
illnesses such as pneumonia and tuberculosis could be treated effectively. A small cut 
no longer had the potential to be fatal if it became infected, and the dangers of routine 
surgery and childbirth were vastly reduced. But bacteria and other pathogens have 
always evolved so that they can resist the new drugs that medicine has used to combat 
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them. Resistance has increasingly become a problem in recent years because the pace at 
which we are discovering novel antibiotics has slowed drastically, while antibiotic use 
is rising. And it is not just a problem confined to bacteria, but all microbes that have the 
potential to mutate and render our drugs ineffective (AMR, 2014). 
The damaging effects of antimicrobial resistance are already manifesting 
themselves across the world. Antimicrobial-resistant infections currently claim at least 
50,000 lives each year across Europe and the US alone, with many hundreds of 
thousands more dying in other areas of the world. But reliable estimates of the true 
burden are scarce. There is considerable variation globally in the patterns of AMR, with 
different countries often experiencing different major problems. Despite this and in 
contrast to some health issues, AMR is a problem that should concern every country 
irrespective of its level of income. For instance, in 15 European countries more than 
10% of bloodstream Staphylococcus aureus infections are caused by methicillin-
resistant strains (MRSA), with several of these countries seeing resistance rates closer 
to 50%.  
Although in modern, well-funded healthcare systems, obtaining access to second 
and third-line treatments may often not be an issue, mortality rates for patients with 
infections caused by resistant bacteria are significantly higher, as are their costs of 
treatment. And we are seeing in parts of Europe an increasing number of patients in 
intensive care units, hematology units and transplant units who have pan-resistant 
infections, meaning there is no effective treatment available. The threat of increasingly 
drug-resistant infections is no less severe in poorer countries. Emerging resistance to 
treatments for other diseases, such as TB, malaria and HIV, have enormous impacts in 
lower-income settings. The variation in the AMR problems of individual countries is 
linked to huge differences in how heavily they use antimicrobial drugs. Global 
consumption of antibiotics in human medicine rose by nearly 40% between 2000 and 
2010, but this figure masks patterns of declining usage in some countries and rapid 
growth in others (Van Boeckel et al., 2014). Any use of antimicrobials, however 
appropriate and conservative, contributes to the development of resistance, but 
widespread unnecessary and excessive use makes it worse. Overuse and misuse of 
antimicrobials is facilitated in many places by their availability over the counter and 
without prescription, but even where this is not the case prescribing practices vary 
hugely between (and often within) countries. Such issues are only made worse by large 
quantities of counterfeit and sub-standard antimicrobials permeating 
the pharmaceuticals markets in some regions.  
As with all infectious diseases, the speed and volume of intercontinental travel 
today creates new opportunities for antimicrobial-resistant pathogens to be spread 
globally. Such mixing of different microbes, particularly bacteria, provides them with 
opportunities to share their genetic material with each other, creating new resistant 
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strains at an unprecedented pace. No country can therefore successfully tackle AMR by 
acting in isolation. 
Currently, it is considered that multiresistant bacteria cause more than 700,000 
deaths a year in the world, 25,000 of them in Europe (with an additional cost of 1,500 
million euros to health systems), according to the data of the Center for Prevention and 
Control of Diseases of the United States (CDC) and the European Center for Disease 
Control (ECDC) (Laxminarayan et al., 2013; Laxminarayan et al., 2016). If this trend 
continues, in 2050 there could be 10 million deaths per year in the world due to this 
cause and it would constitute the first cause of death worldwide (as a reference it is worth 
saying that cancer currently causes around 8.2 million deaths per year) (WHO, 2014) 
(Figure 16). The figures are particularly alarming among the youngest, with an estimate 
of approximately 214,000 deaths per year due to neonatal sepsis caused by resistant 
pathogens (Laxminarayan et al., 2016). 
 
Figure 16. Deaths attributable to antimicrobial resistance every year compared to 
other major causes of death. Source: AMR (2014). 
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VI.3. IAP AND THE DEVELOPMENT OF THE HOST MICROBIOME  
IAP causes a strong impact on the acquisition and development of the infant 
microbiota (Tanaka et al., 2009; Aloisio et al., 2016) and it is becoming evident that 
such an effect has short-, and long term negative consequences for a host health (Blaser, 
2016).  
After birth, the infant microbiota is characterized by a very low diversity and a 
high instability in comparison with that of an adult, which makes it especially vulnerable 
to those factors that, like antibiotics, can modify its normal development (Koenig et al., 
2011; Yatsunenko et al., 2012; Goodrich et al., 2014). The vulnerability of the 
microbiota to antibiotics, and its long-term impact, seems to be greater as the infant age 
is lower (Schulfer and Blaser, 2015). Paradoxically, the first two years of life is the 
period in which the use of antibiotics per capita is higher in developed countries (Blaser, 
2016); it is estimated that a person receives between 10 and 20 treatments with 
antibiotics before in his/her first 18 years of life (Sharland, 2007). 
Currently, there are two very interesting emerging hypotheses that will have to be 
carefully evaluated since their implications can be really important in the future. The 
first, supported by epidemiological and experimental data, is that the effects of 
antibiotics can be cumulative in an individual (Blaser and Falkow, 2009). Successive 
antibiotic treatments can lead to the loss of species, especially of taxa that may be in low 
numbers at that time but may have important metabolic functions in the future. 
Obviously, the problem would be more relevant in the case of taxa with unique 
functions. The second, equally relevant, is that the environmental impacts on the 
microbiome (including exposures to antibiotics, form of birth or diet) are cumulative 
across generations since, under normal conditions, an individual inherits a large part of 
the mother's microbiome (Blaser and Falkow, 2009; Sonnenburg et al., 2016) (Figure 
17). 
The microbiome constitutes an important factor in individual health and 
development. The composition of the microbiome is complex, distinct between 
individuals and subject to environmental changes and adaptation to host factors. Each 
body site contains a unique microbial community. It seems evident that exposure to 
bacteria in the birth canal impacts on the colonizing microbiota in the infant. However, 
the fetus may be less sterile than thought, i.e., that the microbiome might develop 
already in utero (Jiménez et al., 2005; Jiménez et al., 2008; Aagaard et al., 2014). 
Intrauterine colonization data have to be interpreted with some caution, since microbial 
viability is usually not confirmed and the risk of contamination is high in many of the 
investigated samples (Lauder et al., 2016; Perez-Muñoz et al., 2017). Accordingly, the 
contribution of colonization in utero to microbiome development is still unclear, 
whereas that of colonization after rupture of fetal membranes is beyond doubt. As an 
example, vaginal delivery and cesarean section result in different bacterial communities 
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on skin, nares, and gingiva (Chu et al., 2017). Yet, the impact of the delivery mode on 
the expansion and functional diversification after the first 6 weeks of life is surprisingly 
modest (La Rosa et al., 2014; Chu et al., 2017). Instead, the infant’s microbiome follows 
a rather predictable successive colonization pattern and reaches a stable state resembling 
the adult microbiome already at 1–3 years of age (Palmer et al., 2007: Koenig et al., 
2011; Lozupone et al., 2012). Oxygen abundance in the neonatal gut facilitates the 
colonization by facultative anaerobes, e.g.,Lactobacillus and Streptococcusfollowed 
byEnterobacteriaceae. After oxygen is consumed and anaerobic conditions are 
established, obligate anaerobic species, e.g.,Bifidobacterium, Bacteroides, and 
Clostridiumspp. populate the intestine (Adlerberth and Wold, 2009; Tourneur and 
Chassin, 2013). 
Administration of antibiotics, on the other hand, heavily affects the postnatal 
microbiome (Penders et al., 2006; Yassour et al., 2016; Bokulich et al., 2016). Postnatal 
exposure to antibiotics alters the gut microbiome in the first 2–3 years of life by delaying 
microbiome development and altering phylogenetic diversity, e.g., affecting early 
colonization with Lactospiraceae spp. (Bokulich et al., 2016; Yassour et al., 2016). In 
addition, antibiotics reduce the stability of the microbiota composition as indicated by 
an increased variation between consecutive samples as compared to controls (Yassour 
et al., 2016). Notably, very preterm infants with a gestational age of <33 weeks, who in 
many cases receive antibiotics within 24 h of birth, showed a 10-fold reduced bacterial 
diversity in comparison to term infants (Gibson et al., 2016). 
VI.4. GBS AS PART OF THE HUMAN MICROBIOME 
Streptococcus is, together with Lactobacillus, Staphylococcus, and 
Propionibacterium, one of the most commonly found bacterial genera in the neonatal 
intestine and oral cavity (Jiménez et al., 2008a; Chu et al., 2017). Streptococcal species 
account for up to 10% of total bacteria in fecal samples during the first months of life 
(Arboleya et al., 2015; Heida et al., 2016; Mazzola et al., 2016). In pregnant women, 
GBS colonization is found in up to 30% of rectovaginal samples (Hansen et al., 2004; 
Stoll et al., 2011) and stable colonization with the same clone for several years has been 
demonstrated (Hansen et al., 2004). Spread from the gastrointestinal tract to the genital 
tract is considered to be a probable colonization sequence for GBS (Dillon et al., 1982). 
Since strains might be lost or reacquired in relatively short time periods (Manning et al., 
2008; Kwatra et al., 2014), GBS screening is recommended relatively late in pregnancy, 
i.e., between gestational weeks 35 and 37 (Verani et al., 2010). 
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Figure 17.  Models of microbiota change in different societies. The decline in 
microbiota diversity in the United States happened simultaneously with the early 
introduction of sanitation, including filtered and chlorinated drinking water, and early 
antibiotic use. The scale is arbitrary and reflects the aggregate of species and strain 
losses. The numbers shown represent the generations since the earliest population-wide 
microbiota species and strain losses and show progressive and cumulative loss of 
diversity. Each line represents an average; within every generation, there is variation in 
individual positions, based on their founding populations, exposures, and timing. In a 
country with late modernization, the diversity loss occurred later, but generation times 
are shorter, and the steps more irregular and increasing, which reflects the effects of the 
accelerated pace of modernization in recent years on human microbiota biodiversity loss 
in developing countries. For the future, three trajectories are shown for the developed 
country. Source: Blaser (2016). 
Colonization by GBS is not exclusively confined to humans. Instead, GBS was 
first described in the 1880s as a cause of mastitis in goats and cows and it is a frequent 
commensal in seals and fish (Manning et al., 2008; Delannoy et al., 2013). Although 
rare, invasive GBS disease can be a zoonotic disease as outbreaks in adults have been 
linked to raw fish consumption (Rajendram et al., 2016). Moreover, the hypervirulent 
ST-17 strain, which emerged 40 years ago, shares greater genetic similarity with bovine 
than with many human strains, indicating that it originated from a bovine lineage. 
Therefore, GBS may—under very specific conditions—cross species barriers (Bisharat 
et al., 2004). However, since virulent strains in humans are distinct from those causing 
disease in animals (Manning et al., 2008; Bohnsack  et al., 2008), person-to-person 
transmission plays the primary role in human GBS dissemination. Data on GBS spread 
are largely confined to mother-infant pairs. In contrast, the contribution of fecal-oral 
transmission by other family members than the mother to GBS colonization of the infant 
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remains unclear. While strains are largely shared between sexual partners (Manning et 
al., 2002; Meyn et al., 2002), cohabitation appears to play a minor role in transmission 
(Manning et al., 2004). 
Intrapartum antibiotic prophylaxis during delivery may transiently increase the 
GBS colonization risk of the infant yet probably does not affect the relative abundance 
of Streptococcus spp. in the stool beyond the first few weeks of life (Manning et al., 
2008). While a number of studies longitudinally analyzed the development of the 
microbiome after birth on the level of phylum, class or order, studies on species or even 
genus level, e.g., with a specific focus on Group A Streptococcus (GAS) or GBS are rare 
and do not allow for robust statements on this level of resolution. Infants which were 
tested negative for GBS after IAP administration frequently acquire maternal GBS 
strains at later time points (Berardi et al., 2013). Breast milk is hence a probable source 
of GBS in LOD. Some LOD case studies detected GBS in breast milk (Filleron et al., 
2014). However, it is often unclear whether GBS in breast milk results from maternal 
colonization or infant oropharyngeal contamination. Mutated strains from infants which 
have been detected in the maternal breast milk (Almeida et al., 2015) support the latter 
hypothesis.  
In addition, most breastfed infants remain unaffected by GBS in breast milk and, 
in fact, some researchers consider that human milk may protect neonates from GBS 
infections (Le Doare and Kampmann, 2014). Mechanisms associated with transmission 
of GBS in breast milk and potential factors that may protect the infant from transmission 
remain poorly understood. Understanding factors involved in protection or transmission 
of GBS infection via breast milk is important both for premature infants who are a high-
risk group and for infants in the developing world where breastfeeding is the only 
sustainable infant feeding option. There is increasing data from recent publications that 
enhanced protection against diarrhea, respiratory tract infections, otitis media 
and H. influenzae infections, as well as wheezing illness may persist for years after 
breastfeeding. However, the role of breast milk antibody in protection from neonatal 
GBS disease remains poorly understood. Breast milk provides considerable amounts of 
specific SIgA antibodies that are produced as a result of microbial and food antigens the 
mother has previously encountered. Such SIgA antibodies from breast milk provide 
protection to the neonate at the mucosal surface. Breast milk additionally contains high 
concentrations of non-specific protective molecules, such as lactoferrin that has 
bactericidal, viricidal, and fungicidal properties. Milk oligosaccharides might block 
adherence of microorganism at the mucosal surface by functioning as receptor 
analogues. 
Although GBS is the most prevalent streptococcal strain in neonatal sepsis, other 
streptococci, notably Groups A, D, and G, are isolated from blood cultures of newborns 
as well (Berkley et al., 2005; Talbert et al., 2010). Indeed, the connection of GBS and 
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neonatal sepsis was only found in the 1960s and its predominance was established in the 
1970s (Bisharat et al., 2004; Da Cunha et al., 2014). Prior to that, GAS 
and Streptococcus pneumoniae accounted for most neonatal sepsis cases (Bizzarro et al., 
2005; Shah and Padbury, 2014). As in other ecological niches, competition for nutrition 
and space occurs between bacterial species on colonized human body sites (Hibbing et 
al., 2010). Indeed, examples of mutual exclusion are found in the genus Streptococcus, 
e.g., in the case of Streptococcus mutans, the predominating cause of caries. The 
presence of other streptococcal species in the oral cavity, namely Streptococcus 
sanguinis and Streptococcus oligofermentans, is inversely correlated with the abundance 
of S. mutans which has been linked to the production of hydrogen peroxide in 
vitro (Kreth et al., 2005; Tong et al., 2007). Another example is the observation that 
Corynebacterium and Dolosigranulum in the upper respiratory tract are protective 
against colonization with Streptococcus pneumonia, which causes otitis media in infants 
after colonization of the airways (Laufer et al., 2011). More importantly in the context 
of this review, growth of GBS is inhibited by Streptococcus salivarius both in vitro and 
in a vaginal colonization mouse model (Patras et al., 2015). Competitive growth was 
also shown for Bifidobacterium and GBS in vitro (Aloisio et al., 2014) and lactobacilli 
inhibited growth (Ruiz et al., 2012) and attachment of GBS to vaginal epithelial cells 
(Zarate et al., 2016). In addition, Lactobacillus reuteri reduced vaginal colonization in 
a mouse model (De Gregorio et al., 2015) and—importantly—as a probiotic in a 
placebo-controlled trial in pregnant women (Ho et al., 2016). These findings are in line 
with a very recent randomized, double-blind, placebo-controlled trial from Indian, where 
Lactobacillus plantarum plus fructooligosaccharides protected newborns from sepsis 
(Panigrahi et al., 2017). In general, however, the presence of GBS appears not to be 
linked to an abnormal microbiome or a reduction of the predominant Lactobacillus 
genus in the vaginal tract of the mother (Brzychczy-Wloch et al., 2014; Rick et al., 2017; 
Rosen et al., 2017). Interestingly, a small study found significant taxonomic differences 
in stools of 6-month infants, when mothers were GBS carriers, as compared to non-
carriers (Cassidy-Bushrow et al., 2016). Yet, robust epidemiological evidence for a 
correlation of neonatal colonization with GBS and that of other specific intestinal 
commensals such as other streptococcal species is not existent. 
Next to streptococci, staphylococci cause bacteremia and sepsis in newborns. 
Indeed, coagulase-negative staphylococci are the most common cause of nosocomial 
sepsis in newborns, yet do not play a role in healthy term infants. The generally more 
virulent S. aureus is isolated in variable frequency from neonatal blood cultures, but it 
is rarely found in cerebrospinal fluid (Talbert et al., 2010). Furthermore, in view of the 
omnipresence of S. aureus as a colonizer in up to 50% of neonates, infants of this age 
group are not specifically susceptible to staphylococcal infections, unless they are 
subject to medical interventions such as indwelling catheters or surgery (Lowy, 1998; 
Berkley et al., 2005). Hence, the contact with GBS and potentially other (beta-
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hemolytic) streptococci and the establishment of coexistence with these bacteria appears 
to impose a greater risk to the infant compared to other genera. 
VI.5. THE IMPACT OF ANTIBIOTIC PRESSURE AND RESISTANCE ON 
GBS-RELATED LOD  
The majority of GBS strains isolated from humans are resistant to the antibiotic 
tetracycline. Indeed, the insertion of tetracycline resistance (TcR) elements, i.e., the 
ribosomal protection proteins Tet(M) and Tet(O), in few GBS clones led to their 
selection and expansion after the onset of extensive tetracycline usage since 1948 (Da 
Cunha et al., 2014). These clones have since replaced a prior diverse GBS population, 
concurrent with the rise of GBS as major cause of neonatal sepsis. Notably, TcR 
elements are the most widely spread resistance genes in the human gut microbiota (Hu 
et al., 2013). Moreover, a subset of GBS strains, especially ST-1, carry genes which 
confer general resistance to macrolids and lincosamides, i.e., the methylases erm(B) and 
erm(TR) (Da Cunha et al., 2014). Resistance rates to clindamycin (lincosamid) and 
erythromycin (macrolide) range up to 30 and 50%, respectively (Hays et al., 2016; 
Teatero et al., 2016). A rise of resistance to fluoroquinolones has been described in 
serotype V strains (Kimura et al., 2013; Hays et al., 2016). In addition, GBS with 
reduced penicillin susceptibility due to mutations in the penicillin-binding proteins are 
isolated with increasing frequencies in Japan (Kimura et al., 2008; Seki et al., 2015) and 
were also reported to occur spontaneously in an American patient after prolonged 
penicillin treatment (Longtin et al., 2011). In this context, it seems likely that the 
frequent use of antibiotics other than tetracyclines may also lead to selection of 
hypervirulent strains. In the Netherlands, the incidence of EOD caused by ST-17 has 
significantly increased after implementation of a risk-based approach of antibiotic 
prophylaxis (Bekker et al., 2014). ST-17 strains are also significantly more prevalent in 
women with IAP as compared to other strains (Manning et al., 2008). Thus, a relatively 
short course of intrapartum antibiotics, usually penicillin and ampicillin, may allow for 
seeding and expansion of hypervirulent GBS strains, which may not affect the majority 
of infants but propagate LOD development in few colonized individuals. 
In addition, the capsular serotypes of GBS are not fixed but subject to frequent 
exchange by conjugative transfer between strains, explaining for the diversity of 
serotypes within clonal complexes. Lately, serotype IV has emerged as a causative agent 
of adult GBS disease in the USA (Teatero et al., 2015; Teatero et al., 2016). This seems 
important, as serotype IV is not included in the latest efforts in vaccine development to 
capsular antigens of GBS. Sequencing has revealed that a predominating serotype IV 
strain acquired large genomic fragments by horizontal gene transfer from the 
hypervirulent ST-17 and ST-23 strains (Campisi et al., 2016). Additionally, ST-17 
strains with capsular switching to serotype IV have been identified in several countries 
(Bellais et al., 2012; Meehan et al., 2014). Since maternal antibodies can impact on 
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colonization with the antibody-specific GBS strains in mothers and early infants (Le 
Doare and Kampmann, 2014; Kwatra et al., 2015; Baker et al., 2017), it remains an open 
question whether targeting certain serotypes may eventually select for strains which 
have acquired novel capsule genes and allow for their expansion. 
Interestingly, single-nucleotide polymorphisms (SNPs) in virulence-associated 
genes were detected in neonatal invasive GBS strains in comparison to the respective 
colonizing strains from the mothers, possibly contributing to the transition from a 
maternal commensal to a neonatal pathogen (Almeida et al., 2015). This suggests that 
mutations are positively selected for in the neonatal environment. Moreover, mutations 
in the virulence regulator CovR/S leading to hyperhemolytic activity were found in 
invasive isolates of women in preterm labor (Whidbey et al., 2013). The acquisition of 
antibiotic resistance, serotype switching and SNPs can therefore lead to microevolution 
in the individual newborn, which may explain the pathogenicity of GBS in only a very 
small number of infants. 
VI.6. THE ROLE OF ANTIBIOTICS AND DYSBIOSIS IN THE 
DEVELOPMENT OF GBS SEPSIS  
The microbiota may have beneficial but also detrimental, acute, and chronic 
effects on infant health. Dysbiosis may predispose the neonatal intestine to inflammation 
(Tourneur and Chassin, 2013) and facilitate the expansion of otherwise infrequent 
pathobionts (Ayres et al., 2012; Stecher et al., 2013). Dysbiosis with lower bacterial 
diversity and decreased density of Propionibacterium spp. was found to precede the 
onset of necrotizing enterocolitis (NEC) (Morrow et al., 2013; Stewart et al., 2016). 
Moreover, lactate-producing bacilli such as staphylococci and streptococci were reduced 
after birth in infants with NEC (Mazzola et al., 2016). Even though the increased 
prevalence of opportunistic pathogens such as uropathogenic E. coli (Ward et al., 2016) 
and Clostridium perfringens (Mazzola et al., 2016) has been linked to NEC, a common 
bacterial signature has not been found (Stewart et al., 2016; Pammi et al., 2017). In 
addition, it is often unclear whether dysbiosis and the development of organ pathology 
are causally linked or whether they both depend on upstream disturbances, which may 
be diverse. Mai et al. found signs of dysbiosis in preterm infants already 2 weeks before 
onset of sepsis (Mai et al., 2013). Dysbiosis meant a delayed colonization 
with Proteobacteria and decreased density of Bifidobacteria spp. This observation 
receives support by the finding that Bifidobacterium spp. in the gut are protective for 
LOD (Stewart et al., 2017), although the data on this issue are not fully consistent 
between studies (Taft et al., 2015). In view of these observations, a reduced intestinal 
Bifidobacterium density in infants whose mothers received IAP constitutes an important 
warning sign for the most careful usage of antibiotics in this sensitive period (Aloisio et 
al., 2014). In support of this notion, the risk for LOD caused by various pathogens 
including GBS in preterm infants is threefold higher after prolonged empirical antibiotic 
treatment (Kuppala et al., 2011). Antibiotics can affect the composition of the 
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microbiome in many ways, including the depletion of competitive microbes, a delay in 
immune cell maturation (see below) and dysbiosis, all of which widen the niche for 
pathogenic bacteria. 
VI.7. GBS COLONIZATION RATES 
In this PhD Thesis, the GBS colonization rates were 25% and 20% among non-
pregnant and pregnant women, respectively. Globally, there is a limited knowledge of 
GBS colonization prevalence and risk. While regional GBS vaginal colonization rates 
have been estimated, colonization rates in many individual countries, including Spain, 
are unknown. Estimates of GBS vaginal colonization in different countries can be highly 
variable, with interstudy rates differing by as much as 20% (Hillier et al., 1991). This 
variability may be due to differences between subregions of large countries (e.g., India) 
or the means of diagnosing colonization (culture-based methods vs. PCR-based methods 
vs. serology-based methods). More comprehensive country-based and subregional-
based studies are necessary to fully understand the burden of GBS colonization. New 
studies should focus on areas where preterm birth rates and neonatal mortality rates are 
especially high, such as sub-Saharan Africa or south Asia. Additionally, few studies 
provide information about GBS serotype prevalence, colonization load, antibiotic-
resistance profiles, or valuable genetic information, such as virulence gene prevalence. 
While diagnostic technologies exist to evaluate these indicators, they can be time-
consuming, expensive, technically challenging, and overall impractical. Diagnostic 
methodology for GBS colonization has not advanced as rapidly as our understanding of 
the disease itself, and new technologies need to be developed to garner more information 
from future studies to further refine our knowledge of GBS colonization. Finally, more 
studies need to be designed to conclusively identify risk factors for GBS colonization, 
ascending infection, and GBS-associated preterm birth. It is clear that previous GBS 
colonization is a risk factor for colonization during a subsequent pregnancy (Allen et al., 
1999), but few risk factors for initial GBS colonization have been identified. Recent 
studies have identified obesity (Lawn et al., 2010) and black ethnicity as possible risk 
factors for colonization (Romero et al., 2014). Future studies should be designed to 
identify population characteristics beyond ethnic demography and age of GBS-
colonized women in an effort to improve our ability to identify at-risk individuals. 
Ultimately, universal screening programs are needed in more countries to measure the 
burden of GBS colonization and successfully prevent disease. 
Recently, significant effort has been dedicated to measuring the global rates of 
GBS colonization, invasive disease, and related risk factors. In the USA and many other 
countries (including Spain), women are routinely screened in the late third trimester 
(between 35 and 37 weeks' gestation) for GBS colonization by rectovaginal swab and 
subsequent culture. If the rectovaginal swab is culture-positive, or if the patient has GBS 
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in the urine, or has a prior history of GBS perinatal infection, intrapartum prophylactic 
antibiotics are administered to prevent vertical transmission of GBS to the neonate 
during labor and delivery. Unlike the USA, some European countries (e.g., UK) have 
not adopted the GBS screening program but instead administer antibiotics upon the 
development of a risk factor for GBS neonatal disease (e.g., prolonged rupture of 
membranes). However, none of these approaches have eliminated neonatal GBS 
infections. This is because these prevention strategies do not address the risk of 
ascending infection, which can potentially occur anytime during pregnancy, leading to 
preterm birth or stillbirth. Also, these approaches do not prevent late-onset GBS 
infections (observed in neonates who are older than 1 week of age) where vertical 
transmission is not the only mode of acquisition. 
Overall, prevention of GBS infection in pregnancy is still a complex question, with 
risk likely imparted by several factors, including: pathogenicity of the GBS strain, host 
factors, influence of the vaginal/rectal microbiome, false-negative screening results, 
and/or changes in GBS antibiotic resistance. As current interventions targeting GBS 
infections are limited to antibiotic therapy, and given that antibiotic resistance is on the 
rise, a deeper understanding of how GBS is able to colonize the vagina and cause 
neonatal disease is critical for the development of new therapeutics. Recently, a number 
of studies have described host and bacterial factors important for GBS infections during 
pregnancy.  
Currently, strategies are mainly focus on the prevention of GBS transmission 
during labor and delivery through the use of antibiotics. This strategy does not fully 
capture the biology of GBS infection, nor does it completely address the full burden of 
GBS disease. Moreover, antibiotic resistance is increasing, and the use of antibiotics 
during pregnancy has consequential effects for neonatal health that are only now being 
appreciated (Bokulich et al., 2016). To successfully eradicate the burden of disease, 
interventions need to be specifically targeted, have minimal detrimental effects on the 
microbiome, and target processes upstream of vertical transmission, such as colonization 
and ascending infection. Multiple studies have focused on a probiotic approach to 
reducing vaginal GBS colonization. This issue will be discussed in the next section. 
VI.8. SEARCHING FOR ALTERANTIVES TO IAP: GBS-TARGETING 
PROBIOTIC  
As stated above, there is a need for alternatives that are respectful with the neonatal 
and infant microbiota, and that do not compromise the health of future generations. In 
this context, the final objective of this work was the selection of safe probiotic strains 
with the in vitro and in vivo ability to eradicate GBS from the intestinal and 
genitourinary tracts of pregnant women and/or their infants.  
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The genus Lactobacillus constitutes the dominant bacterial group of the vaginal 
tract in most healthy women, playing a key role in the genitourinary homeostasis (Boris 
and Barbés, 2000; Reid and Burton, 2002; Ravel et al., 2011; Ma et al., 2012). In 
addition, this genus is also commonly found in the gastrointestinal tract. As a result, the 
selection and characterization of lactobacilli strains to be used as probiotics in a very 
wide array of gastrointestinal and genitourinary conditions has been a hot topic in 
Biomedicine for the last years, with hundreds of reviews and in vitro and in vivo original 
work articles being published each year. Lactobacillus strains have been proposed for 
use in women before, during and after pregnancy (Fernández et al., 2014; Reid et al., 
2016).  
In this study, all the vaginal isolates (from either pregnant or non-pregnant healthy 
women) that fulfilled the initial selection criteria belonged to the same species: L. 
salivarius. This species is part of the indigenous microbiota of the human 
gastrointestinal tract, oral cavity, genitourinary tract and milk (Rogosa et al. 1953; Casey 
et al. 2004; Martín et al., 2006; Al Kassaa et al., 2014; De Gregorio et al., 2014), and 
some strains have been studied as probiotics because of their in vitro and in vivo 
antimicrobial, antiinflammatory and immunomodulatory properties (Dunne et al., 1999; 
Mattila-Sandholm et al., 1999; Dunne et al., 2001; McCarthy et al., 2003; Dunne et al., 
2004; Sheil et al., 2004; Martín et al., 2006; Olivares et al. 2006; Pérez-Cano et al., 2010; 
Neville and O’Toole, 2010; Langa et al., 2012; Messaoudi et al., 2013; Sun et al., 2015). 
Administration of probiotic bacteria benefits the host through a wide array of 
mechanisms that are increasingly recognized as being either species- and/or strain-
specific (Hill et al., 2014). A comparative genomics study that included 33 L. salivarius 
strains isolated from humans, animals or food revealed that this species displays a high 
level of genomic diversity (Raftis et al. 2011). Therefore, selection of L. salivarius 
strains for probiotic use requires pragmatic experimental validation of target-tailored 
phenotypic traits. Some L. salivarius strains have shown to be efficient to prevent 
infectious diseases, such mastitis caused by staphylococci and streptococci, when 
administered during late pregnancy (Fernández et al., 2016). Moreover, oral 
administration of L. salivarius strains is also a valid strategy for the treatment of such 
condition during lactation and, in fact, one of the strains was more efficient that 
antibiotics for this target (Arroyo et al., 2010; Vázquez-Fresno et al., 2014; Espinosa-
Martos et al., 2016). In this PhD Thesis, the target was antagonism towards GBS and, as 
a consequence, properties such as antimicrobial activity against S. agalactiae strains or 
coaggregation with this species were considered particularly relevant.  
The production of antagonistic substances such as bacteriocins, hydrogen peroxide 
or organic acids represents an important contribution to the defense mechanisms exerted 
by intestinal and vaginal lactobacilli (Martín et al., 2006; Martin et al., 2008). Some L. 
salivarius strains produce bacteriocins or display bacteriocin-like activity against a 
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variable spectrum of Gram-positive bacteria (Ocaña et al., 1999; Flynn et al., 2002; 
O'Shea et al., 2012), including S. agalactiae strains (Ruiz et al., 2012). In our study, 
none of the selected L. salivarius strains displayed bacteriocin-like activity against S. 
agalactiae strains. Future antimicrobial assays and/or analysis of the L. salivarius V4II-
90 will determine if this strain produces bacteriocin/s with activity against other bacterial 
species. Therefore, the antimicrobial activity that the selected L. salivarius strains 
exhibited against S. agalactiae must be related with the production of other antimicrobial 
compounds, such as organic acids. The ability of lactobacilli to acidify the vaginal milieu 
contributes to the displacement and inhibition of pathogens proliferation (Charlier et al., 
2009) and, more specifically, acid production by lactobacilli has been directly correlated 
with the inhibition of GBS growth (Açikgöz et al., 2005). Another antimicrobial defense 
mechanism attributed to some intestinal or vaginal lactobacilli is the production of 
peroxide hydrogen, a compound that is toxic for catalase-negative bacteria, such as 
streptococci (Borges et al., 2014). Production of this compound by L. salivarius has 
already been reported (Ocaña et al., 1999; Martín et al., 2006). In our study, L. salivarius 
V4II-90 (the strain that showed the highest anti-GBS activity) produced high amounts 
of lactic acid and, in addition, was able to produce peroxide hydrogen. 
The ability to adhere to intestinal or vaginal epithelial cells or to mucin, and to co-
aggregate with potential pathogens constitutes one of the main mechanisms for 
preventing their adhesion and colonization of mucosal surfaces. Therefore, it is not 
strange that such properties are considered relevant for the selection of probiotic strains 
(Reid et al., 1988; Younes et al., 2012). High adherence of L. salivarius strains to Caco-
2 and HT-29 cells or to mucin has been previously observed (Dunne et al., 1999; Martín 
et al., 2006; Martín et al., 2009). Globally, L. salivarius V4II-90 showed the best 
combination of adherence to epithelial cells, co-aggregation with S. agalactiae and 
inhibition of S. agalactiae strains in broth co-cultures. This strain showed a high survival 
rate during transit through an in vitro gastrointestinal model, similar to those obtained 
with other L. salivarius strains using the same model (Martín et al., 2006; Martín et al., 
2009). Survival of lactobacilli when exposed to conditions found in the gastrointestinal 
tract seems to be a critical pre-requisite for a probiotic strain when use as a food 
supplement is pursued, as it was the case. 
Some vaginal strains of L. gasseri and L reuteri have also been reported to co-
aggregate with GBS (De Gregorio et al., 2014). In contrast, no co-aggregation activity 
between S. agalactiae and other vaginal lactobacilli belonging to the species L. 
acidophilus, L. gasseri and L. jensenii was observed in other study (Boris et al., 1998), 
a fact suggesting that such property is a highly strain-specific trait (Collado et al., 2007; 
Ekmekci et al., 2009) related with cell surface components and influenced by different 
factors (Boris et al., 1997; Boris et al., 1998; Ocaña and Macías, 2002). In relation to 
broth co-cultures, the capacity to antagonize the growth of S. agalactiae by lactobacilli 
strains belonging to different species, including L. salivarius, has been previously 
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reported (Bodaszewska et al. 2010; De Gregorio et al., 2014). Similarly to our results, 
this activity was strain-dependent (De Gregorio et al., 2014).  
One of the most important criteria for the selection of probiotic strains is the 
assessment of their safety, particularly to the target population. In this work, no adverse 
effect was reported by any of the women participated in the clinical trial and ascribed to 
the probiotic group (thus, receiving L. salivarius V4II-90 at 9 log10 cfu daily for several 
weeks). Previously, other L. salivarius strains have been shown to be well tolerated and 
safe in animal models (Lara-Villoslada et al. 2007) and in human clinical assays (Arroyo 
et al. 2010; Maldonado et al. 2010; Vázquez-Fresno et al., 2014; Espinosa-Martos et al., 
2016), including pregnant women (Fernández et al., 2016). However, safety must be 
assessed in a strain by strain manner since, although rare, adverse effects due to the 
consumption of lactobacilli strains have been reported (Doron and Snydman, 2015). In 
a study to assess the ability of a collection of lactobacilli to bind fibrinogen, only one 
strain (L. salivarius CCUG 47825) isolated from a case of septicemia, was found to 
strongly adhere to fibrinogen (Collins et al., 2012). Furthermore, this strain was found 
to aggregate human platelets at a level comparable to the human pathogen S. aureus. By 
sequencing the genome of CCUG 47825, candidate genes responsible for fibrinogen 
binding were identified. Complementing the genetic analysis with traditional molecular 
microbiological techniques enabled the identification of the novel fibrinogen receptor, 
CCUG_2371. Although only strain CCUG 47825 bound fibrinogen under laboratory 
conditions, homologues of the novel fibrinogen binding gene CCUG_2371 are 
widespread among L. salivarius strains, maintaining their potential to bind fibrinogen if 
expressed. This serves to highlight the fact that without a full genetic analysis of strains 
for human consumption, potential pathogenicity traits may go undetected (Collins et al., 
2012). 
The L. salivarius strains included in this study were very susceptible to most of 
the antimicrobials tested. In fact, their MICs were lower than the cut-offs established for 
lactobacilli to seven out of the eight antibiotics required for this species by the European 
Food Safety Authority (EFSA, 2012). The only exception was kanamycin. Intrinsic 
resistance of lactobacilli to kanamycin and other aminoglycosides (such as neomycin or 
streptomycin) has been repeatedly reported (Charteris et al. 1998; Danielsen and Wind 
2003; Gueimonde et al., 2013), and this is thought to be a L. salivarius species-specific 
trait due to the lack of cytochrome-mediated transport of this class of antibiotics (Bryan 
and Kwan, 1981); the L. salivarius strains were also resistant to vancomycin but 
assessment of vancomycin sensitivity is not required by EFSA in the case of 
homofermentative lactobacilli (including L. salivarius) since they are intrinsically 
resistant to this antibiotic probably due to the presence of D-Ala-D-lactate in their 
peptidoglycan structure (Handwerger et al., 1994). As recognized by EFSA (2012), these 
types of intrinsic resistances do not represent a human health risk. Therefore, L. 
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salivarius V4II-90 and the other strains evaluated in this study can be considered as safe 
from this point of view. 
Lactobacilli are among the Gram-positive bacteria with potential to produce 
biogenic amines and these substances can cause several toxicological problems and/or 
may act as potential precursors of carcinogenic nitrosamines (Bover-Cid and Holzapfel, 
1999). The screened L. salivarius strains neither produced histamine, tyramine, 
putrescine or cadaverine nor harbored the gene determinants required for their 
biosynthesis. Additionally, they were unable to degrade gastric mucin in vitro.  
Some studies have evaluated the potential of different lactic acid bacteria strains 
or their metabolites to inhibit the growth of S. agalactiae (Marsalková et al., 2004; Lee, 
2005; Açikgöz et al., 2005; Zárate et al., 2006; Ermolenko et al., 2007; Bodaszewska et 
al., 2010; Tsapieva et al., 2011; Ruiz et al., 2012; De Gregorio, 2014). However, to our 
knowledge, this work includes the first human clinical trial focused on the rectal and 
vaginal eradication of GBS in pregnant women by using a probiotic strain. The criteria 
followed for the selection of the best candidate for such a target (L. salivarius V4II-90) 
allowed a notable reduction in the rate of GBS-colonized women and led to a sharp 
reduction in the use of antibiotics during the peripartum period. Hopefully, this strain 
will be applied in the next future to decrease GBS colonization during pregnancy, thus 
allowing a reduction in the use of IAP. In addition, it can be a very valuable tool to 
prevent GBS in the neonatal units or as a treatment adjunct in GBs infections.  
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The conclusions derived from this PhD Thesis are the following: 
Las conclusiones derivadas de esta Tesis son las siguientes: 
FIRST.  Lactobacillus was the dominant genus in the vaginal microbiota of both 
non-pregnant and pregnant fertile women that participate in the first objective of this 
PhD Thesis, while the rate of Streptococcus agalactiae colonization was 25 and 20%, 
respectively.   
PRIMERA. Lactobacillus fue el género dominante en la microbiota vaginal de 
las mujeres no embarazadas y embarazadas que participaron en el primer objetivo de 
esta tesis, mientras que la tasa de colonización de Streptococcus agalactiae fue del 25 
y 20%, respectivamente. 
********************************************** 
SECOND. Among the 89 strains of lactobacilli isolated in this thesis, only 10 met 
the requirements initially established for their pre-selection as probiotics: (1) absence 
of S. agalactiae, Gardnella vaginalis, Candida spp., Ureaplasma spp. and Mycoplasma 
spp in the vaginal samples from which the lactobacilli were originally isolated; (2) 
Qualified Presumption of Safety (QPS) status of the Lactobacillus species; and (3) good 
growth and stability under laboratory conditions. The 10 preselected strains belonged 
to the same species: Lactobacillus salivarius. 
SEGUNDA. Entre las 89 cepas de lactobacilos aisladas en esta tesis, únicamente 
10 reunieron los requisitos que se habían establecido inicialmente para su preselección 
como probióticos: (1) ausencia de S. agalactiae, Gardnerella vaginalis, Candida spp., 
Ureaplasma spp. y Mycoplasma spp. en las muestras vaginales de las que se habían 
aislado; (2) pertenecer a una especie con presunción cualificada de seguridad (estatus 
QPS); y (3) buen crecimiento y estabilidad en condiciones laboratoriales. Las 10 cepas 
preseleccionadas pertenecían a la misma especie: Lactobacillus salivarius. 
********************************************** 
THIRD. Assessment of several probiotic properties, including specific 
antagonism against GBS, showed that L. salivarius V4II-90 was the strain with the 
highest potential for the eradication of GBS during pregnancy. This strain also fulfilled 
all the requirements of the European Food Safety Authority to be considered as a safe 
strain for human use, including the evaluation of its in vivo toxicity in a rat model.  
 
TERCERA. La evaluación de varias propiedades probióticas, incluyendo el 
antagonismo específico frente a S. agalactiae, mostró que L. salivarius V4II-90 era la 
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cepa con un mayor potencial para la erradicación de S. agalactiae durante el embarazo. 
Esta cepa también cumplía todos los requisitos exigidos por la Autoridad Europea de 
Seguridad Alimentaria para ser considerada como una cepa segura para uso humano, 
incluyendo la evaluación de su toxicidad in vivo en un modelo rata. 
********************************************** 
FOURTH. The administration of L. salivarius V4II-90 to GBS-positive pregnant 
women (109 cfu orally, once a day from week 26 to week 38 of pregnancy) led to the 
eradication of this species in the rectal and vaginal samples of 72% of the recruited 
women. No adverse effects were recorded from any of the women who ingested the 
probiotic strain.  
CUARTA. La administración de L. salivarius V4II-90 a mujeres embarazadas 
positivas a S. agalactiae (109 ufc por vía oral, una vez al día desde las semana 26 hasta 
la 38 de embarazo) condujo a la erradicación de dicha especie en las muestras rectales 
y vaginales del 72% de las mujeres participantes. No se registraron efectos adversos en 
ninguna de las mujeres que ingirieron la cepa probiótica. 
********************************************** 
GENERAL CONCLUSION/CONCLUSIÓN GENERAL 
The administration of L. salivarius V4II-90 to GBS-positive pregnant women is 
a safe and successful strategy to significantly decrease the rates of GBS colonization 
during pregnancy and, therefore, to reduce the exposure of pregnant women and their 
infants to intrapartum prophylaxis. 
La administración de L. salivarius V4II-90 a mujeres embarazadas positivas a S. 
agalactiae es una estrategia segura y eficaz para disminuir significativamente las tasas 
de colonización durante el embarazo y, por lo tanto, para reducir la exposición de las 
mujeres embarazadas y sus hijos a la profilaxis intraparto. 
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